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Abstract 
In order to improve DNA transfection/siRNA silencing, a series of novel bifunctional peptides 
had been designed in the present study. The bifunctional peptides had a complexing moiety 
(denoted B), and a targeting moiety (denote Y), connected by linker L. All the BLY peptides had 
the same sequence in region L and Y.  Region B was composed of ether a single histidine (H), 
arginine (R) and lysine (K) residue, denoted Series I, or a combination of them, Series II. These 
peptides have been shown to be more efficient vectors for DNA/siRNA delivery, especially when 
assembled with cationic vesicles (DOTMA:DOPE 1:1 molar ratio) into a ternary LPD or LPR 
complex composing cationic Lipids/bifunctional Peptide/DNA or siRNA. The delivery of these 
LPDs/LPRs was assessed by luciferase transfection/silencing on lung carcinoma A549 cells.  
Of a combination of preparation and transfection aqueous solutions, the LPDs/LPRs prepared in 
water and in NaCl solutions had the same level of transfection/silencing when diluted in 
Optimem to incubate with cells. However, only the LPDs/LPRs prepared in NaCl solutions 
showed effective transfection/silencing (proportional to NaCl concentration of up to 0.12 M) 
when diluted in RPMI-1640 Media containing 10% v/v fetal bovine serum. Of various 
combinations, the LPDs/LPRs containing Series II peptides appeared to be superior over those 
containing Series I. Agarose gel electrophoresis showed that the LPDs/LPRs prepared in NaCl 
solutions afforded more protection against enzyme than those prepared in water without 
difference in condensation and release. Picogreen fluorescence assay revealed that 
DNA/siRNA was weakly condensed in LPDs/LPRs when prepared in NaCl solutions due to 
charge screening effect of salt. Moreover, dynamic light scattering showed that the LPDs/LPRs 
prepared in NaCl solutions were larger than those prepared in water due to alleviated 
condensation as shown in picogreen fluorescence assay. Small angle neutron scattering 
exhibited that the LPDs/LPRs prepared in both water and NaCl solutions had the same single 
lipid bilayer structure with the same bilayer thickness.  
The present study suggests that these novel LPDs/LPRs should be further studies in vivo. In 
particular, 0.12 M NaCl solution is close to isotonic NaCl solution (0.15 M) which can be injected 
directly into bodies, revealing that those LPDs/LPRs may have potential in clinical therapy of 
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Chapter 1 Introduction 
1.1 Nucleic acid 
Nucleic acid, alongside with proteins and carbohydrate, are three major macromolecules 
essential for all known forms of life. Nucleic acid carries genetic information and is responsible 
for its transmission from generation to generation. Therefore, nucleic acid represents the most 
important and interesting molecules in life.  
1.1.1 DNA and RNA 
Nucleic acid can be sub-divided into deoxyribonucleic acid, denoted DNA, and ribonucleic acid, 
denoted RNA.  
DNA 
The basic unit of DNA molecule is composed of a nucleobase, a ribose sugar and a phosphate. 
A nucleobase and a ribose sugar make up a nucleoside. The ribose sugar of DNA is deoxylated, 
with a C-H bond on the 2’-position of pentose ring. The C-H bond is less reactive than C-OH 
bond and therefore improves its molecular stability. The nucleobase is attached to the 1’-
position of ribose ring and the 5’-positon of the ribose ring is connected with phosphate via 
phosphodiester bonds. The connection of the ribose sugar and the phosphate forms a regular 
phosphate-ribose backbone chain with irregular nucleobases protruding outside. As the 
phosphates are negatively charged, the adjacent phosphates of the backbone chain repel each 
other, forming a helical 3-dimentional structure. While the molecular composition of the 
phosphate-ribose backbone chain is fixed, different nucleobases are incorporated into the two 
backbone chains, which interact with each other via strong hydrogen bonds.  
DNA molecules contain four types of nucleobases: adenine (A), guanine (G), cytosine (C) and 
thymine (T). These nucleobases stick with strict pairing rule: adenine complementarily pairs with 
thymine via two hydrogen bonds (A=T) and cytosine with guanine via 3 hydrogen bonds (C  G). 
The strong hydrogen bond interactions between the protruding nucleobases on two chains 
leads to the formation of a double helical structure as proposed by Watson and Crick (Watson 
J.D. et al, 1953). The space-filling model of DNA and siRNA helix is depicted in Figure 1.1. 










Figure 1.1 Space filling model of double helices (a) A form and (b) B form. The phosphorus, 
oxygen and heterocyclic nitrogen are shown in yellow, red and blue, respectively (Rana 2007).  
 
Notably, the double helix can adopt different geometries such as A-form, B-form and Z-form. A-
form and B-form DNA are right-handed in orientation while the Z-form DNA is left-handed. B-
form DNA is the most common form found in vivo, as shown in Figure 1.1(b). The A-form, 
(Figure 1.1(a)), not found in vivo, resembles B-form DNA but is less hydrated. The helical 
structure of the DNA molecule is composed of alternating turns of nucleobase pairs attached to 
sugar-phosphate backbone. As the sugar-phosphate backbone is on the outside, the 
nucleobase pairs are protruding inwards. The nucleobase pairs occupy a much larger volume 
than the sugar-phosphate backbone. Therefore, as the sugar-phosphate backbone double 
chains are twisting and turning, the nucleobase pairs are exposed as two grooves not equal in 
size, forming a major groove and a minor groove. The major groove and the minor groove are a 
consequence of the geometry of the nucleobase pairs. The helical strands in the major grooves 
are further apart, while the strands in the minor groove are closer together. Therefore, the major 
groove is deep and wide, whereas the minor groove is narrow and shallow. These grooves, in 
particular major grooves, make the DNA molecule accessible to functional proteins. Each turn of 
the B-form DNA double helix has 10.5 nucleobase pairs with a diameter of 20 Å while that of A-
form siRNA has 11-12 nucleobase pairs with a diameter of 23 Å. 
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In eukaryotes, most DNA is located in the nucleus with some found in mitochondria. The double 
helix of nuclear DNA can serve as a template to replicate exactly the same nucleobase pairs. 
This function makes it possible for genetic information to be passed on to daughter cells, which 
is critical for cell division. DNA is a large molecule, composed of millions of nucleobase pairs. 
For instance, human DNA consists of about 1.5 billion nucleobase pairs. The total length of 
DNA in a single somatic cell is approximately two meters, which is remarkable considering the 
size of an average cell is only several micro meters in diameter. In addition, the DNA molecule 
is very hydrophilic due to the presence of the negatively charged phosphates on the sugar-
phosphate, behaving like a polyanion. Note, phosphodiester bonds connecting DNA backbones 
are prone to the ‘attack’ of DNA-degrading enzymes and therefore, DNA is not stable upon 
injection into human body. 
RNA 
Like DNA, RNA is assembled as a chain of nucleotides which contains a sugar-phosphate 
backbone chain and nucleobase pairs. However, the sugar for RNA is ribose and there is a C-
OH bond on the 2’-position of pentose ring. The hydroxyl bond is more reactive than the 
hydrogen bond, making RNA less stable than DNA, especially in alkaline conditions. Another 
important difference is that there is a uracil base (U) in place of thymine (T). Therefore, pairing 
nucleobases are (A=U) and (C  G) for RNA. Unlike DNA, RNA is more often found in nature as 
a short single-chain, rather than a paired double-chain. The single chain of RNA folds in on itself 
to link up its nucleobases. Therefore, not all nucleobases get partnered and RNA has a rough 
surface of sugar-phosphate backbone chain.  RNA also has different resultant three-
dimensional shapes, the most common being the hairpin loop. RNA is found in the nucleus, 
cytoplasm and ribosomes. Nuclear RNAs such as messenger RNA (mRNA) and transfer RNA 
(tRNA) are involved in protein translation, together with ribosomal RNA (rRNA). Cytoplasmic 
RNA includes micro RNA and small interfering RNA (siRNA) which act as down regulators of 
protein translation through RNA interference. Therefore, they play a complementary role with 
nuclear DNA.  
siRNA is known to target a single gene while microRNA may target to 250-500 genes. 
Therefore, siRNA possesses a 100% perfect complementary match to target specific gene with 
minor off-target exception(Mack 2007). In addition, siRNA is a right-handed double-helix which 
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usually has 21-23 base pairs with two nucleotides overhanging at 3’ ends. The space-filling 
model of the siRNA helix is shown in Figure 1.1(a). The helix of siRNA is usually found in vivo in 
the A form, which is more tightly packed than the B form. Therefore, the major groove of siRNA 
is narrower and deeper, making functional groups inaccessible for other molecules. However, 
the minor groove of siRNA is accessible for protein recognition. A siRNA comparison with DNA 
is described in Table 1.1.  
Table 1.1 Comparison of DNA and siRNA 
Properties DNA siRNA 
Full name Deoxyribonucleic acid Ribonucleic acid 
Backbone Deoxyribose and phosphate Ribose and phosphate 
Bases A, T, C, G A, U, C, G 
Base pairs  thousands  21-23 
Helix geometry B-form double-helix A-form double-helix 
Location Nucleus Cytosol 
Role Storage and transmission of genetic 
information, controlling protein 
synthesis 
Transfer of genetic code from 
nucleus to cytosol, involved in 
protein synthesis 
 
1.1.2 DNA expression and siRNA silencing 
DNA and siRNA play an essential role in regulating the amount of cellular proteins through DNA 
expression and siRNA silencing. 
DNA expression 
The main function of DNA is to express proteins, namely gene expression. The functional 
sequence of DNA in a gene corresponds to a specific protein. The process of DNA expression 
is depicted in Figure 1.2. In the nucleus of a eukaryote, the double-helix of DNA is unwound. 
One strand of the double-helix is used as a template for the production of mRNA. The other 
strand is called the coding strand because it has the same sequence as newly formed mRNA 
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(but with uracil in place of thymine). The production of complementary RNA copies from DNA 
follows the Watson-Crick base-pairing rule. This process is called transcription.  
 
Figure 1.2 DNA expressions depicting the process of DNA-RNA transcription and RNA-protein 
translation in a eukaryotic cell. 
 
During transcription, DNA is read by RNA polymerase from 3’ end to 5’ end and RNA is 
produced from 5’ end to 3’ end. In addition, only one RNA nucleotide is added to the growing 
RNA at a time. This ensures a strictly controlled process to limit error.  The RNA copies formed 
are immature because of the intervening sequences, called introns. Therefore, the introns of 
immature RNA are removed leaving the remaining regions, which are called exons. The exons 
are spliced together to produce the mature messenger RNA (mRNA) including the protein-
coding regions. Additionally, mRNA must be transported through nuclear pore into the cytosol in 
order for protein production to take place. This cytosolic process of protein production involves 
the translation of mRNA to protein. mRNA carriers encoding information for the protein is 
decoded by ribosomes during the translation process.  As the mRNA passes through and is 
read by ribosomes, the specific amino acids are carried by tRNA and chained together in order 
to synthesise proteins.  
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Proteins are essential components of a single living cell. The combination of thousands of 
proteins that genes express determines what a single cell type can do. However, in human cells, 
if a piece of DNA encoding a protein is defective, the protein will not be produced or an 
abnormal protein is produced. The inadequate or defective protein can cause a disease. 
siRNA silencing 
Complementary with DNA, the main function of siRNA is to down regulate production of specific 
proteins, a process known as siRNA silencing. siRNA silencing was first discovered in a plant in 
1997, and then demonstrated in nematodes (Caenorhabditis elegans) in 1998 (Ratcliff et al, 
1997, Fire et al, 1998). It was founded that the gene expression of a myofilament protein in the 
nematode was effectively silenced by an exogenous double-stranded RNA (dsRNA) (Fire et al, 
1998). The silencing was initialised by cleaving dsRNA to siRNA which then induced the 
degradation of the host mRNA coding for the myofilament protein (Montgomery et al, 1998).  
As proteins are produced in the cytosol, this is the location where siRNA exerts its silencing 
effect, as depicted in Figure 1.3. siRNA is naturally cleaved from dsRNA by RNAse Dicer 
following cellular presentation (Bernstein et al, 2001). In the cytosol, siRNA is associated with a 
multi-protein complex, called RNA-induced silencing complex (RISC), which is activated through 
an Adenosine triphosphate (ATP)-dependent process. RISC contains several enzymatic 
activities including a helicase, dsRNA nuclease (possibly Dicer-like) and an RNA-dependent 
RNA polymerase activity. The siRNA molecules that are associated with RISC provide the 
sequence specificity to target a particular mRNA. Therefore, following the incorporation of 
siRNA into RISC, one strand of siRNA is cleaved by the enzyme components in the RISC, while 
the other strand remains incorporated in RISC. RISC is directed by the remaining strand to 
recognise a specific mRNA, followed by an ATP-independent cleavage of mRNA (Zamore et al, 
2000) . The main components of the RISC complex are the Argonaute-2 protein, which is a 
member of the Argonaute family of proteins, responsible for mRNA degradation and single 
strand RNA formation (Hammond et al, 2000). As a consequence, the particular protein 
corresponding to the specific mRNA is silenced. Notably, the guiding strand of siRNA can be 
recycled to get involved in several rounds of mRNA degradation. Therefore, RNA silencing 
through siRNA can be long lasting.  
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Figure 1.3 siRNA silencing process including siRNA associating with RNA-induced silencing 
complex (RISC) to directly target mRNA degradation in a eukaryotic cell (Takahashi et al, 2009).  
 
1.1.3 Therapeutic effect 
Most diseases are related to a failure in production of a particular protein or through the 
production of defective proteins. Therefore, DNA and siRNA can be used therapeutically to 
regulate the production of functional protein through DNA expression and siRNA silencing. 
DNA 
To correct failure or defective proteins, an exogenous DNA sequence can be introduced into 
cells by inserting it into a plasmid vector which can initiate DNA expression. Therefore, as a 
consequence, the amount of specific protein will be increased to normal and a disease is cured. 
Plasmid vector construction has been well established (Xu et al, 2004, Nguyen et al, 2005, 
Zhang et al, 2014), which is not the focus of the present study. However, it is worth noting that 
the resultant plasmid containing the therapeutic DNA sequence has all the functions of DNA 
molecules abovementioned in section 1.1.2. 
The first clinical trial of DNA therapeutics was launched in 1990 (Blaese et al, 1995). In this 
treatment, DNA encoding adenosine deaminase (ADA) was introduced into T cells of patients 
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who had severe combined immunodeficiency (SCID). ADA is an enzyme that transforms 
adenosine (-OH) to deoxyladenosine (-H). Deoxyladenosine is DNA nucleoside A which pairs 
with deoxythymidine T in DNA double strands. In absence of ADA, adenosine accumulates in T 
lymphocytes and kills these cells, resulting in a genetic disorder known as ADA-SCID or ADA 
deficiency. Therefore, by introducing ADA-expressing DNA into T cells, the level of ADA and 
therefore the number of T cells are expected to be established to normal. Indeed, the number of 
T cells was normalized with the persistence of ADA expression, though DNA treatment ended 
after 2 years (Blaese 1995).  
The first DNA therapeutic in market, trademarked as Gendicine, occurred in 2003 in China 
(Pearson et al, 2004, Wilson 2005). The DNA in Gendicine encodes a p53 protein, called p53-
DNA. p53-DNA is a tumour suppressor gene, and is found to mutate or disappear in 
approximately 50% to 70% of human tumours. By injecting p53-DNA to patients, the exogenous 
p53-DNA can replace mutated endogenous p53-DNA which has been used for treating head 
and neck cancer. The introduction of p53-DNA has been shown to control or eliminate tumor 
cell growth by growth cycle arrest or apoptosis (Pearson 2004, Wilson 2005). In addition, p53-
DNA therapy has a synergistic effect with radiotherapy and chemotherapy. Promisingly, in 2012, 
another DNA therapeutic, trademarked as Glybera, was recommended for approval for clinical 
use in the European Union (Bryant et al, 2013, Wirth et al, 2013). Glybera is used to treat a 
disease caused by a defect in DNA encoding lipoprotein lipase which can cause 
severe pancreatitis. Besides the above market products, numerous clinical trials using DNA as 
therapeutics are ongoing, involving various diseases such as cancer, monogenic disease, 
cardiovascular disease and infectious diseases (Sakurai et al, 2001, Sheridan 2011). Among 
these, cancer is the most common disease treated by DNA as demonstrated in Figure 1.4. 
It has been suggested that cancer occurs due to DNA mutation. Mutations in two families of 
genes, namely oncongenes and tumour suppressor genes, are known to play a role in the 
pathogenesis of cancer. When an oncogene mutates, it becomes aggressive, protein-productive 
and eventually tumorous. In order to treat cancer, exogenous DNA that can suppress the 
‘growing’ of the tumorous cells can be used. Oncogenes that have been evaluated to treat 
cancer include DNA-methyltransferase (Kanai et al, 2003). DNA-methyltransferase is a major 
enzyme that determines DNA methylation. The outcome of DNA methylation is that DNA cannot 
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start the process of making proteins which turns off the DNA. Tumour suppressor genes have 
the opposite function to tumour oncogenes, by slowing down cell division, repairing DNA 
mistakes, or by inducing apoptosis. When tumour suppressor genes do not work properly, cells 
can grow uncontrollably, which can also lead to cancer. The most famous tumour suppressor 
gene is p53 and abnormalities in p53 DNA have been found in more than half of human cancers. 
Therefore, by introducing exogenous p53-DNA, tumour cells can be killed in a variety of p53-
inactivated tumour cells such as lung, colorectal, breast cancer and leukemia (Fang et al, 2003).  
 
 
Figure 1.4 Diseases addressed by DNA therapy in clinical trials. Cancer became major interest 
(Wirth et al, 2013). 
 
siRNA 
The first successful siRNA study on human and animal cell lines was carried out as early as 
2001 (Caplen et al, 2001). This lead to a rapid increase in the development of siRNA as a 
promising therapeutic platform (Timmons et al, 1998, Miyagishi et al, 2003, De Souza et al, 
2006, Pushparaj et al, 2008). Over last 16 years, much progress has been made in research 
and development in both academia and the pharmaceutical industry (Pushparaj et al, 2008, 
Takahashi et al, 2009). The very recent study has reported a first clinical effect on the reduction 
in low density lipoprotein cholesterol levels using a siRNA silencing strategy (Fitzgerald et al, 
2014). Other diseases that have been treated or that are undergoing clinical studies include 
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age-related macular degeneration, viral diseases, cystic fibrosis, metabolic diseases, ocular 
diseases and cancer (Devi 2006).  
 Of these diseases, much attention has been paid to the treatment of cancer. siRNA is generally 
used for oncogenes that encode protein kinases, e.g. epidermal growth factor receptor (EGFR) 
(Sharma et al, 2007) echinoderm microtubule-associated protein like lymphoma kinase (Kwak 
et al, 2010), and guanosine triphosphatease (Quaye et al, 2008). Increased levels of EGFR 
expression are observed in cancers of the head and neck, ovary, cervix, bladder, stomach, 
brain, breast, colon and lung, and frequently seem to confer an adverse prognosis (Nicholson et 
al, 2001, Hynes et al, 2005). EGFR has been explored to be silenced for the combinational 
treatment of non-small cell lung cancer with other inhibitors (Chen et al, 2012).  
siRNA in clinical trial includes the targets of vascular epithelial growth factor (VEGF), kinesin 
spindle protein (KSP), protein kinase N3 (PKN3) and M2 subunit of ribonucleotide reductase 
(RRM2), as described below.  
VEGF and KSP are over-expressed in numerous cancer cells, and are essential in tumour 
growth and survival. VEGF siRNA and KSP siRNA have been formulated in lipid nanoparticles 
used for intravenous administration. A decrease in microvessel density and vascular leakage 
due to VEGF knockdown, and in the formation of mitotic spindle due to KSP knockdown, was 
observed to cause tumour cell death in liver cancer mouse models (Tabernero et al, 2013). The 
following evaluation of activity and safety in patients with cancer suggests a target down 
regulation of VEGF and KSP, and complete regression of liver metastases in endometrial 
cancer. It becomes the first human trial of an RNA interference therapeutic targeting VEGF and 
KSP used for liver cancer (Tabernero 2013).  
PKN3 is used as a therapeutic target, which when inhibited resulted in the reduction of lymph 
node metastases in orthotopic prostate cancer models (Leenders et al, 2004). Aleku et al 
showed that systemic administration of Atu027, a liposomal formulation containing protein 
kinase N3 siRNA, resulted in specific protein kinase N3 silencing and a significant inhibition of 
tumour growth and lymph node metastasis in various animal models (Aleku et al, 2008). RRM2 
expression is involved in DNA replication. A transferrin receptor-targeted nanoparticle 
encapsulating a non-chemically modified RRM2 siRNA inhibits the expression of RRM2 and 
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thus prevents the proliferation of tumour cells (Davis et al, 2010). In addition, it clearly 
demonstrated that siRNA administered systemically to human patients was able to silence the 
cancer-associated gene in specifically-targeted tumour cells (Davis et al, 2010) .  
1.2 Barriers for DNA/siRNA delivery  
DNA and siRNA play their therapeutic role inside cells. It means that DNA/siRNA need to travel 
from their injection site to target cells. However, the physico-chemical environment of the human 
body makes it extremely difficult. DNA and siRNA are biological molecules which are large size 
and hydrophilic. Therefore, they will face many barriers upon administration. 
The barriers that intravenous DNA/siRNA will experience can be categorized into extracellular 
and intracellular, as depicted in Figure 1.5. The preferred route of administration for DNA or 
siRNA is intravenously because this route avoids the danger of deactivation and degradation in 
the gastrointestinal tract in oral administration. Soon after intravenous injection, DNA/siRNA is 
distributed all over the body via blood circulation. However, DNA/siRNA is exposed to degrading 
enzymes present in serum, which ‘attack’ phosphodiester bonds in the phosphate-ribose 
backbone. This presents the first barrier for DNA/siRNA delivery (barrier I). Indeed, 
systematically delivered DNA/siRNA is readily degraded by serum endonucleases, resulting in a 
short plasma half-life of < 10min (van de Water et al, 2006, Liu et al, 2007). Moreover, in serum, 
the most abundant protein is albumin. Albumin is a globular protein with a molecular weight of 
65,000 Daltons, and is ionised and negatively charged in a physiological environment. If 
negative DNA/siRNA is wrapped in a protective positively charged material, a non-specific 
interaction between the positive vector and the negative albumin would occur. As a 
consequence, the loaded DNA/siRNA, together with the positively charged carrier, will be 
recognised by the immune system and eliminated from blood circulation (Nel et al, 2009). This 
composes barrier II. Between blood vessels and tissue organs is the interstitium. To enter the 
interstitium, DNA/siRNA needs to cross the blood vessel via extravasation. To enter diseased 
tissues, such as tumours, DNA/siRNA needs to overcome physical barriers such as high 
pressure in the tumour site. Therefore, getting close to tumour cells represents the third barrier 
for DNA/siRNA delivery (barrier III). Barriers I, II, III are originated from outside of the cells and 
therefore denoted extracellular barriers.  
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 Upon reaching target cells, wrapped DNA/siRNA may undergo cell internalisation via 
endocytosis. In the process of endocytosis, DNA/siRNA is initially coated by cell membrane 
which buds off as an endocytic vesicle. The endocytosis is an active molecule uptake process. 
It does not occur randomly but requires ‘a driving force’ to initialise such as ligand-receptor 
interaction (Nel et al, 2009). Therefore, DNA/siRNA needs to be somehow decorated by ligands 
specific to receptors present on cell surface, which represents the fourth barrier (barrier IV). 
Following endocytosis, the endocytic vesicles develop into endosomes. Endosomal pathways 
have been consistently observed for delivery (Lechardeur et al, 2005, Hama et al, 2006). The 
problem with endosomes is that the pH is only 4.5 in its compartment. Moreover, endosomes, 
behaving as the stomachs of cells, possess a lot of enzymes to digest foreign particles including 
DNA/siRNA molecules. Additionally, the large size of DNA/siRNA and their hydrophillicity do not 
support endosomal escape. Therefore, DNA/siRNA is easily swallowed into endosomes, unable 
to escape, and liable to complete degradation. For the above reasons, endosomes can be taken 
as the fifth barrier (barrier V). Generally, barrier V is the most challenging and endosomal 
escape is a rate-limiting step for DNA/siRNA delivery. Numerous strategies have been 
developed to facilitate DNA/siRNA to escape from endosomes, which will be discussed in the 
following section. Once DNA/siRNA has escaped from an endosome, it is released into the 
cytosol. In the cytosol, siRNA will induce a silencing effect by binding to RISC. In contrast, DNA 
takes effect in the nucleus which is surrounded by a thick wall of nuclear membrane. Therefore, 
DNA needs to be translocated from the cytosol to the nucleus, which forms an extra barrier for 
DNA delivery (barrier VI). 
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Figure 1.5 Extracellular barriers (I, II, II) and intracellular barriers (IV, V, VI) of DNA/siRNA 
delivery. Extra cellular barriers include enzyme degradation (barrier I), non-specific interaction 
(barrier II), crossing the blood vessel wall and migration to tumour cells (barrier III). Intracellular 
barriers are uptake via endocytosis (barrier IV), degradation in endosomes (barrier V), and the 
translocation of DNA into the nucleus (barrier VI) (Scholz et al, 2012). Barrier V and VI are the 
rate-limiting steps. 
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1.3 Strategies for DNA/siRNA delivery  
In order to deliver DNA/siRNA, a vector that can overcome the above barriers is required. It is 
well known that viral vectors are highly efficient at DNA/siRNA delivery. However, the high risks 
arising from the characteristics of viral vectors seriously impede its clinical applications. It has 
been reported that a viral vector could integrate viral genes into the patient’s gene regulatory 
areas or into transcriptionally active areas, which can adversely result in insertional 
mutagenesis and oncogenesis (Donsante et al, 2001, Cesana et al, 2014). In serious cases, 
using a viral vector can be fatal. For example, in 1999, 18 year-old Jesse Gelsinger died during 
a DNA therapy trial because of vector-associated toxicity (Sibbald 2001).  
Compared with viral vectors, non-viral vectors including polymers, liposomes, 
nanoparticles/nanocapsules and carbon nanotubes are relatively safe, and could be further 
tailored according to the requirement for diverse bioactive delivery. Of non-viral vectors, lipid 
nanoparticles/nanocapsules have an advantage at loading lipophilic drugs (Huynh et al, 2009), 
while carbon nanotubes have problems associated with cytotoxicity (Varkouhi et al, 2011). As 
DNA and siRNA are highly hydrophilic and anionic, only cationic polymers, cationic lipids or a 
combination of both are focused on here. 
Generally, polymers and lipids used for DNA/siRNA delivery are cationic. Therefore, anionic 
DNA/siRNA can be condensed and packaged via electrostatic interaction. Currently, there are 
three types of related complexes reported for DNA/siRNA delivery, which is shown in Figure 1.6. 
In complex A, cationic polymers/peptides are used to condense DNA/siRNA. The resultant 
complex forms a disordered structure, denoted polyplex. In complex B, cationic lipids are pre-
prepared into liposomes that are vesicles with a single lipid bilayer. There is a strong 
electrostatic repulsion between cationic lipid molecules along the lipid bilayer. Therefore, upon 
mixing with anionic DNA/siRNA, vesicles break and rearrange into multiple bilayers to reduce 
electrostatic repulsion, resulting in DNA/siRNA being sandwiched between multilamellars. This 
complex is denoted lipoplex. Complex C is formulated from mixing a combination of cationic 
polymers and cationic lipids with DNA/siRNA. Correspondingly, the resulting complex is denoted 
lipopolyplex. 
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Figure 1.6 Non-viral vectors for DNA/siRNA delivery. Cationic polymers, cationic liposomes and 
a combination of them, used to complex DNA/siRNA via electrostatic interactions. The resultant 
complex is denoted (A) polyplex, (B) lipoplex and (C) lipopolyplex. Cationic polymers used are 
poly-L-lysine (PLL), polyethylenimine (PEI) and their derivatives. Typical cationic liposomes 
include cationic dioleylpropyltrimethylammonium chloride (DOTMA) and neutral 
dioleoylphosphotidylethanolamine (DOPE).  This figure is modified from literature (Vercauteren 
et al, 2012). 
 
It is worth noting that the abovementioned polymers, peptides and lipids can be further 
functionalised to achieve an efficient delivery for DNA/siRNA. The related strategies and 
examples are shown in Figure 1.7. Among these strategies, conjugating a poly(ethylene glycol) 
(PEG) motif onto polymers, peptides or lipids is the most popular. This is because a PEG motif 
modification could physically block the contact of serum protein with the delivery materials when 
circulating in the blood stream (Knop et al, 2010). In addition, water soluble PEG motifs cannot 
be recognised by the immune system and therefore could effectively avoid immune-related 
clearance. As a consequence, the resultant vector’s plasma half-life can be significantly 
increased. Apart from PEGylation, tailoring the size, surface charge and composition of the 
delivery vector could also achieve a reduced affinity to serum proteins (Lundqvist et al, 2008).  
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Figure 1.7 Biological barriers for DNA/siRNA delivery and the corresponding 
strategies/examples to overcome the barriers. 
 
Along with PEGylation, conjugating specific ligands onto polymers, peptides or lipids is 
generally required to improve the tissue specificity of DNA/siRNA delivery. The improved 
specificity could not only avoid non-specific toxicity resulting from a wide distribution of vectors 
in the body, but also reduce the administration dose of DNA/siRNA. Commonly used ligands 
include antibodies, galactose, endothelial growth factor (EGF), and transferrin. By decorating 
with these ligands, the delivery vector carrying DNA/siRNA will be directed to specific cells and 
endocytosed. It is worth noting that ligand-receptor mediated endocytosis is indirectly affected 
by the surface charge property of the delivery vector. It is known that the cell surface is 
negatively charged due to cell surface elements, such asproteoglycan and sialic acids 
(Mounkes et al, 1998). Therefore, the positively charged vector is preferential for contact with 
cells, which is a prerequisite for endocytosis. 
Among all strategies, endosomal escape is the key for both DNA and siRNA delivery. The 
escape from endosomes can be achieved by increasing interior osmotic pressure to swell the 
endosomal membrane using protonatable polymers/peptides. The disruptive effect of 
protonatable polymers/peptides is described as a ‘proton sponge’ effect, depicted in Figure 1.8. 
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Endosomes are the stomachs of cells and the interior is acidic (pH ~5). In such an acidic 
environment, the protonatable polymers/peptides can be heavily protonated and therefore 
distort the acidification of endosomes. As a result, more protons are actively pumped into the 
vesicles. To keep a neutral environment in endosomes, chloride ions passively diffuse into the 
endosomes, increasing ionic concentration. As a consequence, water is purged in, leading to a 
huge rise in osmotic pressure. Therefore, the endosome bursts and its contents are released.  
 
Figure 1.8 The proposed endosomal escape process of cationic polyplexes via the ‘proton 
sponge’ effect (Aied et al, 2013).  
 
In the case of DNA delivery, it has to be transported into the nucleus to achieve therapeutic 
effect. Naturally, nuclear membrane, as a physical barrier, could block molecules with a MW 
above 40 kD or with a size larger than 10 nm (Shulga et al, 2000, Strasser et al, 2012). 
However, nuclear membrane has numerous nuclear pore complex (NPC) channels that 
transport proteins in and out. The mass flow of active translocation signal molecules through a 
single NPC was reported to be 100 mD at a flux rate of up to 1,000/s (Ribbeck et al, 2001). 
Therefore, NPC can be targeted to deliver DNA to the nucleus. It was reported that protamine-
condensed DNA could be successfully delivered into the nucleus in vitro by the aid of NPC 
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targeting ligand-modified lipids (Masuda et al, 2008).Alternatively, active nuclear translocation 
signal peptides and their analogues could also be used to deliver DNA to the nucleus (Kalderon 
et al, 1984, Dingwall et al, 1991, Zanta et al, 1999).  
1.3.1 Peptides  
The peptides used to complex DNA/siRNA are generally made cationic by incorporating cationic 
amino acid residues such as, lysine, arginine and histidine. The following part mainly focuses on 
various cationic polypeptides and their application in gene delivery. The purpose is to gain an 
insight into the relationship between a vector’s structure/properties and its improved transfection 
efficiency. 
1.3.1.1 Linear polylysine and its derivatives 
Polylysine is a synthetic repeat of the amino acid lysine. It is one of the earliest and well-known 
vectors for DNA/siRNA delivery. The advantages of using polylysine as a gene delivery vector 
include its degradability, low cytotoxicity and high modifiability. The progress in solid phase 
peptide synthesis technology also makes its large-scale production possible. It has been 
revealed that molecular weight, charge ratio and functional modification could tailor its potential 
in DNA/siRNA delivery. 
The molecular weight of polylysine plays an important role in DNA/siRNA condensation and 
transfection. The most commonly used polylysines have a molecular weight in the range of 3 
000-40 000 Daltons (Laemmli 1975, Mannisto et al, 2002). Poly-D-lysine (PDL) with a molecular 
weight of 40 000 Daltons was reported to condense DNA to a doughnut and rod-like mixed 
structure; 3 to 4 layers of DNA was estimated across the doughnut and rod particles as 
detected by transmission electron microscopy (Laemmli 1975). Doughnut particles were also 
observed in others’ studies, such as  poly-L-lysine (PLL, 27 000 Daltons)/DNA complexes (Tang 
et al, 1997) and PLL/DNA complexes (20 000 Daltons) (Mannisto et al, 2002). However, in 
another study, the DNA complexed by PLL was reported to be mainly spherical as revealed by 
atom force microscopy (Wolfert et al, 1996). The different structures of PLL/DNA complexes 
revealed by atom force microscopy and electron microscopy, may be a consequence of sample 
preparation for different techniques (Tang et al, 1997).  
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Besides molecular weight, the (+/-) charge ratio of positive polylysine to negative DNA is also 
important for the formulation of the PLL/DNA complex. It was found that PLL (2 900 Daltons) 
could not condense DNA efficiently at a (+/-) charge ratio of less than 2.5 while PLL (30 000 
Daltons) condensed DNA at a (+/-) charge ratio of more than 0.6 (Mannisto et al, 2002). 
Interestingly, although at a (+/-) charge ratio of 1:1, the ζ-potential of the PLL/DNA complex was 
negative (-30 mV) and at least a 2:1 (+/-) charge ratio was required to get a positive ζ-potential 
(Zhu et al, 2014). The phenomenon is probably due to the large molecular nature of DNA and 
the relatively low condensation ability of polylysine (Mannisto et al, 2002, Zhu et al, 2014).  
The above formulations have also been investigated in terms of transfection and their intra-
cellular fates. Encouragingly, PLL with a molecular weight of 20 000 Daltons showed more 
effective transfection in vitro than that with a molecular weight of 2 900 Daltons at a 1:1 
PLL:DNA weight ratio. However, PLL at both molecular weights were less efficient than positive 
controls, polyethelyneimine (PEI), N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium 
methyl-sulfate (DOTAP) and DOTMA, respectively (Akinc et al, 2002). Further investigation 
showed that the PLL/DNA complex was taken by cells more than the positive controls. The high 
cellular uptake and low transfection of PLL was proposed to be related to intracellular events 
such as endosomal trapping. The reasonable assumption was confirmed by the low pH 
environment (4.0-4.5) of the PLL/DNA complex following cellular uptake (Akinc et al, 2002). The 
above studies indicate that PLL is not an ideal gene delivery carrier due to serious endosomal 
trapping, in spite of its excellent DNA condensation capacity and high cellular uptake 
(Lechardeur et al, 2005).  
To improve the transfection efficiency of PLL/DNA, PLL decorated with histidine groups has 
been developed. Histidine has imidazol groups with a pKa ~6. It means upon incorporation into 
endosomes (pH ~5), histidine can be heavily protonated, which would exert a ‘proton sponge’ 
effect in endosomes (Behr 1997). The ‘proton sponge’ effect of histidine has shown a positive 
contribution to polylysine used for DNA/siRNA delivery (Midoux et al, 1999, Benns et al, 2000, 
Putnam et al, 2001). It was reported that PLL grafted with poly-L-histidine (PLH) (known as 
PLH-PLL) could condense DNA to 100-300 nm (Benns et al, 2000). Further studies revealed a 
strong buffering capability for PLH-PLL but none for PLL alone. Therefore, as a consequence, 
PLH-PLL demonstrated a higher transfection efficacy in 293T cells than PLL at all equivalent 
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weight ratios with DNA. In addition, it was found that chloroquine, an endosomolytic agent, 
could further enhance the transfection efficiency of both PLL and PLH-PLL (Benns et al, 2000). 
The above study showed that endosomal escape is the key step and that the presence of 
histidine residues is beneficial for efficient DNA transfection. The efficient gene transfer derived 
from histidylated polylysine/DNA complexes was also observed by others (Midoux et al, 1999). 
In addition,  effective DNA delivery systems using conjugated imidazole groups to polylysine 
have also been studied (Putnam et al, 2001). 
Another benefit from endosomal escape mediated by histidine residues is the resulting low 
cytotoxicity (Benns et al, 2000, Putnamet al, 2001). It was reported that the relative cell viability 
was still greater than 80% at a PLL:DNA 20:1 weight ratio (Benns et al, 2000). Further 
investigation revealed that the improved endosomal escape and the reduced cellular toxicity are 
due to the imidazole groups of histidine (Benns et al, 2000, Okuda et al, 2004).  It was found 
that imidazole conjugated polylysine in varying mole ratios (73.5, 82.5, 86.5 mol % imidazole) 
condensed DNA into nanostructures <150 nm and possessed little cytotoxicity in vitro (Putnam 
et al, 2001). In addition, their transfection efficiency, as measured by luciferase protein 
expression, increased with increasing imidazole content of the polymers in a nonlinear 
relationship. The polymer with the highest imidazole content (86.5 mol %) mediated the highest 
protein expression, with levels equal to those mediated by polyethylenimine, but with little 
cytotoxicity. 
For in vivo use, histidylated polylysine was also PEGylated and was used to carry and deliver 
siRNA for silencing endogenous vascular endothelial growth factor (VEGF) expression. The 
resultant polyplexes were reported to show distinct tumour suppression in terms of macroscopic 
tumour volume and molecular analysis in HepG2 tumour-bearing mice (Zhu et al, 2014). 
The above studies suggested that linear polylysine with the appropriate molecular weight could 
efficiently complex DNA/siRNA at a certain charge ratio but exerts a limited transfection 
efficiency due to endosomal trapping. However, polylysine modified with histidine residues or 
imidazole groups could significantly improve DNA/siRNA transfection/silencing efficiency in vivo 
via ‘proton sponge’-mediated endosomal escape. 




- 39 - 
1.3.1.2 Dendritic polylysine  
Besides chemically modified linear polylysine, dendritic polylysine was also explored as a 
DNA/siRNA delivery vector. Dendritic polylysine is a dendrimer consisting of L-lysine residues 
as a branch unit. Each branching is described as one generation.  
Effect of generations of dendritic polylysine (PLL) 
Ohsaki etc synthesized dendritic polylysine of the 1st to 7th generation (Ohsaki et al, 2002). They 
found that the 3rd generation and higher could form a complex with a plasmid DNA, and the 
degree of compaction of DNA was increased by increasing the number of generations. The 
dendritic polylysine of the 5th and 6th generation, which have 64 and 128 amine groups on the 
surface of the molecule respectively, showed efficient DNA transfection in several cultivated cell 
lines. In particular, the 6th generation shows a buffering effect in a weak acidic environment. It is 
likely that the escape of the DNA complex from the endocytotic vesicle to the cytosol was 
enhanced by the ‘proton sponge’ effect of the dendritic polylysine of the 6th generation itself 
(Boussif et al, 1995, Ohsaki et al, 2002). Encouragingly, the transfection efficiency of the 6th 
generation was not seriously reduced even in the presence of 50% serum. The superior stability 
of the complex in serum was attributed to a neutral or slightly positive ζ-potential even when the 
(±) charge ratio was increased to 8 (Ohsaki et al, 2002).  
Dendritic PLL (5th/6th generation) and linear PLL 
The 5th generation of polylysine/siRNA complexes were compared with linear PLL/siRNA 
counterparts. Significantly, the 5th generation of polylysine/siRNA complexes were reported to 
show a 300-fold increase in luciferase silencing in vitro compared with linear polylysine (Byrne 
et al, 2013). Moreover, the 5th generation of polylysine/siRNA complexes had a discrete 
spherical shape while the linear polylsine/siRNA complexes were elongated and irregular, as 
revealed by atom force microscopy. These differences in shape were consistent with the lower 
(+/-) charge ratio of the 5th generation of polylysine (<5) required to complex siRNA to nano size 
(<250 nm) in comparison with the linear polylysine (<300 nm).  
In addition, Yamagata et al further compared dendritic PLL of the 6th generation and linear PLL 
(15 000 - 30 000 Daltons) in terms of their DNA condensation ability, cellular uptake, and 
transfection efficiency (Yamagata et al, 2007). Their studies showed that dendritic PLL of the 6th 
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generation formed a weaker DNA condensation than linear PLL, and that DNA binding and 
uptake into cells mediated by linear PLL was 4-fold higher. However, dendritic PLL-mediated 
DNA expression was 100-fold higher than that by linear PLL due to the ‘proton sponge’ effect 
mediated by amines of the dendritic PLL. In addition, weakly compacted DNA by dendritic PLL 
was advantageous in accessing transcription machinery in the nucleus. It is worth noting that 
dendritic PLL is suitable for in vivo application due to its low cytotoxicity. Indeed, little cytokine 
was produced by dendritic PLL after intravenous injection (Ohsaki 2002, Yamagata et al, 2007).  
Derivatives of dendritic PLL (6th generation) 
In another study, the terminal amino acids of the 6th generation dendritic polylysine were 
replaced by arginines and histidines, respectively (Okuda 2004). Interestingly, the arginine-
replaced dendritic polylysines showed 3- to 12- fold higher transfection efficiency in vitro. In 
contrast, the DNA-binding ability of histidine-replaced dendritic polylysine was significantly lower 
than that of the unreplaced polylysine, and no transfection mediated by histidine-replaced 
dendritic polylysine was observed. However, once histidine-replaced dendritic polylysine was 
mixed with the DNA under acidic conditions, transfection was observed to be as effective as the 
unreplaced polylysine.  
The above studies suggested that dendritic polylysine and its derivatives could be used as ideal 
DNA delivery vectors due to their excellent complexation, endosomal escape and release 
capacities. The terminal histidines, especially their imidazole groups, had a key role in the pH-
dependent complex formation and transfection (Okuda 2004).  
Besides DNA, the 6th generation of polylysines was also explored for siRNA delivery. 
Encouragingly, the 6th generation of polylysines was found to deliver fluorescein-labelled 
oligonucleotide into cells with high efficiency. However, a large amount of the fluorescence was 
localised and trapped in the endosomal compartment. In order to resolve this problem, the 6th 
generation of polylysines was combined with Endo-Porter which is a weak-base amphiphilic 
peptide that was expected to promote endosomal release (Summerton 2006). As expected, a 
combination of the 6th generation of polylysines and the Endo-Porter resulted in a widespread 
fluorescence in the cytosol as shown by confocal fluorescence microscopy. Moreover, the 
resulting polyplexes showed effective knockdown of several genes with low cytotoxicity, while 
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no knockdown was observed for the complex formed from either the 6th generation of polylysine 
and the Endo-Porter alone (Inoue et al, 2008). Used for siRNA delivery, the 6th generation of 
polylysines has also shown in vivo silencing promise. A significant reduction of serum low 
density lipoprotein cholesterol was observed after intravenous administration of the 6th 
generation of polylysines/siRNA complexes into diseased mice (Watanabe et al, 2009). 
1.3.1.3 Branched histidine-lysine (HK) peptides 
In an early report, highly branched histidine-lysine (HK) peptides were also explored in terms of 
DNA transfection by Mixson et al (Leng et al, 2005). It was shown that the histidine-rich tails of 
these peptides markedly improved DNA transfection efficiency in a variety of cell lines. 
Presumably, the improved transfection was attributed to the increased buffering capacity of the 
polymer. Significantly, one polymer with a histidine-rich tail was compared favourably with other 
commonly used transfection agents. The same branched HK peptides were also explored for 
siRNA delivery in the same group and it exhibited more than 80% knockdown in vitro (Leng et al, 
2005). The histidine-rich domain and the length of the terminal arms of HK peptides were 
important for siRNA delivery.  
Besides the siRNA silencing effect, the resulting complex was found to have minimal toxicity 
(Leng et al, 2005). In contrast, carriers of siRNA such as Oligofectamine and Lipofectamine 
2000 were significantly more toxic. Notably, the HK peptides with a higher content of histidines 
induced the least cytokines in vivo. As the greater pH-buffering capacity of HK peptides helps 
the release of endosomal entrapped foreign particles, it may explain why cytokine levels were 
reduced (Leng et al, 2012). 
Promisingly, these HK peptides have shown effective in vivo delivery of siRNA (Leng et al, 
2008). The target Raf-1 protein within tumours was significantly decreased after treatment with 
the HK:Raf-1 siRNA polyplexes compared to the control treatment groups. Despite the striking 
effect of the HK peptides/siRNA complex on the tumour, there was little evidence of toxicity in 
normal tissues with this therapy. Following the above success, they sought to develop a more 
effective HK carrier of siRNA by modifying them with different ligand (cyclic arginine-glycine-
aspartic acid, RGD)-pegylation patterns (Chou et al, 2011). Although the modified HK peptides 
by themselves did not form stable nanoplexes with siRNA, a combination of a highly charged 
unmodified HK peptide, H2K4b, with the modified HK peptides did form stable siRNA 
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nanoparticles. In contrast, the modified complex administered intravenously was more effective 
than the unmodified in silencing Luciferase in a tumour xenograft model. Moreover, the siRNA 
complex incorporating the highly modified peptide was the most effective at silencing its target 
in vivo. Their investigation reveals that through control of targeting ligand surface display in 
association with a steric PEG layer, modified HK peptides/siRNA complexes show promise to 
advance RNAi therapeutics in oncology and potentially other critical diseases (Chou et al, 2013).  
1.3.1.4 Polyethylenimine (PEI) 
Besides peptides, polymeric PEI is another highly investigated DNA/siRNA delivery vector. Like 
peptides, PEI contains amines in its repeating units. The idea of using PEI to deliver DNA was 
inspired by that of polycations such as lipopolyamines and polyamidoamine, which possess 
substantial buffering capacity below physiological pH, and are efficient transfection agents 
(Boussif 1995). Luciferase DNA delivery with PEI into a variety of cell lines and primary cells 
gave results comparable to, or even better than, lipopolyamines. Their hypothesis is that its 
efficiency relies on extensive endosomal buffering that protects DNA from nuclease degradation, 
and consequent lysosomal swelling and rupture that provides an escape mechanism for the 
PEI/DNA particles.  
Following the above success, Behr proposed how PEI/DNA complexes can transfect cells and 
exert its ‘proton sponge’ effect (Behr 1997). Firstly, polycation/DNA complexes enter cells by 
spontaneous endocytosis. Secondly, a complex wholly covered with positive charges interacting 
with the cell membrane will produce a high local concentration of PEl in endosomes. During 
intracellular trafficking, PEl will not only tend to inhibit the action of the lysosomal nucleases, but 
will also alter the osmolarity of the vesicle, that is ‘proton sponge’ effect of PEI. Indeed, every 
third atom of each PEI unit is a protonable amino nitrogen atom, which makes it an effective 
‘proton sponge’ at virtually any pH. As a consequence, DNA complexed with PEl will be rapidly 
released from the damaging endosomal environment. He concluded that this molecule 
constituted of PEI is a promising vector for gene therapy and an ideal structural base for 
constructing more sophisticated vectors. 
The above hypothesis has been supported by measuring protonatability of PEI. At a pH 7, 
approximately 85% of the amines of PEI remain unprotonated compared to 52% at a pH of 5 
(Suh J. et al, 1994). This buffering capacity allows PEI/DNA complexes to avoid lysosomal 
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trafficking and degradation once inside the cell. Sonawane et al. also showed reduced 
acidification and increased swelling and chloride concentration for PEI polyplexes as compared 
to those of polylysine, supporting the buffering capacity of polyethylenimine (Sonawane et al, 
2003). Akinc et al. later showed that the removal of protonable amines reduced PEI transfection 
activity 50-fold, thus quantitatively verifying the ‘proton sponge’ hypothesis (Akinc et al, 2005). 
Therefore, the ‘proton sponge’ theory has gained widespread acceptance. 
Transfection efficiency of PEI has been studied over a wide range of molecular weights. While 
Godbey et al. showed that transfection efficiency of PEI polyplexes increases with increased 
molecular weight ranging from 600 to 70 000 Daltons (Godbey et al, 1999). High molecular 
weight polymers also result in significantly higher cytotoxicity. In addition to the molecular 
weight, the degree of branching of PEI has been shown to affect DNA complex formation and 
stability. Dunlap et al. showed that linear PEI is less effective at condensing DNA compared to 
the branched form for similar molecular weights (Dunlap et al, 1997). Owing to high charge 
density, the branched polymers exhibit high transfection efficiency, and particularly PEI at a 
molecular weight of 25 000 Daltons is considered as a gold standard (Patnaik et al, 2013). 
However, a major drawback of the PEI polymers is the cytotoxicity which has limited its 
application in vivo and halted progress into clinical trials (Moghimi et al, 2005).  
1.3.2 Lipids 
Lipids are another class of synthetic materials which could be used for DNA/siRNA delivery, 
which are usually cationic. Generally, lipid needs to be prepared into liposome vesicles 
with/without other ingredients before formulating with DNA or siRNA via electrostatic interaction.  
The resultant complex is named as a lipoplex (Figure 1.6). 
The cationic lipids used for DNA/siRNA delivery are summarised in these reviews (Zhang et al, 
2004, Tros de Ilarduya et al, 2010, Balazs DA 2011). Among these lipids, DOTMA is one of the 
most famous cationic lipids, which is also the first synthetic cationic lipid that has shown 
successful DNA delivery (Felgner et al, 1987). The lipids that gives a higher in vivo transfection 
activity generally shares the following structural characteristics (Ren et al, 2000): (1) a cationic 
head group and its neighbouring aliphatic chain being in a 1,2-relationship on the backbone; (2) 
an ether bond for bridging the aliphatic chains to the backbone; and (3) paired oleyl chains as 
the hydrophobic anchor. Cationic lipids without these structural features were reported to have 
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lower in vivo transfection activity. A DOTMA/DOPE (1:1 w:w) liposome formulation, Lipofectin®, 
has been commercialised as a DNA/RNA transfection agent. 
The role of neutral DOPE in this commercial formulation is to form a non-bilayer structure with 
endosomal membrane and aid in endosomal escape. DOPE adopts a reversed hexagonal HII 
phase favourably and is widely used as a helper neutral lipid. DOPE has both a cationic amine 
and an anionic phosphate in the headgroup, described as a zwitterionic lipid. DOPE plays an 
important role in membrane fluidity and substance exchange. The endosomal membrane 
destabilisation mediated by DOPE in DNA/lipid complexes is depicted in Figure 1.9 (below). The 
cellular membrane and endosomal membrane are composed of both anionic and zwitterionic 
lipids, displaying a negatively charged surface. After forming electrostatic interactions with the 
negative cell membrane, cationic lipoplexes are endocytosed (Step 1). In the early endosomes, 
membrane destabilization results in anionic phospholipid flip-flop (Step 2). The anionic lipids 
diffuse into the complex and form a charge neutral ion pair. Eventually, the intermediate inverse 
micelles form between the opposed monolayers and assemble into an inverse hexagonal HII 
phase (Step 3). The DNA/siRNA dissociates from the complex and is released into the 
cytoplasm (Step 4).  
 
Figure 1.9 Mechanism of cellular uptake and endosomal escape of DNA/siRNA facilitated by 
non-bilayer lipid DOPE (Xu et al, 1996).  
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1.3.2.1 DOPE-containing lipoplexes 
DOPE has been widely used for novel liposomal DNA/siRNA delivery (Hirsch-Lerner et al, 2005, 
Kazunori et al, 2005, Liu et al, 2011, Goldring et al, 2012, Opstad et al, 2013). For instance, 
DOPE was formulated with a cyclen-based cationic lipid to liposomes which then were 
complexed with DNA. The resultant lipoplexes (+/- 6:1) had a slightly higher transfection in vitro 
than that of Lipofectamine 2000 (Liu 2011). DOPE was also formulated with a novel lipid 1,2-
dimyristoyl-sn-glycero-3-ethylphosphocholine (EPC) to make liposomes. The produced 
lipoplexes exhibited DNA binding and protection from DNase I degradation and concentration 
dependent cytotoxicity in vitro (Goldring et al, 2012). In addition, compared with cholesterol-
containing liposomes, the DOPE-containing liposomes were less efficient at DNA transfection.  
In another study, protamine was introduced to the EPC-derivative/DOPE/DNA formulation. The 
resultant complex showed comparable in vitro transfection to EPC itself and performed equally 
to the standard reference Lipofectamine 2000 (Opstad et al, 2013). 
1.3.2.2 DOTMA-containing lipoplexes 
DOTMA has been formulated into liposomes with Tween 80 and used to complex DNA. The 
resultant lipolexes showed the best in vivo transfection in lungs among various organs (Liu et al, 
1997). In addition, a higher (+/-) charge ratio resulted in a higher in vivo transfection in lungs 
which was correlated with cellular uptake and retention. It is worth noting that Tween 80 was 
used in the formulation because it was the best in preventing the formation of large DNA/lipid 
complexes and serum-induced inhibition of transfection activity among the surfactants they 
investigated so far (Liu et al, 1996). It was speculated that such inhibitory activity of the Tween 
80 is related to the steric barrier formed by its four branched polyethylene oxide chains on its 
head group.  
1.3.2.3 DOTMA/DOPE-containing lipoplexes 
DOTMA/DOPE liposomes and DOTMA/Cholesterol liposomes have been compared in terms of 
DNA delivery in vivo. A higher DNA transfection efficiency was observed in the lung for DOTMA-
cholesterol lipoplexes than that for DOTMA-DOPE lipoplexes (Sakurai et al, 2001a, Yoshioka et 
al, 2009). The higher transfection of DOTMA/Cholesterol/DNA complex compared with that of 
DOTMA/DOPE/DNA was also observed in ocular tissue after intravitreal injection on a rabbit 
model (Li et al, 1997). Further investigation showed that the low transfection activity of 
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DOTMA/DOPE complexes was due to their binding and fusion with erythrocytes. (Sakurai et al, 
2001a). They also speculated that the DOTMA/DOPE complexes that fused with erythrocytes 
had a large size which could embolise lung capillaries and be washed away in the blood stream 
(Sakurai et al, 2001b). Consequently, they were no longer available for efficient internalization 
by the endothelial cells. In addition, DOTMA/Cholesterol and DOTMA complexes had a stable 
lamellar structure while DOTMA/DOPE complexes had a highly curved structure with high 
fluidity, which particularly absorbs serum proteins (Li et al, 1998). These results indicate that the 
interaction with erythrocytes and the resultant toxicity depends on the properties of the cationic 
lipid vectors, which is an important factor for intravenous DNA/siRNA delivery using cationic lipid 
vectors (Sakurai et al, 2001a). 
1.3.2.4 Functionalisation of liposomes used for lipoplexes 
PEG can be physically inserted into liposome bilayers or covalently bonded to the lipid 
component of liposomes (Immordino et al, 2006). The PEGylated liposome could be further 
formulated with DNA/siRNA to form PEGylated lipoplexes. It was reported that PEGylated 
lipoplexes yielded improved transfection efficiencies in the presence of serum as compared to 
the un-modified lipoplexes (Kim et al, 2003). In addition, targeting ligands can be attached to the 
lipid or the distal end of PEG and therefore giving the resultant lipoplexes a specific targeting 
function. Transferrin has been attached to the distal end of PEG-liposomes bearing 
approximately 25 Transferrin molecules per liposome and formulated with DNA. The resultant 
lipoplexes were administered to tumour-bearing mice. It was found that such Transferrin-PEG-
liposomal formulation showed a prolonged residence time in the circulation and low 
reticuloendothelial system uptake, resulting in enhanced extravasation of DNA into the solid 
tumour tissue (Ishida et al, 2001). Moreover, the extravasated Transferrin-PEG-liposomal 
lipoplexes were internalized into tumour cells by receptor-mediated endocytosis (Ishida et al, 
2001). Haloperidol is a ligand that associates with sigma receptors that are overexpressed in 
many types of cancer. Haloperidol-modified lipoplexes have been demonstrated to mediate 
efficient targeting of DNA to sigma receptor-overexpressing breast cancer cells (Mukherjee et al, 
2005).  
1.3.3 A combination of lipids and peptides 
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Lipopolyplexes are inspired by the advantage of lipoplexes and polyplexes in cellular 
transfection. Lipopolyplexes can be prepared by mixing lipids, peptide with DNA or siRNA. The 
resultant complexes are named LPD and LPR respectively. Upon mixing, the components can 
spontaneously rearrange to form a condensed DNA/siRNA core coated by lipid membranes (Li 
et al, 1998). It is worth noting that DNA and siRNA take effect in different sub-cellular sites and 
the delivery materials that are effective for DNA are not necessarily effective for siRNA. For 
example, Mixon et al has reported that branched HK peptides that were effective for DNA 
transfection were not effective for siRNA silencing (Leng et al, 2005). Therefore, lipopolyplexes 
used for DNA and siRNA delivery will be discussed separately. 
1.3.3.1 Lipopolyplexes containing DNA (LPD) 
Synergistic effect of lipids and peptides as a LPD 
As previously mentioned, cationic liposomes can be used as promising vectors to complex and 
deliver DNA (lipoplexes). Numerous studies have proved its potential in DNA delivery (Xiong et 
al, 2011, Chen et al, 2012, Sugano et al, 2012). Unfortunately, it was found that cationic 
liposomes, alone, used for nucleic acid delivery had a dose-dependent cytotoxicity both in vitro 
and in vivo (Hofland et al, 1996, Scheule et al, 1997, Alton et al, 1999). In order to reduce the 
amount of cationic liposomes used to complex DNA, Gao et al incorporated polycations (PLL, 
protamine, spermine, decapeptide derived from SV40 T-antigen)  into lipoplex formulations and 
investigated in vitro transfection efficiency of the resultant LPD complex. Surprisingly, up to a 
28-fold increase in transfection was achieved in the presence of less liposomes (Gao et al, 
1996). The above synergistic effect of PLL and liposomes on transfection was proposed to be 
due to reduced complex size, high cationic charges and therefore enhanced cellular uptake, 
and the protection of DNA from enzymatic degradation. In addition, PLL can possibly help with 
DNA release and nuclear transport which may contribute the synergistic effect (Gao et al, 1996).  
The synergistic effect of peptides and lipids on LPD transfection has also been observed by 
other groups (Chen et al, 2010, Hart et al, 1998, Scott et al, 2001, Hyndman et al, 2004, 
Hyndman et al, 2004, Song et al, 2012). For example, in a LPD containing K16 targeting 
peptides and DOTMA/DOPE lipids, its transfection was observed to be more than 100-fold of 
the PD counterpart alone (Hart et al, 1998). The role of the DOTMA/DOPE lipids was proposed 
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to be a co-factor of enhancing transfection efficiency. The mechanism of the enhancement 
possibly involves a reduction in the extent of endosomal degradation of DNA (Hart et al, 1998). 
Yan etc. synthesized a polylysine derivative and the resultant DOTAP-containing LPD also 
exhibited higher transfection efficiency than the LD counterpart (Chen et al, 2010). 
It was also found that molecular weights of polypeptides could significantly influence their 
performance on the aforementioned synergistic effect. For example, high molecular weight 
peptides, such as PLL and protamine, were found to significantly enhance DNA transfection 
while small peptides, such as spermine and a cationic decapeptide derived from SV40 T-
antigen, were only moderately active in vitro (Gao et al, 1996). Considering increased DNA 
transfection, more attention was paid to PLL or protamine-containing lipopolyplexes (Kogure et 
al, 2004, Khalil et al, 2007, Yamauchi et al, 2010). 
Functional modification of LPD 
The purpose of functional modification of LPD is to improve its in vivo profiles, such as long-
circulation and targeting delivery at cellular level or subcellular level. The modification of LPD 
can be achieved via: 1. lipid modification; 2. peptide modification; 3. modification of other 
ingredients. Generally, a long-circulation profile could be achieved through PEGylation of either 
lipids or peptides. However, the PEGylation covering on the surface of the LPD may hinder its 
contact with cells and therefore lead to a reduced cellular uptake. To solve this problem, a 
targeting ligand is generally required. The attachment of targeting ligand onto the LPD can be 
realized through conjugation modification of lipids and peptides, which is similar to that of 
PEGylation. Currently, a combination of PEGylation and targeting ligand is a very popular 
strategy to achieve high DNA transfection efficiency. However, both PEGylation and targeting 
ligands should be ideally exposed outside of the LPD particles in order to exert their desired 
effect. 
The beneficial effect of PEGylation and targeting ligand modification of LPDs has been well 
investigated. Harvie et al compared a modified LPD with non-modified LPD composing of 
protamine and 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) lipid in terms of 
cellular binding, uptake and transfection (Harvie et al, 2003). DSPE was modified by PEG and 
RGD ligand which could target integrin receptors present on tumour cells. The resulting DSPE-
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PEG-RGD was then formulated into a LPD. Such a LPD-(DSPE-PEG-RGD) was shown to 
result in a 5-fold and 15-fold increase in cellular binding and uptake, respectively, compared 
with the unmodified LPD. Moreover, the increased cellular binding and uptake lead to a 100-fold 
enhancement of transfection efficiency in vitro (Harvie et al, 2003).  
Besides at a cellular level, the targeting delivery potential of modified LPD at a subcellular level 
was also investigated. Masuda et al developed a nuclear pore complex-targeting DNA delivery 
carrier, which consisted of protamine, ligand-conjugated cholesterol, DOPE and stearylated 
octa-arginine. The subcellular (nuclear pore complex) targeting function of the carrier is derived 
from sugar (mannose, galactose, GlcNAc) modified cholesterol, while incorporating stearylated 
octa-arginine is to achieve an improved cellular uptake of this carrier. As expected, the resultant 
LPD showed a higher transfection efficiency than the unmodified in both non-dividing and 
dividing cells (Masuda et al, 2008). Moreover, their studies also suggested that destabilization 
of the lipid structure in the LPD on nuclear membrane was closely related to nuclear 
translocation and DNA transfection activity. The above study suggested that not only DNA 
binding but also DNA release inside cells should be considered when designing a novel DNA 
delivery system.  
Apart from lipid and ingredient modification, peptide could also be functionally modified. For 
instance, the C-terminus of K16 peptide was modified with α5β1 integrin targeting motif to target 
lung tumour cells. The resulting LPD (containing DOTMA/DOPE lipids) showed a higher 
transfection in vitro than that containing K16 peptide without the targeting motif (Hart et al, 
1998), suggesting the importance of incorporating targeting ligands into LPDs. The K16 peptide 
with the α5β1 targeting motif was further decorated with a PEG motif and the resultant LPDs 
were considerably more stable, and aggregated more slowly, than a complex formulated using 
a similar peptide lacking the short PEG spacer (Pilkington-Miksa et al, 2008).  
Effect of cationic peptides on LPD transfection 
For synthetic peptides, its components and sequence can significantly affect the transfection 
efficiency of the resultant LPD. Welser et al synthesised a series of peptides containing a 
cationic condensation moiety (lysine, arginine and histidine) and a targeting moiety, and then 
formulated these peptides with DNA in a combination of DOTMA/DOPE liposomes (Welser et al, 
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2013). The transfection efficiency of the resulting LPD was compared. They found that the LPDs 
containing R-rich branched peptide and K-rich linear peptides gave better transfection while 
those containing H-rich peptides were inefficient (Welser et al, 2013).  
Besides condensational PLL and protamine, a functional protein, Tat, has also been explored in 
LPD delivery. Hyndman et al synthesized a PTD peptide (SYGRKKRRQRRRGPPCA), used for 
LPD formulation. In the presence of DOTAP lipid, the resulting LPD was taken up through 
endocytosis and showed effective transfection in vitro (Hyndman 2004). Moreover, the LPD 
possessed a higher transfection than the LD counterparts, suggesting that other processes 
such as nuclear entry and endosomal release are significant barriers to DNA transfection 
(Hyndman 2004). In the same studies, they also compared K16 peptide and K16 decorated with 
the PDT peptide (K16-PDT). Interestingly, when K16 was used in LPD, the transfection 
efficiency was less than for the K16-PDT formulation. Their results indicate that both the primary 
sequence of Tat or its derivatives, their net charge, and particle characteristics such as size and 
zeta potential, may all play a role in determining peptide enhanced transfection efficiency 
(Hyndman 2004). 
The other small cationic peptides that bind to virus DNA are also identified and used for LPD 
formulation. Cationic µ peptide (MRRAHHRRRRASHRRMRGG), is known to be associated with 
the core complex of adenoviruses. The µ peptide-containing LPDs showed a comparable 
transfection efficiency in an undifferentiated neuronal ND7 cell line with PLL or protamine, which 
is five-fold more effective than a lipoplex counterpart (Murray et al, 2001). Cationic peptide Vp1 
(MAPKRKSGVSKCETKCT) derived from the polyoma virus also enhanced LPD gene delivery 
in comparison with the corresponding lipoplexes (Wiseman et al, 2005). Vp1 possessed a DNA 
condensing region which overlapped with a classical nuclear localisation signal (NLS) region 
and was proposed to contribute to the enhancement. 
1.3.3.2 Lipopolyplex containing siRNA (LPR) 
Similar to DNA, siRNA has been attempted to be formulated in ternary lipopolyplexes, namely 
LPRs, to achieve effective silencing. As siRNA exerts its silencing effect in the cytosol, nuclear 
delivery is not necessary and endosomal escape represents the main barrier for siRNA delivery. 
Basically, fewer barriers mean simpler formulation. However, due to the small size and rigidity of 
siRNA, siRNA is usually more difficult to be condensed and delivered when compared with DNA. 
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This may explain why vectors working for DNA delivery are generally inefficient for siRNA 
delivery. Indeed, reports on LPR are not seen as much as that on LPD. However, theoretically, 
the cell targeting and endosomal escape strategies which work for DNA may be also suitable for 
siRNA delivery. 
Effect of cationic peptides on LPR silencing 
As mentioned above, endosomal trapping can lead to complete degradation of therapeutic 
siRNA. Therefore, functional vector is generally required to facilitate siRNA escape from 
endosomes after endocytosis. The escape from endosomes can be achieved by incorporating 
cell penetrating peptides into the siRNA formulation. Most of cell penetrating peptides are 
cationic peptides which contain arginine/lysine residues.  
Stearyl octaarginine (STR-R8) peptide, together with cholesteryl hemisuccinate and DOPE 
lipids, has been explored to form LPR for siRNA delivery (Nakamura et al, 2007). The resultant 
LPR was less than 100 nm, exhibiting greater than 80% luciferase silencing in vitro. In another 
study, to achieve successful silencing, cholesterol was modified with Gala peptide 
(WEAALAEALAEALAEHLAEALAEALEALAA) (Hatakeyama et al, 2009). Gala is a pH sensitive 
fusogenic peptide which is designed to interact with lipid bilayers and induce leakage of its 
contents at pH 5.0 (Subbarao et al, 1987). The resulting LPR produced more efficient gene 
silencing compared with that containing unmodified cholesterol by in vivo topical administration. 
The improved gene silencing was proved to be due to Gala peptide-mediated endosomal 
escape of siRNA after internalization (Hatakeyama et al, 2009). To further trigger cytosolic 
release, stearyl octahistidine (STR-H8) was introduced to the above STR-R8/cholesterol-
Gala/DOPE vector (Toriyabe et al, 2013). Significantly, the resulting complex showed increased 
in vitro luciferase silencing in contrast to the original vector, which was related with increased 
cytosolic release. Therefore, it would be beneficial to siRNA silencing by introducing functional 
peptide to the delivery vector. 
Targeting modification of peptides used for LPR  
Similar to DNA delivery, siRNA delivery requires disease site accumulation to maximise 
silencing and minimise cytotoxicity. The commonly used strategy is to decorate delivery vector 
with ligands that target specific receptors present on the surface of cancer cells. One of the 
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most employed receptors for siRNA delivery is integrins (Kim et al, 2009, Chen et al, 2013). 
Integrins mediate adhesion to the extracellular matrix and provide the traction necessary for cell 
motility and invasion. A wide variety of integrins contribute to tumour progression (Desgrosellier 
et al, 2010).  
A ternary LPR, composed of K16 peptide linked with a α5β1 integrin targeting motif 
(K16GACYGLPHKFCG) and the silencing effect of the resulting LPR was evaluated (Tagalakis 
et al, 2011). Significantly, such a targeting LPR showed a significant 80% silencing observed in 
vitro, similar in efficiency to the positive control Lipofectamine 2000. Furthermore, it was found 
that the LPR prepared from liposomes containing DOTMA, which has an 18-carbon alkyl tail, 
were significantly better in silencing than that containing cationic lipid with shorter alkyl tails. 
Moreover, the LPR can effectively package the siRNA to less than 100 nm in size, protect it 
from enzymatic cleavage, can be dissociated by heparin and is localised in cytoplasm following 
transfection of cells, suggesting the importance of the balance between condensation and 
release and the localisation in the cytoplasm. Therefore, the balance between siRNA 
condensation and release could be used as a factor to evaluate its efficiency as a delivery 
vector. 
Branching peptides used for LPR  
The branching of cationic peptides can affect their binding ability and therefore siRNA delivery 
and silencing. Tagalakis et al compared the LPR containing DOTMA/DOPE lipids and peptides 
with linear and branched structures regarding siRNA condensation and silencing (Tagalakis et 
al, 2013). Interestingly, they found that the LPR containing linear peptides were more 
condensed and stable than those containing branched peptide. However, the former possessed 
a lower silencing activity than the latter. Reassuringly, it suggests the importance of a balance 
between condensation and release within the cells (Tagalakis et al, 2013). 
Other strategies used for LPR 
To improve in vivo behaviour, novel strategies have been attempted. Based on the success of 
LPD containing protamine and lipids, anionic DNA was added to protamine and lipids to 
encapsulate siRNA. It was shown that the particle size of the resultant LPR was reduced by 10 - 
30% while siRNA delivery efficiency increased by 20 - 80% (Li et al, 2008). The reduced size 
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was proposed to be due to improved core compaction provided by high molecular weight DNA. 
It is worth noting that the anionic DNA used is calf thymus DNA rather than plasmid DNA 
because calf thymus DNA contains limited amounts of immunostimulating CpG motifs. The 
resultant LPRs were also decorated with PEG and anisamide as a targeting ligand of a receptor 
overexpressed in many human tumour cells. It was found that the presence of the targeting 
ligand facilitated the internalization of siRNA by tumour cells and only siRNA formulated in the 
targeted complex showed significant gene silencing activity (Li et al, 2008). In addition, the 
results of in vivo animal experiments using Xenograft lung tumour models revealed that about 
70 - 80% of siRNA formulated in the LPR accumulated in the tumour 4 hours after IV injection. 
Further investigation confirmed a 15% tumour cell apoptosis after three daily injections (1.2 
mg/kg) (Li et al, 2008). 
In their further studies, hyaluronic acid was used to replace calf thymus to work with liposomes 
and protamine to systemically deliver siRNA. The resultant LPR was also modified with PEG 
and anisamide to achieve a longer circulation and more efficient lung tumour cell targeting. The 
targeted LPR was found to show similar silencing activity compared to the calf thymus DNA 
containing LPR (Chono et al, 2008). However, the hyaluronic acid-containing LPR significantly 
improved the therapeutic window by at least 2.7-fold on metastatic tumour models. In addition, 
the hyaluronic acid-containing LPR possessed very little immunotoxicity in a wide dose range 
(0.15 - 11.2 mg/kg). They concluded that such a LPR without the presence of foreign DNA has 
a potential use in humans (Chono et al, 2008). 
Similar to the above LPR, a novel ternary complex consisting of calcium phosphate/siRNA 
precipitates covered by cationic lipids was also reported (Li et al, 2010). Compared with 
conventional LPR, acid-sensitive calcium phosphate was used to replace peptide, making a 
LCR. However, similar endosomal escape could be achieved by a calcium phosphate-mediated 
‘proton sponge’ effect. This replacement is also based on the hypothesis that after entering cells, 
LCR would disassemble in the acidic pH found in endosomes, which would increase the 
osmotic pressure, and as a consequence burst the endosome, releasing siRNA into the 
cytoplasm. In the LCRs, siRNA formed an amorphous nanoprecipitate with calcium phosphate 
coated with PEGylated lipids with or without anisamide, a sigma-1 receptor ligand for systemic 
administration. The anisamide modified LCP NP silenced about 70% and 50% of luciferase 
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activity for the tumour cells in culture and those grown in a xenograft model, respectively. The 
untargeted NP showed a very low silencing effect. It reveals that targeted delivery is important 
for in vitro and in vivo siRNA silencing (Li et al, 2010).  
The success of the above novel LPR formulation suggested that effective siRNA silencing can 
be achieved in vitro and in vivo by adjusting delivery materials and making use of modification 
strategies.  
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1.4 Aim and objectives 
The aim of the present project is to achieve efficient DNA/siRNA delivery through constructing 
multifunctional lipopolyplex carriers (LPDs and LPRs) containing novel bifunctional peptides. 
The bifunctional peptides are expected to have several key properties: condensation, protection, 
targeting, endosomal escape, and nuclear localisation for DNA. 
The bifunctonal peptides have been designed shown in the upper panel in Figure 1.10. The 
bifunctional peptides are composed of complexing moieties and a targeting moiety, connected 
by a linker. The complexing moieties are branched, denoted B. B regions are designed to be 
cationic to complex DNA or siRNA. The targeting moiety, denoted Y, is designed to target 
integrin receptors on lung cancer cells. The linker, denoted L, is designed to be degradable in 
endosomes. So the bifunctional peptides are called BLY peptides. All the BLY peptides have 
the same amino acid sequence on regions L and Y, with  differences only in region B. Region B 
is composed of either one amino acid,  histidine, arginine or lysine (denoted Series I) or a 
combination of them (denoted Series II). A schematic representation of the bifunctional peptides, 
H12BLY from Series I peptides, is shown in the lower panel in Figure 1.10. 
 
 
Figure 1.10 Structure depictions of bifunctional peptides and a representation, H12BLY in 
Series I peptides. 
 
The peptide containing lipopolyplexes are constructed by mixing the peptide and liposomes 
followed by the addition of DNA or siRNA, producing LPDs or LPRs. The liposomes are used in 
the formulation because liposomes and peptide have been shown to exhibit a synergistic effect 
on the delivery of LPDs/LPRs (Chen 2010, Hart 1998, Scott 2001, Hyndman 2004, Song 2012). 
Targeting moiety    Linker  K 
    Complexing moiety  
    Complexing moiety 
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The resultant LPDs/LPRs were proposed to have a core-shell structure as depicted in Figure 
1.11 (Mustapa et al, 2007). DNA/siRNA is condensed by the peptide, forming an inner core. The 
DNA or siRNA/peptide inner core is coated by a lipid bilayer with the targeting moiety of the 
peptide protruding outside. This structure affords the dual protection of DNA/siRNA by peptide 
and lipid bilayer, and the effective targeting of the complex. 
 
Figure 1.11 Proposed macromolecular structure of LPDs or LPRs. DNA/siRNA (yellow) 
interacts with peptide (brown) forming an inner core coated by lipid bilayer (cyan) with the 
targeting moiety of peptide protruding outside (Mustapa et al, 2007). 
 
Thereafter, another aim of the present study is to investigate the delivery potential of the LPDs 
or LPRs to cancer cells. This will be performed by incubating LPDs or LPRs with lung carcinoma 
A549 cells in vitro and assessing their biological effect, that is DNA transfection and siRNA 
silencing. The DNA transfection and siRNA silencing will be conducted in either reduced serum 
Optimem or Media containing 10% fetal bovine serum (FBS). A reporter of luciferase-expressing 
DNA and a luciferase-silencing siRNA will be used as the methodology of luciferase 
quantification which has been well established in vitro and in vivo.  
The third aim is to study the physico-chemical properties of the LPDs/LPRs and investigate their 
contributions to their transfection/silencing effect. For this reason, the condensation, release 
and protection properties of the LPDs/LPRs will be assessed by agarose gel electrophoresis. 
Particularly, the condensation will be quantified using a picogreen fluorescence assay. The size 
and the macromolecular structure of the LPDs/LPRs will also be measured using dynamic light 
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scattering (DLS) and small angle neutron scattering (SANS). For all the above studies, the 
LPDs/LPRs will be prepared in both water and NaCl solution to see the effect of salt, due to the 
presence of electrolytes in biological environments. Therefore, the physic-chemical properties of 
the LPDs or LPRs will be correlated with their in vitro biological behaviour.  
 
Chapter 2 Methodology 
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Chapter 2 Methodology 
2.1 Materials 
2.1.1 Peptide synthesis 
Fmoc-Gly-NovaSyn TGT resin (0.21 mmol·g-1, 150 mg, 31.5 μmol) was purchased from Merck 
Chemicals Ltd (Nottingham, UK). Novabiochem® Fmoc-protected amino acids were obtained 
from Merck Millipore (Darmstadt, Germany). Peptide coupling reagent O-benzotriazole-
N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) and reaction catalyst, N,N-
diisopropylethylamine (DIPEA) were supplied by Sigma-Aldrich (Pool, UK) as where piperidine, 
HPLC-grade dimethylformamide (DMF), trifluoroacetic acid (TFA), triisopropylsilane (TIPS), 1, 
2-ethanedithiol (EDT), water (HPLC- grade) and diethyl ether. 
2.1.2 Vesicle preparation 
Trimethyl [2,3-dioleyloxy-propyl] ammonium chloride (DOTMA) was obtained from Tokyo 
Chemical Industry (Tokyo, Japan). Dioleoylphosphotidylethanolamine (DOPE) was purchased 
from Avanti Polar Lipids (Alabama, US). Chloroform was supplied by Fisher Scientific 
(Loughborough, UK). 
2.1.3 DNA Transfection and siRNA knockdown  
A549 cells (adenocarcinomic human alveolar basal epithelial) were obtained from ATCC 
(Manassas, USA). A549 cells, stably transduced with the luciferase gene (Type I), were kindly 
donated by Dr Maya Thanou (King’s College London, London, UK). gWiz-luciferase plasmid 
DNA (pDNA) was purchased from Aldevron (Frago, USA). Ambion® Silencer® firefly luciferase 
(GL2+GL3) siRNA® (+siRNA) and negative control siRNA (-siRNA), InvitrogenTM, Lipofectamine 
and Lipofectamine 2000, InvitrogenTM, 4% w/v of Trypan blue in phosphate buffer saline (PBS) 
and Gibco® reduced serum medium OPTI-MEM® I were all supplied by Life Technologies 
(Paisley, UK). Luciferase assay kit was obtained from Promega (Southampton, UK). 
Bicinchoninic acid (BCA) protein assay kit was purchased from Fisher Scientific (Loughborough, 
UK). RPMI-1640 cell culture medium, 0.25% w/v trypsin/ethylenediaminetetraacetic acid (EDTA) 
solution, foetal bovine serum (FBS), 1% v/v of 100x strength non-essential amino acids, 1% v/v 
of penicillin/streptomycin antibiotic solution (10 000 U·mL-1/10 mg·mL-1), L-glutamine were 
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purchased from Sigma-Aldrich (Pool, UK). CELLSTAR® 96 well clear or white polystyrene flat 
bottom plates and CELLSTAR® T75 filter cap tissue culture flasks were supplied by Greiner 
Bio-One (Stonehouse, UK). 
2.1.4 Agarose gel electrophoresis 
Gelred nucleic acid gel stain (10 000x in water) was purchased from Biotium (Heyward, USA). 
Ribonuclease A from bovine pancreas, ribonuclease inhibitor from human placenta, 
deoxyribonuclease I (DNAse I) Type II from bovine pancreas, poly-L-aspartic acid sodium salt 
(pAsp), tris(hydroxymethyl)aminomethane hydrochloride (trizma base), agarose, 
ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA), boric acid, glacial acetic acid, 
bromophenol blue sodium salt, sucrose, magnesium chloride were all obtained from Sigma-
Aldrich (Pool, UK). Glacial acetic acid was purchased from VWR International Ltd (West Sussex, 
UK). EDTA (0.5 M, pH 8.0) solution was supplied by Promega (Southampton, UK). Tris-acetic-
EDTA (TAE, pH 7.4) buffer and tris-borate-EDTA (TBE, pH 8.3) buffer were prepared from the 
above ingredients. Picogreen fluorescence assay Quant-iTTM PicoGreen® dsDNA reagent was 
purchased from Life Technologies (Paisley, UK). Greiner CELLSTAR® 96 well black polystyrene 
flat bottom plates were obtained from Sigma-Aldrich (Pool, UK). 
2.1.5 Small angle neutron scattering  
Calf thymus DNA (ctDNA), custom-made siRNA (CUU ACG CUG AGU ACU UCG dTdT), 
described as Sigma siRNA, and D2O (>99.9% purity) were obtained from Sigma-Aldrich (Pool, 
UK). 
2.2 Methods 
2.2.1 Peptide design 
The bifunctional peptides developed in the present study consisted of a DNA/siRNA complexing 
moiety (denoted B), and a cellular targeting moiety (denoted Y), joined by a linker (denoted L) 
as shown before in Figure 1.10.  
Region B is either composed totally of histidine (H), arginine (R) or lysine (K) residues (Series 1) 
or a combination thereof (Series 2), as shown in Figure 2.1. The use of two series of peptides, 
namely Series I and II, allow the effect of single and mixed amino acid residues on transfection 
or knockdown to be compared. Moiety Y was designed to target human airway lung epithelial 
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cells and was developed after screening by phage display (unknown epithelial cell receptor) 
(Writer et al, 2004). Moiety Y is cyclic in nature due to the presence of a disulfide bond formed 
from the two cystine residues. Interpeptide disulfide bonds between two cystine residues have 
been demonstrated to stabilise peptide/DNA complexes, leading to greater transfection 
efficiency (Lo et al, 2008). Linker L has a degradable sequence -RVRR-, which has been shown 
in vitro to be cleaved by the furin enzyme in 4 h under conditions approximating those found in 
the endosome. The introduction of the enzyme cleavable -RVRR- sequence in other bifunctional 
peptides has been found to significantly increase transfection efficiency in mouse 
neuroblastoma (Neuro 2A) cells, mouse endothelial (bEND.3) cells, mouse embryonic fibroblast 
(AJ3.1) cells, human bronchial epithelial (16HBE14o-) cells, and primary porcine vascular 
smooth muscle (PVSMCs) cells of lipopolyplexes  (Mustapa et al, 2009).  
 
Figure 2.1 Two series of the bifunctional branched peptides investigated. 
 
2.2.2 Peptide Synthesis 
All peptides were synthesised by Standard Fmoc Solid Phase Peptide Synthesis (SPPS) 
methodology. SPPS synthesis was performed in reaction syringes housed in a MultiSynTech 
Syro I automated system (Witten, Germany). Fmoc-Gly-NovaSyn TGT resin (0.21 mmol·g-1, 150 
mg, 31.5 μmol) was loaded into the reaction syringes and the resin pre-swelled in 3 mL DMF 
(HPLC-grade) for at least 30 min prior to the start of the synthesis. The total volume of all 
reagents in the reaction syringe was maintained as 1.5 mL. All reagents used for the peptide 
synthesis were dissolved in DMF (HPLC-grade). The MultiSynTech Syro I automated system 
was programmed with the following automatic deprotection/coupling cycle: 
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Cycle one: deprotection 
The resin-loaded reaction syringe was filled with 1.5 mL of 40% v/v piperidine in DMF. The 
mixture contained in the reaction syringe was then automatically agitated for 20 s every minute 
for a total of 3 min after which the reagent was removed by filtration under vacuum and the resin 
was washed with DMF (4 × 1.5 mL). 0.75 mL of 40% v/v piperidine in DMF was then added to 
the reaction syringe followed by a further 0.75 mL of DMF to make a 20% v/v solution of 
piperidine in DMF. The mixture in the reaction syringe was agitated for 20 s every minute for a 
total of 10 min after which time the reagents were removed by filtration under vacuum and the 
resin was washed with 6 aliquots of 1.5 mL DMF. 
Cycle two: coupling 
The reaction syringe was next filled with the required Fmoc-protected amino acid (0.600 mL, 
0.084 M, 4 eq.), HBTU (0.600 mL, 0.084 M, 4eq.) and DIPEA (0.300 mL, 0.168 M, 8 eq.) using 
the automatic dispenser contained in the synthesizer. The resulting mixture was then agitated 
for 20 s every 3 min for a total of 40 min. The reagents were removed by filtration under vacuum 
and the resin was washed with 4 aliquots of 1.5 mL DMF. 
To achieve peptide synthesis, the above deprotection/coupling cycle was repeated until all the 
amino acids were coupled to the resin. Upon the completion of this stage of the synthesis, 3 mL 
of a cleavage solution comprising of TFA/TIPS/EDT/H2O (94:2.5:2.5:1 volume ratio) was added 
to the resin-loaded reaction syringe and the syringe was agitated for 3 h at room temperature. 
The cleavage solution was then removed from the syringe under vacuum and diethyl ether (10-
15 mL) was added to precipitate the peptide. The resultant precipitate in diethyl ether was spun 
at 4°C and 4 000 rpm for 10 min to ensure pelleting the crude peptide. The diethyl ether 
supernatant was then decanted off and the peptide pellet was washed a further twice with 
diethyl ether. The crude peptide pellet was then re-dissolved in the minimum amount of water 
and freeze-dried using a Thermo Scientific Heto PowerDry LL1500 freeze-drier (Loughborough, 
UK) to remove any solvents. In order to form the disulfide bonds via aerial oxidation, the crude 
peptide was re-dissolved in water (1 mg 10 mL-1) and stirred at room temperature for 7-10 days. 
The peptide solution was then concentrated and freeze-dried for storage prior to purification by 
HPLC. 
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2.2.3 Purification and characterisation of the peptides 
Peptides were purified and analysed via reverse phase HPLC using a Varian Prostar system 
equipped with a Model 210 solvent delivery module and a Model 320 UV detector (West Sussex, 
UK). Preparative HPLC purification was performed using a Phenomenex@ Onyx Monolithic 
Semi-Pre C18 column (100 x 10 mm, 2 µm macropore size, 13 nm mesopore size, Macclesfield, 
UK). The column was loaded with 200-400 µL aliquots of 10-20 mg mL-1 of peptide dissolved in 
water containing 0.1% v/v of TFA. The mobile phase consisted of a decreasing gradient of 
water in acetonitrile (CH3CN), both solvents contained 0.1% v/v of TFA. The precise 
experimental conditions, including mobile phase gradients, used are given below as Methods A 
and B.  
Preparative high performance liquid chromatography: 
Method A: Flow rate 9.5 mL/min; UV detection at 215 and 254 nm. Linear gradient: 5-25% B 
over 15 min. A = H2O, 0.1% v/v of TFA, B = CH3CN, 0.1% v/v of TFA. 
Method B: Flow rate 9.5 mL/min; UV detection at 215 and 254 nm. Linear gradient: 5-30% B 
over 20 min. A = H2O, 0.1% v/v of TFA, B = CH3CN, 0.1% v/v of TFA. 
The HLPC fractions containing the required peptide product were pooled and concentrated 
under reduced pressure to yield approximately 2 mL of solution prior to freeze-drying. The 
freeze-dried peptides were subsequently analysed by analytical HPLC using a Phenomenex@ 
Onyx Monolithic C18 column (100 x 3.0 µm, 2 µm micropore size, 13 nm mesopore size, 
Macclesfield, UK). The precise experimental conditions, including mobile phase gradients, used 
are given below as Methods C and D.  
Analytical high performance liquid chromatography: 
Method C: Flow rate 0.85 mL/min; UV detection at 215 and 254 nm. Linear gradient: 5-90% B 
over 20 min. A = H2O, 0.1% v/v of TFA, B = CH3CN, 0.1% v/v of TFA. 
Method D: Flow rate 0.85 mL/min; UV detection at 215 and 254 nm. Linear gradient: 5-90% B 
over 30 min. A = H2O, 0.1% v/v of TFA, B = CH3CN, 0.1% v/v of TFA. 
The analysis of the chromatograms was conducted using Star Chromatography Workstation 
software Version 1.9.3.2. ESI-MS analysis of the purified peptides was performed on a Waters 
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Acquity Ultra Performance LC/MS machine (Elstree, UK). The HPLC and ESI-MS spectra of the 
peptides are shown in Appendix I. 
2.2.4 Vesicle preparation 
Vesicles composed of cationic DOTMA and the neutral helper DOPE at a 1:1 molar ratio were 
prepared using a modification of the thin film method. Specifically the required amount of 
DOTMA and DOPE were weighed out into small glass vials, followed by the addition of 
chloroform (3 mL) to dissolve the lipids (total quantity ~ 2 mg). The chloroform was then 
removed from the clear lipid solution to leave a thin lipid film by storing the lipidic solution under 
vacuum overnight. The resulting thin lipid film was then hydrated by agitation with the required 
amount of ultrapure, double distilled water (resistivity >18 ·cm) from Thermo Scientific 
Barnstead water purification system EASYpure® UV/UF (Loughborough, UK) with or without 
NaCl (up to 0.12 M) to make a crude lipidic suspension, of concentration with respect to 
DOTMA of 1 mg mL-1. The resulting crude suspension of vesicles in water was probe sonicated 
at room temperature for 10 min using a SKL-950WT ultrasonic cell crusher (Ningbo Haishu 
Sklon Electronic Instrument Co. Ltd., Ningbo, China) fitted with a microtip operating at 30% of 
maximum output to produce a more homogeneous vesicle suspension. In the case of vesicles 
made in NaCl solution, the crude vesicle suspension was water bath sonicated at 80% of 
maximum output and 40° for 10 min using a Fisherbrand precision general-purpose water bath 
(Loughborough, UK). Note that the use of bath sonication rather than the probe sonication for 
the vesicles made in 0.12 M NaCl solution used due to their tendency to aggregate/grow when 
probe sonicated. 
2.2.5 Lipopolyplex preparation 
Lipopolyplexes consisting of lipids, peptide and either DNA or siRNA (LPDs and LPRs, 
respectively) were prepared via a self-assembly process, in which the order of addition of the 
various components was controlled. It has previously found that the order of addition of the 
various components in a ternary complex had an impact on the biophysical property and 
biological activity of the resulting complex (Gao et al, 1996, Garcia et al, 2007, Zeng et al, 2007). 
Consequently, unless otherwise stated, the method described below was used for preparation 
of both LPDs and LPRs.  
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In brief, peptide solution was first added to an equal volume of vesicle suspension. Next an 
equal volume of DNA/siRNA solution was added, and the mixture was gently mixed. All 
LPDs/LPRs were prepared by diluting a stock suspension of vesicles composed of a 1:1 molar 
ratio of DOTMA:DOPE (containing 1 mg mL-1 of DOTMA) in water or an aqueous NaCl solution 
(containing up to 0.15 M NaCl). In addition 1 mg mL-1 stock solutions of either peptide, DNA or 
siRNA in water were also used. Note, that the reason that the stock solutions of peptide, DNA 
and siRNA were prepared in water is that so they could be diluted with NaCl solution to give the 
required final NaCl concentration. Unless otherwise stated, LPDs were prepared at 
lipid:peptide:DNA charge ratios of 0.5:6:1 while LPRs were made at lipid:peptide:siRNA charge 
ratios of 0.5:12:1. In all cases, a minimum of 15 min standing time of the lipid:peptide:nucleic 
acid mixture at room temperature was allowed to ensure complexation before use. 
Binary lipoplexes (LDs/LRs) and polyplexes (PDs/PRs) were also prepared to compare their 
ability to tranfect/silence protein production, respectively using the corresponding ternary 
lipopolyplex. The lipoplexes and polyplexes were prepared by adding the aqueous DNA/siRNA 
stock solution to an equal volume of vesicle suspension or peptide solution, respectively 
followed by a gentle mixing and a minimum of 15 min standing time at room temperature before 
use of the complex. LDs/LRs and PDs/PRs were made at the same L:D/R charge ratio as in the 
corresponding LPDs/LPRs. 
2.2.6 Cell culture 
A549 cells and luciferase-transduced A549 cells were maintained in T75 tissue culture flasks in 
RPMI-1640 media supplemented with 10% v/v of FBS, 1% v/v of 100 x strength non-essential 
amino acids (NEAA), 1% v/v of 200 mM L-glutamine solution, and 1% of v/v 
penicillin/streptomycin solution (10 000 IU·mL-1/10 mg·mL-1). The cells were kept at 37°C in a 
CO2 incubator (Nuaire Autoflow CO2 Air-Jacketed Incubator, Plymouth, USA) with an 
atmosphere of 90% humidified air and 5% carbon dioxide. The cells were passaged twice a 
week when ~70% confluent in a Howorth Airtech Safety cabinet (Model SC II, Class 2, 
Farnworth, UK). Briefly, the spent RPMI-1640 media was removed under reduced pressure and 
the single layer of cells remaining washed using a 1 mL aliquot of 0.25% w/v of trypsin-EDTA 
solution. After removal of the preliminary trypsin-EDTA wash, a further 2 mL of trypsin-EDTA 
solution was added to detach the cells from the flask with the aid of an orbital incubator (Stuart 
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Orbital Incubator Model SI 50, Stafford, UK) at 120 rpm, 37°C for ~2 min. 3 mL of warm RPMI-
1640 media was then added to dilute the trypsined cell suspension and the resulting suspension 
centrifuged at 1 500 rpm and 20°C for 5 min (Beckman CounterTM AllegraTM X-22R Centrifuge, 
London, UK). The resultant supernatant was decanted and the remaining pellet of cells gently 
re-suspended in 10 mL of warm RPMI-1640 media until uniform suspension of cells was 
obtained. An aliquot of the cell suspension was then mixed with an equal volume of 0.4 %v/v 
trypan blue in water and the density of cells counted using a cell counter (CountessTM 
Automated Cell Counter, Life Technologies, Paisley, UK) while the shape of the A549 cells was 
observed under an inverted microscope (Hund Wetzlar Wilovert S Inverted Phase-Contrast 
Microscope, Welzlar, Germany). 1 mL of A549 cell suspension or 1.5 mL of luciferase-
transduced A549 cell suspension (both at an ~ density of 1 x 106/mL) was then transferred to a 
new flask containing 13 mL of warm, fresh RPMI-1640 media and the cells (~ density of 1 x 
105/mL) incubated in a CO2 incubator with 90% humidified air and 5% CO2 atmosphere at 37°C. 
2.2.7 Transfection/knockdown of lipopolyplexes 
25 µL of lipopolyplex (LPD/LPR) suspension containing 0.25 µg DNA or 0.07 µg siRNA, 
respectively were prepared as described above, except that each component was diluted in 
different preparation media including water, NaCl solutions (up to 0.15 M), PBS (pH7.0), and 
OptiMEM. The above LPD/LPR suspension was 4-fold diluted with transfection media, e.g. 
OptiMEM or RPMI-1640 media before use for the below transfection. A549 cells or luciferase-
transduced A549 cells were seeded in 96-well transparent plates at a density of 1.2×104 cells 
per well for 24 h prior to transfection with LPDs or knockdown with LPRs, respectively. After 
removal of the spent media, a 50 µL of OptiMEM or RPMI-1640 media was added to each well 
followed by the addition of 50 µL of the LPDs/LPRs (25 µL of LPDs/LPRs diluted with 25 µL of 
OptiMEM or RPMI-1640 media). All lipopolyplexes were seeded at 0.25 µg/well of pDNA or 50 
nM/well of siRNA, in triplicate, and unless otherwise stated, incubated at 37°C in an atmosphere 
of 90% humidified air and 5% CO2 for 4 h for LPDs and 24 h for LPRs. After removal of the 
LPD/LPR suspension from the cells, 100µL of growth media was added to the cells which were 
maintained at 37°C in an atmosphere of 90% humidified air and 5% CO2 for a further 44 h for 
LPDs or 24 h for LPRs. After which time, the cells were rinsed with 50 µL of PBS (pH 7.0) and 
lysed with 50 µL of lysis buffer containing 200 nM Tris-HCl (pH 7.8), 2 mM EDTA and 0.05% v/v 
Triton X-100 using orbital shaking at 150 rpm for 1 h at room temperature. In order to further aid 
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the lysis process, the cells were frozen at -80 °C for 30 min before being defrosted and agitated 
in orbital incubator for a further 1 h at room temperature and used for determination of luciferase 
activity and protein assay. 
Luciferase activity, expressed as relative light units (RLU) per milligram of protein (RLU/mg 
protein), was measured using a Promega luciferase assay kit and a Fisher Scientific BCA 
protein assay kit in accordance with the manufacturers protocol.  
In brief for the luciferase assay,  30 µL of cell lysate was transferred to 96-well white plates and 
luminescence measured at a gain value of 2000 using an a FLUOstar Omega luminometer 
(BMG LABTECH GmbH, Ortenberg, Germany) with an autofeeding system delivering 100 µL of 
the reconstituted luciferase assay reagent into each well containing cell lysate. Measurements 
were made in triplicate and the mean and SD calculated. 
Protein content was measured using placing a 20 µL aliquot of the remaining cell lysate in a 96-
well transparent plate and mixing with 200 µL of protein assay reagent (Promega luciferase 
assay kit) and incubating at 150 rpm, 37°C for 30 min before reading absorbance at 562 nm 
using a SpectraMax 190 plate reader (Molecular Device, USA). Measurements were performed 
in triplicate allowing the mean and SD to be calculated. 
The biological activity of LPDs was evaluated by determining the expression of the luciferase 
gene, expressed as RLU/mg protein. By contrast, the biological activity of LPRs was evaluated 
by determining the silencing (or knockdown) of the luciferase gene, expressed as the RLU/mg 
protein in comparison to a negative siRNA control, designated as 100% luciferase gene 
expression. Lipofactamine and Lipofectamine 2000 were used as positive control for the 
transfection/knockdown of the LPDs/LPRs. 
2.2.8 Agarose gel electrophoresis of LPDs/LPRs 
The biophysical properties of the LPDs/LPRs were assessed by agarose gel electrophoresis. 
LPDs and LPRs were prepared as described above. The lipopolyplexes tested contained either 
0.25 µg of pDNA or 0.1 µg of siRNA and were dispersed in 10 µL of ultrapure double distilled 
water or aqueous NaCl solution (up to 0.12 M). LPDs were run in 0.8 % w/v of agarose gel in 
tris-acetic-EDTA (TAE, pH 7.4) buffer containing 40 mM of tris, 20 mM of glacial acetic acid and 
1 mM of EDTA. In comparison, LPRs were run in 2.0% w/v of agarose gel in tris-borate-EDTA 
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(TBE, pH 8.3) buffer containing 89 mM of tris, 89 mM of boric acid and 2 mM of EDTA. The 
LPDs/LPRs were treated as described below.  
Extent of DNA/siRNA complexation in LPDs/LPRs After standing at room temperature for 15 
min after preparation, 10 µL of the LPDs or LPRs were mixed with 2 µL of gel loading buffer 
containing 40% w/v of sucrose and 0.25% w/v of bromophenol blue. 
Release of DNA from LPDs Release of DNA from the ternary complexes was assessed by first 
adding 0.625 µL of a 10 mg mL-1 aqueous polyaspartic acid (pAsp) sodium salt solution to 10 µL 
of a LPD suspension. 2 µL of gel loading buffer was then added to the resultant mixture and the 
whole same added to the gel.  
Release of siRNA from LPRs Release of siRNA from the ternary complexes was assessed by 
first adding 1.25 µL of a 1 mg mL-1 aqueous pAsp sodium salt solution to 10 µL of a LPR 
suspension, respectively. 2 µL of gel loading buffer was then added to the resultant mixture and 
the whole same added to the gel.  
Protection of DNA in LPDs The extent of protection afforded to DNA by incorporation into a 
ternary complex was determined by pre-treating 10 µL of a LPD suspension with 0.5 µL of a 0.1 
M solution of MgCl2 in water and then mixing with 0.5 µL of a 500 U mL-1 aqueous solution of 
DNAse I followed by incubation at 37oC for 10 min. 1.25 µL of a 0.5 M aqueous solution of 
EDTA was added and the resulting mixture incubated for 10 min at room temperature to ensure 
complete deactivation of the DNAase I enzyme, after which time 0.625 µL of a 10 mg mL-1 pAsp 
aqueous solution was added to release any DNA remaining associated with the LPDs for 
detection on the agarose gel. The LPD suspension was then mixed with 3 µL of gel loading 
buffer. 
Protection of siRNA in LPRs The extent of protection afforded to siRNA by incorporation in a 
complex was determined by incubating 10 µL of a LPR suspension with 0.4 µL of a 0.1 mg mL-1 
aqueous solution of RNAse A at 37oC for 30 min. 0.4 µL of an aqueous solution of RNAse 
inhibitor (45 units µL-1) was then added and the resulting mixture incubated at room temperature 
for 10 min to ensure complete deactivation of the RNAse A enzyme. 1.25 µL of a 1 mg mL-1 
aqueous solution of pAsp was then added to the mixture to release any siRNA remaining 
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associated with the LPRs for detection on the agarose gel. The LPR suspension was then 
mixed with 3 µL of gel loading buffer. 
Finally, both the treated LPDs and LPRs were loaded on to the agarose gel containing 3 µL gel 
red. The electrophoresis was performed at 80 mV (Fisher Brand Model HU12 electrophoreses 
chamber, Loughborough, UK) for 40 min and the gel visualized under UV light illumination using 
an Alphalmage EP MultiImage Light Cabinet (Randpark Ridge, South Africa). Uncomplexed, 
free DNA/siRNA and the enzyme-treated uncomplexed, free DNA/siRNA were used as controls. 
Each gel was repeated on more than one occasion to ensure reproducibility. 
2.2.9 Picogreen fluorescence assay of LPDs/LPRs 
A picogreen fluorescence assay was performed to determine the extent of 
condensation/complexation of DNA/siRNA in the LPDs/LPRs. When the LPDs were made in 
water, 0.2 µg of pDNA was used per well in 96-well black plates, while when the LPDs were 
prepared in a 0.12 M NaCl aqueous solution, only 0.1 µg/well of DNA was used due to the 
enhancing effect of salt on picogreen fluorescence (Georgiou et al, 2006). However, as there 
was no fluorescence enhancement due to NaCl, for the LPRs 0.2 µg of sigma siRNA was used 
in both water and 0.12 M NaCl conditions. This could be due to the small size of siRNA in 
comparison with DNA, supported by the enhanced picogreen fluorescence observed for the 
whole DNA molecules rather than its fragments (Georgiou 2006). Two protocols were used to 
assess the extent of picogreen-binding to the LPDs/LPRs. 
Protocol 1, 100 µL of LPDs/LPRs were prepared as described in Section 2.2.5. After 
preparation, 50 µL of picogreen reagent (namely 1:150 v:v picogreen in 3 x tris-EDTA (TE) 
buffer) was added to the LPD/LPR suspension and incubated at room temperature for 5 min 
before its fluorescence was determined as described below.  
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Protocol 2, 50 µL of DNA/siRNA solution was mixed with 50 µL of picogreen reagent (1:150 v:v 
picogreen in 3 x TE buffer) and the resulting solution used to prepare 150 µL of LPD/LPR 
suspension as described in Section 2.2.5. After preparation the suspension was incubated for 5 
min at room temperature before its fluorescence was measured as described below. 
For the picogreen complexation experiments, the lipid:DNA/RNA charge ratio was fixed at 0.5:1 
while the peptide:DNA/RNA charge ratio varied in the range of 18-1:1 (i.e. 1:1, 2:1, 4:1, 6:1, 9:1, 
12:1, 18:1).  
The fluorescence associated with the ternary complexes was measured at an excitation 
wavelength of 485 nm and an emission wavelength of 520 nm with a gain of 1000 using a 
FLUOstar Omega fluorimeter (BMG LABTECH GmbH, Ortenberg, Germany) equipped with a 
plate reader. Any DNA/siRNA not incorporated in the lipopolyplexes was quantified and 
expressed as relative fluorescence units (RFU) compared to the free DNA/siRNA control, which 
was denoted as 100% RFU in order to normalise the fluorescence signal. All experiments were 
performed in triplicate and the mean and SD calculated. 
2.2.10 Apparent hydrodynamic size and ζ-potential of LPDs/LPRs 
50 µL of LPD/LPR suspension containing 0.5 µg of pDNA/1.25 µg of Sigma siRNA, respectively 
was prepared as described above. The apparent hydrodynamic size of the LPDs/LPRs in 
suspension was measured without dilution using a Malvern low-volume quartz cuvette, while the 
determination of ζ-potential was performed by diluting 50 µL of the LPD/LPR suspension with 
either 900 µL of ultrapure double distilled water or an aqueous NaCl solution, as appropriate, 
and measuring using disposable Malvern capillary cells using a Malvern Nano ZS Zetasizer 
(Worcestershire, UK) at a back scattering angle of 173° at 25 ± 0.1 °C. At these concentrations 
the number of particles was sufficiently low to ensure the absence of any inter-particle 
interactions interfering with the measurement by dynamic light scattering.  All samples were 
measured in triplicate and the mean and SD value of the apparent hydrodynamic size and the ζ- 
potential calculated. 
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2.2.11 Small angle neutron scattering  
SANS (small angle neutron scattering) studies were performed on the instruments LoQ and 
SANS2D with pulsed neutron source at ISIS (Rutherford-Appleton Laboratories, Didcot, UK).  
LOQ uses neutrons of wavelengths 2.2 to 10 Å, which are separated by time-of-flight and 
recorded at a 64 cm2, two-dimensional detector at a fixed distance of 4.1 m from the sample. 
This setup gives a scattering vector (4/)sin(/2) in the range of 0.008 Å-1 to 0.22 Å-1. SANS 2D 
uses neutrons of wavelengths 2 to 14 Å, which are separated by time of flight and recorded by a 
96.5 cm square, two-dimensional detector at 4 m from the sample. The instrument set up gives 
a scattering vector in the range 0.0045 ≤ Q ≤ 0.8 Å-1.  The SANS and the transmissions 
(TRANS) of the samples were measured separately on LoQ while they were simultaneously on 
SANS2D. In the present study, a 12 mm circular beam was used for the static neutron 
scattering measurements and an 8 mm circular beam for the stopped flow measurements.  
2.2.11.1 Experimental and data collection 
Before any sample was measured, the instrument was first calibrated with a substance TK49 
whose scattering was known. For the SANS measurements, the LPDs/LPRs were freshly 
prepared as described in Section 2.2.5. Irrespective of the method of preparation, unless 
otherwise stated, the final concentration of the DNA/siRNA in the LPD/LPR suspension was 0.1 
mg mL-1 while the DNA/siRNA concentration in the LD/LR suspension was 0.05 mg mL-1. The 
parent vesicle suspension, comprising of a 1:1 molar ratio of DOTMA/DOPE, was prepared 
using either 1 or 2 mg mL-1 DOTMA in D2O or NaCl in D2O solution (at NaCl concentrations of 
up to 0.12 M). The aqueous solutions of peptide and ctDNA/Sigma siRNA were prepared in D2O 
at concentrations of 4 and 1 mg mL-1, respectively.  
The SANS of the various samples and their corresponding solvents were measured in disk-
shaped fused silica banjo cells of 2 or 1 mm path length depending upon the D2O content of the 
sample being measured, with samples containing greater than 50 vol% D2O being  measured in 
2 mm path length cells. On LoQ, the SANS of vesicles and the LPDs/LPRs were counted for 30 
and 40 µA, respectively, while the TRANS were counted for 10 µA. On SANS2D, the SANS and 
TRANS of all samples and their corresponding solvents were counted for 20 µA. All samples 
and their corresponding solvents were measured at 25 ± 0.1°C. After the SANS measurements, 
the LPDs/LPRs were recovered, diluted with an equal volume of either OptiMEM or media 
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containing 10% v/v FBS and the SANS measured in 1 mm path length banjo cells due to the 
presence of a high concentration of H2O. Appropriate solvents were measured.   
The scattering intensity, I(Q), of the samples as a function of the scattering vector, Q = 
(4π/λ)sin(θ/2) where sin(θ/2) is the scattering angle, was determined by normalising the 
scattering to the appropriate sample transmission after subtraction of the scattering from the 
relevant solvent also normalised to its corresponding transmission.  
2.2.11.2 Data analysis and model fitting 
The fitting of the SANS data always included flat background corrections to allow for any 
mismatch in the incoherent and inelastic scattering between the sample and the solvent, with 
the levels of the fitted background being checked to ensure that they were physically 
reasonable. The SANS data for the DOTMA:DOPE vesicles and LPD/LPR complexes dispersed 
in D2O were routinely modelled either assuming a mixture of (isolated/single) infinite planar 
(lamellar) sheets with or without one-dimensional paracrystals (stacks) to account for the 
presence in the sample of any multilamellar vesicles. When modelling the vesicles and 
LPD/LPR complexes dispersed in D2O as (single) lamellar sheets, the fits to the SANS data 
were obtained by the least-squares refinement of three parameters, namely L, Rσ, and the 
absolute scale factor (together with the background, as described above), where Rσ is the 
Lorentz correction factor which provides information about the extent of rigidity/curvature of the 
lamellar sheets. Unless otherwise stated a Rσ of 300 Å was used. In this study the 
polydispersity on the thickness of the bilayer (σ(L)/L) was fixed at 0.1. When stacks were added 
to the (single) lamellar sheet model, the fit to the SANS data was obtained by least-squares 
refinement of seven parameters, namely, the mean bilayer thickness (L), the Lorentz factor (Rσ), 
the number of bilayers in the stack (M), their mean separation or d-spacing (D), the width of the 
Gaussian distribution in the plane, (σ(D)/D), and the absolute scale factors for the unilamellar 
and multilamellar vesicles. In the present study, σ(L)/L was again fixed as 0.1 and σ(D)/D at 
0.05, with a Rσ of 300 Å was used. In addition, when modeling the SANS data using a mixed 
population of sheets and stacks, L, σ(L)/L, and Rσ were constrained to be the same for the 
isolated/single and stacked lamellae, a not unreasonable assumption. If no Bragg peak was 
seen in the SANS data, it was fitted using a stack with a maximum of 2 bilayers. In such cases 
the data was fitted using a higher number of bilayers comprising the stacks to ensure that it did 
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not improve the quality of the fit obtained. For all models, the least-squares refinements were 
performed using the model-fitting routines provided in the FISH software. 
2.2.12 Small angle neutron scattering with stopped flow mode 
2.2.12.1 Experimental 
The kinetics of the interaction of the formation of the LD/PD and lipopolyplexes were studied on 
SANS2D using stopped flow experiments employing a Bio-Logic SFM-400 (Claix, France) fitted 
with a neutron-scattering observation head and Bio-Kine software (Figure 2.2).  
 
Figure 2.2 SANS stopped flow apparatus consisting of an observation/measurement cell and 
four x 10 mL injection syringes. 
 
SANS measurements were performed at 298 ± 0.1 K, using an 8 mm diameter neutron beam 
and in event mode. Equal volumes (300 µL) of any two of the following systems either (a) 
DNA/RNA solution (0.1 mg/mL for LDs/Rs and 0.2 mg/mL for LPDs/Rs) in D2O, (b) vesicle 
suspension (for LDs/LRs), (c) a mixture of vesicle suspension and peptide (for LPDs/LPRs) or 
(d) D2O were injected into a 1 mm path length measuring cell (Hellma, Essex, UK) at a flow rate 
of less than 2 mL/s to produce the required sample and the SANS measured for a total of 10 
min with the last acquisition being measured for 30 minutes. (For the LPDs/LPRs the charge 
ratio of L:P:DNA/RNA was fixed at 0.5:6:1 while for the LDs/Rs, the charge ratio of L:DNA/RNA 
was fixed at 2:1.)  Note that the total volume injected was more than the volume of the 
measuring cell to ensure complete removal of the previous sample. A D2O background was 
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subsequently subtracted from all data sets. Each experiment was repeated at least 15 times, 
and the corresponding (retrospectively) time-sliced data summed to give SANS profiles with 
acceptable statistics. A series of long time course experiments were performed to model static 
measurements. Each individual kinetic SANS run was time-sliced at the desired interval and 
each time-slice summed (n = 15) using the MantidPlot software.  




Chapter 3 Lipopolyplexes containing DNA  
3.1 Results  
3.1.1 In vitro transfection of lipopolyplexes  
To evaluate the biological effect of the constructed lipopolyplex vector (LPDs), the in vitro 
transfection efficiency is assessed by measuring the luciferase unit produced by lung carcinoma 
A549 cells. The effect of the preparation (mixing protocols) and formulation (+/- charge ratio) of 
the LPDs is evaluated, followed by the transfection factors (incubation time). More importantly, 
the effect of the preparation aqueous solutions for the LPD preparation and the transfection 
medium for cell incubation have been thoroughly investigated, in view of the presence of 
electrolytes and serum in the body. Therefore, the present study is more likely to be related with 
the in vivo transfection. 
3.1.1.1 Preparation of lipopolyplexes 
The effect on transfection in A549 cells and lipopolyplex structure on the order of mixing of each 
component of the LPD was investigated. Series I and II peptides, H12BLY and (HR)6BLY, 
respectively were selected for this study. Mixing protocols 1 and 2 looked at first adding either 
peptide or DNA solution to the vesicle suspension. In protocol 1 (denoted LPD) an equal 
volume of peptide solution and vesicle suspension were mixed (peptide solution added to 
vesicle suspension) followed by the addition of an equal volume of DNA solution, (this is the 
order of mixing has been routinely used by other researchers to prepare LPDs). In contrast in 
protocol 2 (LDP), DNA solution was added to the equal volume of vesicle suspension followed 
by the addition of an equal volume of peptide solution. Mixing protocols 3 and 4 investigated 
first adding either vesicle suspension or DNA solution to peptide solution. In protocol 3 (PLD), 
vesicle suspension was added to an equal volume of peptide solution, followed by the addition 
of DNA solution while in protocol 4 (PDL) DNA solution was added to the equal volume of the 
peptide solution followed by the addition of an equal volume of vesicle suspension. Mixing 
protocols 5 and 6 examined first adding peptide solution and DNA solution to the suspension of 
vesicles. In protocol 5 (DLP), vesicle suspension was first added to an equal volume of DNA 
solution and the resulting solution add to vesicle suspension. In protocol 6 (DPL) peptide 
solution was added to an equal volume of DNA solution which was then mixed with an equal 
volume of vesicle suspension. 




For this part of the study, both the vesicle suspension and the resulting LPDs were prepared in 
water. In order to indicate the use of water in preparation of the vesicles and resulting LPDs, the 
following nomenclature was used, VwLPDw. In addition, the LPDs studied here were prepared 
at a lipid:peptide:DNA charge ratio of 0.5:6:1 and the transfection of the LPDs was performed in 
the presence of OptiMEM (LPDs mixed with OptiMEM such that the final composition contained 
25% v/v of the LPD suspension. OptiMEM is a commercially available, reduced eagle serum 
used to maintain normal cell growth and is commonly used for gene transfection. As can be 
seen in Figure 3.1(a), the A549 cells incubated with the negative control of naked DNA 
exhibited no luciferase expression and therefore no transfection efficiency. In contrast, A549 
cells incubated with the commercially available, positive control, Lipofectamine 2000, expected 
exhibited a high level of luciferase expression and therefore transfection efficiency. All of the 
binary complexes (i.e. LPs and PDs) investigated, with the exception of the PD containing 
(HR)6BLY, resulted in a poor level of luciferase expression in the A549 cells. In contrast, some 
of the LPDs resulted in the production of good levels of luciferase expression in the A549 cells, 
albeit not as great as that achieved after incubation with Lipofectamine 2000. Interestingly, 
regardless of the protocol used to prepare the LPDs, LPDs prepared using the Series II peptide, 
(HR)6BLY, exhibited a greater level of transfection efficiency than those prepared using the 
Series 1 peptide, H12BLY. Furthermore, when comparing data from A549 cells incubated with 
LPDs prepared using (HR)6BLY but using different mixing protocols, differences in luciferase 
expression were observed. Note that corresponding differences between LPDs containing 
H12BLY but prepared using the different protocols was not clear due to the very low levels of 
luciferase production obtained. When examining the levels of transfection resulting from 
incubation with the LPDs containing (HR)6BLY, it was clear that those LPDs made following 
protocols 1, 3, 4 and 6 demonstrated a much higher level of transfection efficiency than those 
prepared using protocols 2 and 5. As a consequence mixing protocol 1 was used in the 
following study, unless otherwise stated. Consideration of the order of mixing shows that the 
LPDs that result in the lowest levels of transfection both involve mixing the DNA and vesicle 
suspension prior to mixing with the peptide solution, suggesting possibly that LD complexes as 
opposed to LPDs prepared using this methodology. 
  









Figure 3.1 (a) levels of luciferase transfection and (b) protein assay after 24+24h incubation of 
A549 cells with LPDs prepared using different protocols to examine the effect of order of mixing: 
1 = LPD; 2 = LDP; 3 = PLD; 4 = PDL; 5 = DLP; 6 = DPL. LPDs were prepared fully in water at a 
L:P:D charge ratio of 0.5:6:1, and mixed in a 1:3 volume ratio of LPDs in water and OptiMEM 
(VwLPDw/OptiMEM), final DNA concentration was  0.25 µg/well. Vesicles used to prepare the 
LPDs composed of DOTMA:DOPE at 1:1 molar ratio. Error bars are the SD of three 
measurements of a single formulation (n=3). Only one experiment was performed. 
 
Significantly for the present study, the protein assay shown in Figure 3.1(b) indicated that 
Lipofectamine 2000 was far more toxic towards the A459 cells than the PDs and LPDs prepared 
with peptides from Series I and II. Although both the Series I and II peptides exhibited some 
toxicity towards the A549 cells, this toxicity was much less than that seen with Lipofectamine 
2000, indicating that, as a whole, the LPDs prepared in the present study were much less toxic. 
Furthermore, the LPDs prepared using Series I peptide, H12BLY was less toxic than those 
prepared using the Series II peptide, (HR)6BLY. Interestingly, the order of mixing appeared to 
have no influence on the toxicity of the LPDs suggesting that it was the components of the 
LPDs that exerted toxicity rather than the delivery system. 
Small angle neutron scattering (SANS) studies were performed in an attempt to detect any 
difference in the macromolecular structure of the LPDs prepared using the different protocols. In 
order to reduce the breadth of the study, only protocols 1 (LPD), 2 (LDP) and 6 (DPL) were 
studied. Protocol 1 (LPD) was selected for study as the LPDs with the maximum transfection 
have been prepared using this methodology (Kudsiova et al, 2011). Preparation of LPDs using 




protocol 3 was not selected for SANS studies as preliminary SANS data (not shown) indicated 
that there was no detectable difference between the cationic vesicles and the cationic peptide, 
hence protocols 1 and 3 were deemed to be equivalent because the DNA was added last. 
Similarly, because protocols 2 and 5 involved mixing vesicle suspension and DNA solution first, 
they were also deemed equivalent and thus only protocol 2 was tested. Finally, protocols 1, 3, 4 
and 6 yielded similar levels of luciferase transfection, suggesting that protocols 4 (PDL) and 6 
(DPL) were similar in structure, a not unreasonable assumption because in both cases the 
vesicle suspension was added last and hence only protocol 6 was studied. In addition because 
preliminary SANS studies (data not shown) indicated no difference in the internal structure of 
LPDs composed of the different peptides, it was decided to study LPDs prepared using the 
Series II peptide, (HHR)4BLY. 
Figure 3.2(a) gives the intensity of the small angle neutron scattering (I) in cm-1 as a function of 
momentum transfer (q) in Å-1 for cationic DOPE:DOTMA vesicles (scaled to the lipid 
concentration present in the final LPDs tested using SANS) and LPDs prepared using protocols 
1, 2 and 6 and containing peptide (HHR)4BLY. Figure 3.2(b) gives the variation in intensity of 
the SANS obtained for LDs and PDs containing (HHR)4BLY, and for the purposes of 
comparison LPDs prepared using protocol 2 and containing (HHR)4BLY. In all cases the 
vesicles, PDs, LDs and LPDs were prepared in D2O as opposed to H2O in order to provide the 
necessary contrast for the SANS measurements. The background, attained at a scattering 
intensity of I of ~ 0.01 is a result of the mismatch in the incoherent and inelastic scattering 
between the LPDs and the solvents.  
  












Figure 3.2 Small angle neutron scattering data (dots) for (a) LPD containing (HHR)4BLY and 
prepared by different protocols (i.e. protocols 1, 2 and 6) and cationic vesicles, (b) PD, LD and 
LPD containing (HHR)4BLY (prepared using protocol 2) and (c) the best fit (solid line) to the 
data in (a). All samples prepared in D2O. LPDs were made at lipid:peptide:DNA charge ratio of 
0.5:6:1 (0.1 mg/mL ctDNA). LD prepared at a L:D charge ratio of 0.5:1 (0.1 mg/mL ctDNA) and 
PD at a P:D charge ratio of 6:1 (0.1 mg/mL ctDNA). Vesicles used to prepare the LPDs 
composed of DOTMA:DOPE at 1:1 molar ratio (1 mg/mL of DOTMA) and were aged ~48 h. 
SANS was measured at 25 ± 0.1°C on LoQ at ISIS.  
 




The SANS data obtained for LPD prepared using protocol 1 (LPD) and 6 (DPL) and their parent 
vesicles, shown in Figure 3.2(a) was well fitted assuming the presence of single sheets – the 
vesicles and LPDs being too large to be analysed as hollow spherical structures (Table 3.1). In 
contrast, however, it was not possible to analyse the SANS data obtained for the LPDs 
prepared using protocol 2 using single sheets even with the presence of some multilamellar 
structure suggesting that the LPDs prepared using this methodology possessed a different 
structure. This observation is consistent with the fact that LPDs prepared by protocol 1 (LPD) 
and 6 (DPL) exhibited a similar level of transfection efficiency to each other and which was 
higher than that obtained using LPDs prepared using protocol 2 (LDP).  
Table 3.1 Structural parameters obtained for cationic vesicles, LPD-(HHR)4BLY (0.5:6:1 charge 
ratio) and LD (2:1 lipid:DNA charge ratio) at 0.1 mg/mL ctDNA (derived from FISH modelling of 
their SANA data). All samples prepared using D2O as solvent. Vesicles used to prepare the 
LPDs and LD composed of DOTMA:DOPE at 1:1 molar ratio.  









Vesicles 39.7 (±0.9) 2.0 60.0 (±7.6) 300 0.058 727 
LPD (protocol 1) 39.7 (±2.5) - - 300 - 436 
LPD (protocol 6) 39.7 (±2.3) - - 300 - 133 
LD 34.5 (±4.2) 4.0 57.8 (±2.4) 800 1.05 9631 
Figures in brackets indicate the standard errors on the fitted parameter values. SWSE is sum of 
weighted square error. Ratio of stack to sheet represents the ratio of multilamellar surface area 
to unilamellar surface area. SANS was measured at 25 ± 0.1°C on LoQ at ISIS for the LPDs 
and SANS2D for the LD. 
 
The model used for analysis of the SANS data obtained for the vesicles and LPDs consisted of 
single lipid bilayer sheets, together with stacks (multilayers) of the same. The d-spacing being 
the sum of the thickness of the vesicle’s lipid bilayer (L) and the thickness of the aqueous layer 
that separates the bilayers (dw) as illustrated in Figure 3.3. The parameters used for the best fit 
to the SANS data are given in Table 3.1 and indicate that for the DOTMA:DOPE vesicles, the 
bilayer thickness and d-spacing were 39.7 ± 0.9 Å and 60.0 ± 7.6 Å, respectively. These values 
are reassuringly consistent with the values of ~41 Å and ~65 Å obtained for vesicles of the 
same composition in a previous study (Welser et al, 2013).  
As mentioned above in the present study, the LPD prepared from protocol 1 (LPD) and 6 (DPL) 
had the same bilayer thickness as their parent DOTMA:DOPE vesicles. In addition, the LPDs 
prepared using protocol 1 (LPD) and 6 (DPL) have the same bilayer rigidity as their parent 




vesicles as indicated by a Rsigma of 300 Å. It is worth noting that the significant difference 
between LPDs prepared using protocols 1 (LPD) & 6 (LDP) with those prepared using protocol 
2 (DPL), was that the DNA solution was mixed with the vesicular suspensions, prior to being 
added to the peptide solution. In this case, it might be anticipated that the LPDs prepared using 
protocol 2 (LDP) would possess a structure more like that of the corresponding LD, which did 
not show high level of transfection efficiency (Figure 3.1(a)).  
 
Figure 3.3 Schematic representation of a lipid bilayer (L) and d-spacing in multilamellar vesicles. 
The d-spacing is the sum of the thickness of the lipid bilayer (L) and the aqueous layer (dw) 
between bilayers (Kudsiova et al, 2011b).  
 
In order to prove this hypothesis, the structure of the LD formed from the DOTMA:DOPE 
vesicles and DNA at the same charge ratio as was present in the LPDs, namely 0.5:1, was 
determined (Figure 3.2(b)). Also included in Figure 3.2(b) for the purposes of comparison is the 
SANS data obtained for (HHR)4BLY-containing LPDs prepared using protocol 2 (LDP). It can 
be seen that the SANS data for the LPDs prepared at a L:P:D charge ratio of 0.5:6:1 protocol 2 
(LDP) and the corresponding LDs at a L:D charge ratio of 0.5:1 overlapped, suggesting that the 
structure of the two types of complex were similar, supporting the hypothesis that LPDs 
prepared in this way possessed a structure comparable to that of the corresponding LDs, 
thereby accounting for their low level of transfection efficiency.  
Note that the scattering pattern obtained for the PD was very weak. This is probably a 
consequence of their large size and ‘fluffy’ (unstructured) nature as the calculated SLD of the 




6:1 PDs is sufficiently different from the SLD of the D2O solvent (6.35x10-6 Å-2) used for the 
experiments to enable their ‘visualisation’.  
The scattering profile of LDs prepared at a 2:1 ratio is also shown in Figure 3.4. It is striking that 
the LDs produce a very different SANS curve compared to the vesicles. The SANS data of the 
LDs exhibited a distinct ‘Bragg peak’ at a q value ~0.1 Å-1, suggesting that the LDs contained a 
regular repeating structure. As a consequence, therefore, the SANS data obtained for the LDs 
were fitted with a model with a large portion of multilamellar stacks, rather than a large portion 
of unilamellar sheets for the LPD and vesicles. The parameters used for fitting the SANS curves 
are shown in Table 3.1. Interestingly it appears that the thickness of the lipid bilayer and the d-
spacing present in the LD were lower than those of its parent vesicles, although the thickness of 
dw in the LDs was 23.3 Å, comparable to that present in the vesicles. However, it should be 
noted that it was necessary to increase the value of Rsigma from 300 to 800 to obtain good fits to 
the SANS data, suggesting that the bilayer has become more rigid in the presence of DNA. The 
slightly higher number of layers used to model the SANS data is not significant other than to 
indicate that the number of repeat structures is higher in the LD complexes (the ratio of stack to 
sheet was 1.05) compared to the vesicles. LDs containing a large number of repeat structures 
were observed in previous studies using electron microscopy (Kudsiova et al, 2011b). 
 
 
Figure 3.4 Small angle neutron scattering data (dots) and the best fit to the data (solid line) for 
LD prepared at a L:D charge ratio of 2:1 (0.05 mg/mL ctDNA). Vesicles used to prepare the LD 
composed of DOTMA:DOPE at 1:1 molar ratio (2.0 mg/mL DOTMA) and were aged ~48 h. 
SANS was measured at 25 ± 0.1°C on SANS2D at ISIS.  
 




3.1.1.2 Effect of charge ratio and incubation time  
During preliminary studies, investigations of LPDs prepared at lipid:peptide:DNA charge ratios 
of 0.5:6:1 and 0.5:12:1 indicated that the optimal transfection occurred within this range (Welser 
2013). Figure 3.4(a) shows the transfection obtained after incubation of A549 cells with LPDs 
for 24+24 h and 4+44 h. Figure 2.4(b) shows the quantification of the protein in the cell lysates 
obtained from the same incubation study.  
As can be seen in Figure 3.4(a) for an incubation of 24+24 h, the LPDs tended to exhibit a lower 
level of transfection efficiency upon increasing the charge ratio from 0.5:6:1 to 0.5:12:1. As a 
consequence therefore, a lipid:peptide:DNA charge ratio of 0.5:6:1 was used to prepare the 
LPDs, except otherwise stated. In agreement with the results shown in Figure 3.1, LPDs 
prepared using Series II peptides, especially (HK)6BLY, exhibited a higher level of transfection 
efficiency, than the LPDs prepared using Series I peptides. The only exception being the LPDs 
prepared with K4BLY where the level of transfection varied greatly from experiment to 
experiment. At present no reason for this variability has been determined. It is worth noting that 
while A549 cells exposed to the positive control, Lipofectamine 2000, exhibited a high level of 
transfection, this result was considered to be largely as consequence of the high toxicity of the 
delivery vehicle towards the cells as evidenced by the low amount of protein present in the cell 
lysates (Figure 3.5(b)). In contrast, the other positive control, Lipofectamine (also commercially 
available) while not as effective at delivering DNA as Lipofectamine 2000 (and indeed many of 
the LPDs prepared in the present study), was much less toxic.  
Interestingly however, irrespective of the charge ratio used to prepare the LPDs, the LPDs 
demonstrated a higher level of transfection efficiency than Lipofectamine at both incubation 
times and Lipofectamine 2000 at the 4+44 h incubation. When examining the effect of LPD 
incubation time on the transfection obtained with the A549 cells, it is clear that at both charge 
ratios, the 24+24 h protocol tended to exhibit the lower level of transfection efficiency. As a 
consequence, unless otherwise stated the 4+44 h incubation protocol was used throughout the 
study.  








Figure 3.5 Levels of luciferase transfection (a) and protein assay (b) after 24+24h (upper panel) 
and 4+44h (lower panel) incubation of A549 cells with LPDs. LPDs were prepared fully in water 
at a L:P:D charge ratio of 0.5:6:1, and mixed in a 1:3 volume ratio of LPDs in water and 
OptiMEM (VwLPDw/OptiMEM). The final DNA concentration was 0.0025 mg/mL. Vesicles used 
to prepare the LPDs composed of DOTMA:DOPE at 1:1 molar ratio. Error bars are the SD of 
triplicate measurements of a single (n = 3). Replicate experiment contained in Appendix II. 
 




3.2.1.3 Effect of solvent  
In the preliminary studies described above, both the vesicles used to prepare the LPDs and the 
LPDs themselves were prepared in water (described as VwLPDw). The ability of the VwLPDw 
to transfect A549 cells were studied after a 4 fold dilution of the LPDs in OptiMEM (denoted as 
VwLPDw/OptiMEM). In order to prepare LPDs suitable for parenteral administration to humans, 
it is necessary to make the LPD suspension isotonic with the body fluids. In addition, 
transfection in vitro using OptiMEM cannot be readily correlated with transfection in vivo 
because of the serum present in the body. As a consequence, it was necessary, therefore to 
examine the effect of varying the nature of the continuous phase in which the LPDs were made 
on their transfection efficiency. In order to do this, the addition of NaCl to the water used to 
prepare the LPDs was studied as was the replacement of OptiMEM by RPMI-1640 media 
containing 10% v/v of fetal bovine serum (FBS).  
The effect of replacing OptiMEM with serum-containing RPMI-1640 media can be seen in 
Figure 3.6. Disappointingly, there was no luciferase expression (i.e. transfection) recorded when 
the LPDs and their constituent vesicles were prepared in water (VwLPDw). Interestingly, 
however, when the LPDs were prepared in OptiMEM in place of water, vesicles still made in 
water (VwLPDo) and transfection performed in the presence of serum-containing RPMI-1640 
media, a high level of transfection was observed. 
This observation is significant, as it is often extremely difficult to experimentally observe any 
DNA transfection in vitro in the presence of serum (Turek et al, 2000). Indeed many researchers 
do not report the ability of their delivery systems to transfect in the presence of serum, 
preferring instead to use OptiMEM for their transfection studies as better levels of transfection 
are generally recorded when using this media (Lo et al, 2008, Tagalakis et al, 2011). OptiMEM 
is a modification of eagle's minimum essential media, buffered with HEPES and sodium 
bicarbonate and supplemented with hypoxanthine, thymidine, sodium pyruvate, L-glutamine, 
trace elements and growth factors as described on the product information sheet. A 
consideration of the composition of OptiMEM lead us to consider using electrolyte solution 
instead of water for the preparation of the LPDs to see if it was possible to retain the activity of 
the LPDs when diluted in serum-containing RPMI-1640 media. The electrolyte selected for the 




present study was NaCl as it is widely used in a range of clinical applications and is already 
used to produce isotonic medicinal preparations.  
 
Figure 3.6 Luciferase expression in A549 cells after a 4+44 h incubation with LPDs containing 
various peptides. LPDs were prepared fully in water (VwLPDw) or partly in OptiMEM (VwLPDo) 
at a L:P:D charge ratio of 0.5:6:1 and transfected in 75% v/v RPMI-1640 media containing 10% 
v/v FBS. Cationic vesicles were composed of DOTMA/DOPE lipids at 1:1 molar ratio. Error bars 
are the SD of 3 measurements of a single formulation (n = 3).  
 
Figure 3.7(a) shows the transfection obtained in A549 cells after incubation with LPDs prepared 
in water (VwLPDw) and in saline solution, i.e. 0.12 M NaCl (VsLPDs) and diluted with OptiMEM. 
As can be observed, a high level of transfection efficiency was obtained for both types of the 
LPDs, with no difference being observed with peptide structure, with the exception of the LPDs 
containing K4BLY, where the LPD prepared in water exhibited a much greater level of 
transfection. In contrast with these results, Figure 3.7(b) shows that the levels of transfection 
obtained in the A549 cells after exposure to LPDs prepared in water (VwLPDw) and LPDs 
prepared in saline (VsLPDs) but diluted with serum-containing media exhibited very different 
levels of transfection, with little/no transfection being observed in the systems containing LPDs 
prepared in water (VwLPDw) and a high level of transfection being seen when LPDs prepared 




in 0.12 M NaCl solution (VsLPDs) was used, supporting the hypothesis that preparing the LPDs 
using electrolyte solution instead of water lead to a retention of activity of the LPDs when diluted 
in serum-containing RPMI-1640 media, albeit not to quite the same levels as obtained using 
diluting in Optimem. Once again, with the exception of K4BLY, the LPDs containing the Series I 





Figure 3.7 Luciferase expression in A549 cells after exposure to LPDs using a 4+44 h 
incubation protocol. (a) LPDs were prepared fully in water or 0.12 M NaCl solution and diluted 
with 75 %v/v OptiMEM (VwLPDw/OptiMEM or VsLPDs/OptiMEM), (b) LPDs were prepared fully 
in water or 0.12 M NaCl solution and diluted with 75% v/v RPMI-1640 media containing 10% v/v 
FBS (VwLPDw/Media or VsLPDs/Media), (c) level of protein assay of (a), and (d) level of protein 
assay of (b). LPDs were prepared at a L:P:D charge ratio of 0.5:6:1. Cationic vesicles used to 
prepare the LPDs were composed of DOTMA/DOPE lipids at 1:1 molar ratio. Error bars are the 
SD of 3 measurements of a single formulation (n = 3). Experiments repeat 4 times; replicate 
experiment contained in Appendix II.  
 




Figure 3.7(c) and 3.7(d) shows the protein assay for the cells exposed to the VwLPDw and 
VsLPDs diluted in Optimem and Media, respectively. Reassuringly, Lipofectamine 2000 was far 
more toxic towards the A549 cells than the LPDs. Moreover, the VsLPDs and those diluted in 
the Media exhibited little toxicity towards the A549 cells. This toxicity was much less than that 
seen with Lipofectamine 2000, indicating that the LPDs prepared in the present study were 
much less toxic. 
A study was performed determine whether it was important for prepare LPDs using vesicles 
made in saline or water. This study was of interest because the vesicles made in saline were 
less stable and therefore less amenable to formulation. As can be seen in Figure 3.8, 
significantly higher levels of transfection were obtained in A549 cells after incubation with LPDs 
prepared from vesicles made in 0.12 M NaCl solution (VsLPDs) when compared to those made 
in water (VwLPDs). Figure 3.8 also shows that LPDs prepared fully in (VsLPDs) when incubated 
with A549 cells for 24 h yielded a higher level of transfection than those incubated for 4 h, 
although for the reasons outlined above and because most researchers incubate the cells with 
the delivery vehicles for 4 h, it was this incubation time that was used for all studies, unless 
otherwise stated. 
To further explore the influence of NaCl on the ability of the LPDs to transfect A549 cells in vitro 
in the presence of serum-containing media, a study was performed in which LPDs were 
prepared using vesicles in water or in varying concentrations of NaCl in water. As can be seen 
from Figure 3.9(a), the amount of NaCl present had a profound effect on the level of transfection 
achieved, with the highest level of transfection being obtained with the LPDs were fully made in 
saline, confirming earlier studies that the presence of NaCl was important in achieving 
transfection in the presence of serum. Figure 3.9(b) shows that the presence of saline when 
preparing the LPDs had no detrimental effect on toxicity of the A549 cells as evidenced by the 
high amount of protein present in the cell lysates. 
On the basis of these preliminary studies, it is possible to conclude that LPDs prepared totally in 
NaCl saline give the highest level of transfection under conditions that were most applicable to 
in vivo use. In order to explore the factors that influence transfection efficiency, the physico-
chemical properties of the LPDs prepared in water and saline are investigated.  








Figure 3.8 Luciferase transfection efficiency of LPDs on A549 cells using either a 4+44 h or 24 
+ 24 h incubation. (a) the level of luciferase transfection and (b) the level of protein assay. LPDs 
were prepared either fully (VsLPDs) or partly (VwLPDs) in 0.12 M NaCl solution and transfected 
in 75% v/v RPMI-1640 media containing 10% v/v FBS. LPDs were prepared at a L:P:D charge 
ratio of 0.5:6:1. Cationic vesicles were composed of DOTMA/DOPE lipids at 1:1 molar ratio. 
Error bars are the SD of three measurements of a single formulation (n = 3).  
 








                                   
Figure 3.9 Luciferase transfection efficiency of LPD-(HHR)4BLY on A549 cells using a 24+24 h 
incubation. LPD-(HHR)4BLY were prepared partly (VwLPDs) or fully (VsLPDs) in various NaCl 
solution (s1 = 0.008 M; s2 = 0.04 M; s3 = 0.08 M; s4 = 0.12 M) and transfected in 75% v/v 
RPMI-1640 media containing 10% v/v FBS. (a) the level of luciferase transfection and (b) the 
level of protein assay. LPDs were prepared at a L:P:D charge ratio of 0.5:6:1. Cationic vesicles 
were composed of DOTMA/DOPE lipids at 1:1 molar ratio. Error bar means SD of three 
measurements of a single formulation (n =3).  
 
3.1.2 Condensation, release and protection properties of lipopolyplexes 
In order to ensure the successful delivery of the anionic DNA macromolecule into the target 
cells, it is essential for it to be packed inside a delivery vehicle that condenses it and reduces its 
size, neutralises its charge thereby removing/reducing negative charge, protects it from 
degradation by enzymes and at the same time facilitates its entry into the cell. In order for DNA 
to exert its effect, it needs to be in the free form and not associated with its carrier vehicle 
(Schaffer et al, 2000). Once inside the target cell it is necessary, therefore, for the delivery 
system to release its DNA payload into cytoplasm from where it can travel to the nuclei. The 
next section will therefore focus on the DNA condensation, release and protection properties of 
the LPDs as measured via electrophoresis on an agarose gel.  
3.1.2.1 LPDs prepared in water 
The results of the electrophoresis experiments performed on the various LPDs prepared fully in 
water (VwLPDw) at charge ratios of 0.5:2.4:1 and 0.5:6:1 are given in Figure 3.10. For each 
LPD, the results are shown in three lanes, with Lane A giving the results of the complexation 
experiment, Lane B, the release studies and Lane C the degradation studies. As expected the 




naked DNA exhibited two bands, an intense ‘lower’ band and a faint ‘upper’ band, attributable to 
the DNA’s open circular and supercoiled forms, respectively. When DNAse I was added to the 
naked/free DNA no bands attributable to the parent DNA were seen in Lane B due to the 
complete degradation by DNAse I of the naked DNA, into much smaller molecular weight 
fragments which were seen as a diffuse bands towards the bottom of the gel.  
(a)                                                                        (b) 
 
Figure 3.10 Condensation, release and protection properties of the LPDs (VwLPDw) containing 
Series I and II peptides using agarose gel electrophoresis (0.025 mg/mL of pDNA per well). 
LPDs were prepared at lipid:peptide:DNA charge ratio of (a) 0.5:2.4:1 (b) 0.5:6:1. Lane A: DNA 
or LPD. Lane B: DNA or LPD treated with pAsp. Lane C: LPD treated with DNAse I at 37 ± 
0.1°C followed by pAsp. Experiment (b) was repeated 2 times, repeat experiment shown in 
Appendix II. 
 
When considering the results of the gel electrophoresis studies on LPDs prepared at a charge 
ratio of 0.5:2.4:1 (Figure 3.10(a)), it can be seen that LPDs prepared using the Series I peptides 
yielded no bands in Lane A that were attributable to free DNA. In contrast, the LPDs prepared 
using Series II peptides, with the exception of (RK)6BLY, all produced some smearing, 
suggesting that the DNA was not fully complexed. These results imply that the Series I peptides 
were generally more effective at condensing DNA than Series II peptides. The lower 
condensation efficiency seen with the Series II peptides was especially noticeable when one of 
the peptide residues contained, in the DNA condensing region, histidine (H) residues. This 
lower condensation seen with these peptides are due to the low pka (6.10) and therefore low 
percent ionisation of H. Interestingly, in this context, the Series I peptide, H12BLY did appear to 
fully condense DNA. The reason for this observation is not currently known. When the LPDs 
were prepared at the higher charge ratio of 0.5:6:1 (Figure 3.10(b)), DNA appeared to be fully 




complexed, regardless of the peptide used to prepare the complex, giving further justification to 
the use of LPDs prepared at this mixing ratio for detailed study. 
The results of the release study, shown in Lane B, suggest that it is possible to release DNA 
from the all the LPDs (regardless of the peptide that was used to prepare them) via 
displacement with the anionic polymer, pAsp. Moreover, the extent of release did not appear to 
change with the charge ratio used to prepare the complex, suggesting that the interaction 
between the DNA and the peptides/lipid was not very strong.  
Encouragingly, while not offering total protection, the LPDs did to some extent protect the DNA 
from enzymatic degradation as can be seen from Lane C. The protection offered by the LPDs 
was in sharp contrast to the degradation seen when the naked/free DNA was exposed to 
DNAse I where a far greater amount of DNA was degraded to smaller molecular weight 
fragments. The LPDs prepared using the higher charge ratio of 0.5:6:1 exhibited the greatest 
level of protection as indicated by the greater prominence of the (upper) bands of DNA, 
attributable to its open circular form. To note, supercoiled DNA is relaxed to the open circular 
and then linear form after which the endonuclease, DNAse I, cleaves DNA preferentially at the 
phosphodiester linkages adjacent to a pyrimidine nucleotide (Weintraub et al, 1986, Cherng et 
al, 1999, Koichiro Kishia 2001). The biological activity of DNA in open circular form was 
reported to be comparable to that in supercoiled form (Weintraub 1986, Xie et al, 1993, Niven et 
al, 1998).  
3.1.2.2 Lipopolyplexes prepared in NaCl solution 
The protection of DNA in LPDs prepared at a 0.5:6:1 charge ratio and made in a 0.12 M 
aqueous NaCl solution (VsLPDs) was also examined (Figure 3.11). For comparison purposes 
LPDs prepared in water (VwLPDw) were also examined at the same time. In agreement with the 
results obtained for LPDs prepared in water (VwLPDw) shown in Figure 3.10, DNA was totally 
complexed in the LPDs (Lane A) and was well released from the LPDs in the presence of pAsp 
(Lane B). Excitingly, and in contrast to the results obtained with the LPDs prepared in water, 
those prepared in NaCl solution appeared to totally protect the DNA from DNAse I degradation 
as the bands in Lane C were identical to that in Lane B and for the naked DNA in Lane A. This 
protection of DNA could be one of the reasons for high level of transfection efficiency observed 
with the VsLPDs, although interestingly no difference was observed between the two series of 




LPDs. Indeed it has been reported that incubation of plasmid DNA with serum showed that 
sodium phosphate protected the DNA from degradation and sodium phosphate enhanced 
plasmid DNA expression in vivo, although the mechanism was unclear (Hartikka et al, 2000). 
  
Figure 3.11 Condensation, release and protection properties of LPDs (VwLPDw and VsLPDs) 
using agarose gel electrophoresis (0.025 mg/mL of pDNA). LPDs were prepared at 
lipid:peptide:DNA charge ratio of 0.5:6:1. The effect of the peptide component on DNA 
condensation (Lane A), DNA release (Lane B), and protection from DNAse I (Lane C) was 
studied. Lane A: DNA or LPD. Lane B: DNA and LPDs treated with pAsp. Lane C: LPDs treated 
with DNAse I at 37 ± 0.1°C °C followed by pAsp. Experiment repeated 2 times, repeat 
experiments shown in Appendix II.  
 
3.1.2.3 Lipopolyplexes prepared in NaCl solution of varying concentrations 
In order to further study the effect of NaCl on the protection of DNA afforded by the LPDs, LPDs 
with the vesicles made in water and the LPDs prepared in aqueous NaCl solutions of differing 
strength, namely 0.008, 0.04, 0.08 and 0.12 M NaCl (i.e. VwLPDs) and LPDs made fully in 
aqueous NaCl solutions of differing strength (i.e. VsLPDs) were studied using gel 
electrophoresis. For this study a Series I peptide, K12BLY and a Series II peptide (HHR)4BLY 
were examined, the results are shown in Figure 3.12. Firstly, in line with the electrophoresis 
studies reported above, the DNA was fully complexed (Lane A) and fully released (Lane B) 




irrespective of the amount of NaCl present in the complex. It was clear, however, from the 
results in Lane C that, as the concentration of NaCl solution used to prepare the complex 
increased, the protection afforded by the complex increased. Moreover, there was no difference 
in the DNA protection afforded by VsLPDs and VwLPDs. 
 
Figure 3.12 Condensation, release and protection properties of LPDs (VwLPDs and VsLPDs) 
using agarose gel electrophoresis (0.025 mg/mL of pDNA). LPDs were prepared at 
lipid:peptide:DNA charge ratio of 0.5:6:1. The effect of NaCl concentration on DNA 
condensation (Lane A), DNA release (Lane B), and protection from DNAse I (Lane C) was 
studied. Lane A: DNA or LPD. Lane B: DNA or LPDs treated with pAsp. Lane C: LPDs treated 
with DNAse I at 37 ± 0.1°C °C followed by pAsp. W = water; S1 = 0.008 M NaCl; S2 = 0.04 M 
NaCl; S3 = 0.08 NaCl; S4 = 0.12 M NaCl. 




3.1.2.4 Effect of enzyme incubation time  
A further protection experiment was carried out using gel electrophoresis. Figure 3.13(a) shows 
the effect of the incubation time with DNAse I on the protection provided by the LPDs containing 
H12BLY. The LPDs were prepared in either in water (VwLPDw) or saline solution (VwLPDs). 
Note, there was no difference in gel electrophoresis seen between VwLPDs and VsLPDs 
(Figure 3.12). The incubation time of the LPDs with DNAse I was either 0, 1, 3, 5, 10 or 20 
minutes. As can be seen in Lane C of the lower panel in Figure 3.13, the strength of the lower 
bands arising from the degradation of DNA increased as the incubation time increased from 1 to 
20 minutes, regardless of whether the LPDs are prepared in water or 0.12 M NaCl saline 
solution. Interestingly, it can be seen that amount of supercoiled DNA (middle band) decreased 
and the amount of linear DNA (upper band) increased as the incubation time increased. The 
change from the supercoiled form of DNA to its linear form over time in contact with DNAse I 
has also be observed by other researchers (Cherng et al, 1999). For DNA complexed in LPDs 
prepared using H12BLY in water (VwLPDw), only faint degradation bands were observed while 
in band due to degradation of DNA was seen in when the LPDs were made in 0.12 M NaCl 
solution (VwLPDs). These results suggest that DNA complexed in LPDs prepared using 0.12 M 
NaCl solution (VwLPDs) were both well protected and indeed better protected than DNA 
complexed inside LPDs prepared fully in water (VwLPDw).  
Significantly, the protection of DNA in the VwLPDs lasted at least 20 mins (longer time points 
not measured). It is worth noting that the well-protected DNA in the VwLPDs remained in the 
wells rather than moved down the gel. This could be due to the weak electrostatic interaction 
between H12BLY and DNA. Furthermore, this weak electrostatic interaction is further reduced 
in saline solution due to charge screening effect of salt. Unlike other peptides, histidine residues 
on H12BLY have a pKa value ~6 and therefore H12BLY are more neutral-like. Therefore, 
negative pAsp molecule is not able to interact with H12BLY and is thus not able to replace DNA 
from the LPDs. 
Figure 3.13(b) depicts the condensation, release and protection properties of the LPDs 
containing the peptide (HHR)4BLY diluted 1 in 4 by volume in either in Optimem (o) or Media 
containing 10% v/v FBS (m) (upper panel). The lower panel shows the undiluted LPDs as 
controls. For naked DNA diluted in either Optimem (DNAw/o and DNAs/o) or Media (DNAs/m 




and DNAs/m), in Lane C there were no bands attributable to DNA, rather strong bands due to 





Figure 3.13 Condensation, release and protection properties of LPDs containing (a) H12BLY 
(VwLPDw and VwLPDs) using agarose gel electrophoresis (0.025 mg/mL of pDNA) and (b) LPD 
containing (HHR)4BLY diluted 1 in 4 by volume in Optimem (o) or media containing 10% v/v 
FBS (m). LPDs were prepared at lipid:peptide:DNA charge ratio of 0.5:6:1. The effect of DNAse 
I incubation time on DNA condensation (Lane A), DNA release (Lane B), and protection from 
DNAse I (Lane C) was studied. Lane A: DNA or LPD. Lane B: DNA or LPDs treated with pAsp. 
Lane C: LPDs treated with DNAse I followed by pAsp. S = 0.12 M NaCl. Incubation time = 1, 2, 
3, 5, 10, 20 minutes at 37 ± 0.1°C.  
 
In contrast, when the LPDs were diluted in either Optimem (VwLPDs/o and VsLPDs/o) or Media 
(VwLPDs/m and VsLPDs/m), there were no degradation fragments bands in Lane C, rather just 




bands attributable to DNA, suggesting that DNA complexed in these LPDs was protected from 
enzymatic degradation due to DNAse I. This observation is supported by the fact that only faint 
DNA bands were observable for the LPDs treated with pAsp in Lane B suggesting that DNA 
was not readily released from these LPDs. In addition, there was no free DNA, attributable to 
uncomplexed DNA, present in Lane A for the LPDs diluted in Optimem (VwLPDs/o and 
VsLPDs/o)  and Media (VwLPDs/m and VsLPDs/m), suggesting that the lipopolyplexes was 
efficient at complexing.  
3.1.3 Quantification of DNA condensation in lipopolyplexes 
Picogreen is an ultra-sensitive, fluorescent stain used for DNA quantification. Once bound to 
DNA, picogreen exhibits a greater than 1000 times increase in fluorescence than its unbound 
state. As a consequence, it is possible to determine the amount of DNA free in LPD 
formulations by quantifying the fluorescence of picogreen. A series of LPDs were therefore 
prepared at different P:D charge ratios whilst keeping the L:D charge ratio constant at 0.5:1. As 
picogreen competes with the peptides to bind to the DNA, two preparation protocols were 
explored. In protocol 1, pre-formed LPDs were mixed with picogreen while in protocol 2, DNA 
was mixed with picogreen and then formulated as LPDs. The two protocols were studied as 
previous studies had indicated that the method of addition of the picogreen may influence the 
results obtained. 
3.1.3.1 Lipopolyplexes prepared in water 
The results obtained for the two series of peptides using protocol 1 and 2 are shown in Figures 
3.14(a) and 3.14(b), respectively. As can be seen at a P:D charge ratio of 1:1, ~20 and ~40% of 
naked/free DNA was detected in LPDs prepared with Series I and Series II peptides, 
respectively. The only exception being the Series I peptide, H12BLY, where ~45% naked/free 
DNA was seen. This amount of naked/free DNA corresponds to ~80 and ~60% of the DNA 
being condensed in the LPDs prepared using Series I and Series II, respectively. As can be 
seen, Series I containing LPDs condensed more DNA than those prepared using Series II 
peptides, which was interesting because in theory, all DNA should be condensed at a P:D 
charge ratio of 1:1 (assuming all charges are freely accessible for complexation). This 
observation may help understand the detailed molecular structure of the LPDs. At a charge ratio 




greater than 1:1, the extent of condensation was seen to slowly increase for the LPDs, 





Figure 3.14 Quantification of DNA complexed in LPDs (VwLPDw) as determined using a 
picogreen fluorescence assay. LPDs were prepared by (a) protocol 1 and (b) protocol 2 (0.02 
mg/mL pDNA). Protocol 1 = LPD+picogreen. Protocol 2 = LP+(D+picogreen). Error bar are the 
SD of three measurements of a single formulation (n = 3) at 25 ± 0.1°C.  




At a P:D charge ratio of 6:1, ~75% of DNA was condensed in LPDs prepared using the Series II 
peptides, although little change was seen in the extent of complexation observed with the LPDs 
prepared using the Series I peptides. At P:D charge ratios greater than 6:1, no further increase 
in the extent of complexation was noted. Not surprisingly from a consideration of its pKa, the 
extent of incorporation of LPDs incorporating H-containing peptides tended to be less under the 
conditions of the experiment.  
When protocol 2 was used, the extent of condensation was lower than that observed using 
protocol 1, the only exception being the LPDs prepared using the Series I peptide R12BLY, 
where there was no difference in the extent of condensation between the two protocols. The 
difference between the extents of the condensation achieved with both protocols was 
particularly noticeable for LPDs containing the Series I peptide H12BLY, most probably due to 
its weak interaction with DNA.  
3.1.3.2 Lipopolyplexes prepared in NaCl solutions 
Interestingly, the LPDs prepared in 0.12 M NaCl saline (VsLPDs) exhibited a much lower ability 
to condense DNA when compared to those prepared in water (VwLPDw) as seen in Figure 3.15. 
When studied LPDs prepared using protocol 1, those LPDs made in 0.12 M NaCl saline solution 
(VsLPDs) exhibited a lower propensity to condense DNA than the LPDs prepared in water as 
seen in Figure 3.15(a) and 3.15(b), with the extent of DNA condensation gradually increasing 
over the whole range of P:D charge ratios studied. For example, out of the Series 1 peptides, 
the LPDs containing H12BLY and K4BLY prepared at a P:D charge ratio of 6:1 condensed only 
~50 and ~70% of DNA, respectively. Furthermore, with the exception of (RK)6BLY, the LPDs 
prepared with Series 2 peptides condensed DNA even less well. When using protocol 2, LPDs 
prepared with either series of peptide condensed even less DNA - this was especially true of 
LPDs containing H12BLY, K4BLY, (HHR)4BLY and (HK)6BLY. Clearly, these differences were 
due to the presence of NaCl saline reducing the interaction between DNA and peptides.  
  








Figure 3.15 Quantification of DNA complexed in LPDs (VsLPDs) as determined using a 
picogreen fluorescence assay. LPDs were prepared by (a) Protocol 1 and (b) Protocol 2 (0.01 
mg/mL pDNA). Protocol 1 = LPD+picogreen. Protocol 2 = LP+(D+picogreen). Error bar means 
SD of three measurements of a single formulation (n = 3) at 25 ± 0.1°C.  
 




3.1.4 Size and ζ- potential measurement of lipopolyplexes  
From the gel electrophoresis and picogreen fluorescence studies, there is a suggestion that the 
extent and strength of DNA condensation in the LPDs varies with both the peptides used to 
prepare the LPDs and the presence of NaCl. The effect of peptide structure and the method of 
preparation on other of the biophysical properties of the complexes is not known. In this section, 
dynamic light scattering will therefore be used to determine the apparent hydrodynamic size of 
the LPDs. Moreover, as the surface properties of nanoparticles are known to affect their 
behaviour in vivo, the ζ-potential of the LPDs prepared in water and NaCl solutions will be 
investigated. 
3.1.4.1 Lipopolyplexes prepared in water 
Figure 3.16(a) shows the apparent hydrodynamic size and ζ-potential of DOTMA:DOPE 
vesicles, the binary LD complexes they form,  together with a range of binary PD and ternary 
LPDs containing K4BLY, when prepared in water. Figure 3.16(b) shows the polydispersity index 
(PDI) of the LPDs shown in Figure 3.16(a). As can be seen the cationic vesicles were of ~65 nm 
in diameter with a ζ-potential of ~50 mV. Their small apparent hydrodynamic size indicates that 
the vesicles were predominately small unilamellar in nature. Their high ζ-potential suggests that 
the vesicles will be stable in water. Upon the addition of DNA to the vesicular suspension at a 
range of L:D charge ratios (i.e. 1:1, 2:1 and 4:1), LDs in the size range of 100 - 140 nm, were 
formed. Unlike the LDs, PDs formed by mixing DNA with the peptide K4BLY were small and of 
the order of ~60 nm in size. Interestingly, the ζ-potential of both LDs and PDs were slightly 
negative when the charge ratio was 1:1 or 2:1 and 6:1 for LDs and PDs respectively, possibly 
indicating that a high L/P:D charge ratio is required to completely condense the DNA. This 
observation is supported by the condensation results seen using gel electrophoresis (Figure 
3.10). Furthermore, even at the highest L/P:D charge ratios of 4:1 and 18:1, the ζ-potential of 
LDs and PDs formed exhibited ζ-potentials of no more than 20 mV. Usually, a ζ-potential of no 
less than 25 - 30 mV is required to maintain charge-charge repulsion and therefore size stability 
(Freitas et al, 1998), suggesting that the LDs and PDs may not exhibit long term stability.  
In contrast, the LPDs prepared using K4BLY tended to be small at less than 100 nm and highly 
reproducible in size (size measured on at least 4 separate occasions). While the apparent 
hydrodynamic size of the LPDs decreased upon increasing the amount of peptide present with 




the LPDs prepared at a L:P:D charge ratio 0.5:18:1 exhibiting the smallest size, their ζ-potential 
increased from a value of ~ 25 to ~ 35 mV as the P:D charge ratio increased from 6:1 through 
12:1 to 18:1. The small size of the LPDs, combined with their relatively high ζ-potential suggests 
that the LPDs will exhibit a high degree of stability. The size stability over time of the LPDs 
prepared in water will be discussed later.   
(a)                                                                            (b) 
  
Figure 3.16 Mean hydrodynamic particle size and ζ-potential of LDs, PDs and LPDs (K4BLY) 
using dynamic light scattering (DLS). Both binary and ternary complex prepared at 
lipid:peptide:DNA charge ratio of 0.5:6:1 in water (0.005 mg/mL of ctDNA). Cationic vesicles 
composed of DOTMA:DOPE at 1:1 molar ratio. (a) mean apparent hydrodynamic size and ζ-
potential. (b) polydispersity index (PDI) of mean apparent hydrodynamic size. Error from SD of 
three measurements of one formulation (n = 3) at 25 ± 0.1°C.  
 
A more detailed study of the apparent hydrodynamic size and ζ-potential of the LPDs prepared 
totally in water using the various peptides (VwLPDw) was performed and the results of the study 
shown in Figure 3.17(a). In line with the previous results obtained for LPDs containing the 
peptide K4BLY, the LPDs containing K4BLY and prepared at L:P:D charge ratios of either 
0.5:6:1 or 0.5:12:1 exhibited an apparent hydrodynamic size in the range of ~80-100 nm and 
possessed a ζ-potential of ~35 mV. When considering the LPDs as a group, apparent 
hydrodynamic sizes in the range of 80-140 nm were seen, with the exception of the LPDs 
containing (HHR)4BLY where a large apparent hydrodynamic size of 170 nm was obtained. The 
LPDs prepared at the higher L:P:D charge ratio of 0.5:12:1 tended to be smaller. Furthermore, 




the LPDs containing the Series II peptides exhibited a larger size than those containing Series I 
peptides. This is consistent with the fact that the LPDs containing the Series II peptides tended 
to condense DNA to a less extent than those containing Series I peptides (Figure 3.14).  
The polydispersity index (PDI) determined for particle size is another indicator of the size quality 
of the preparation as reported in Figure 3.17(b). A particulate system such as an LPD would be 
considered to be homogeneous if the LPDs exhibited PDIs of less than 0.15 (or ideally 0.10). 
For comparison with a PDI of 0.2 obtained for the cationic vesicles is also reported. As shown in 
Figure 3.17(b), all LPDs were heterogeneous in nature. With the exception of the LPDs 
containing (HHR)4BLY, the PDI of the LPDs fluctuated around 0.25. The LPDs containing 
(HHR)4BLY and prepared at a L:P:D charge ratio of 0.5:6:1 exhibited a higher PDI of  ~0.35 
which maybe a consequence of there being insufficient peptide present to fully complex the 
DNA. In accordance with the sizing results, the PDI of the LPDs prepared at 0.5:12:1 charge 
ratio tended to be very slightly lower than that of the LPDs prepared at 0.5:6:1 charge ratio. 
There was no obvious difference in PDI obtained for the LPDs containing the various peptides. 
  
(a)                                                                            (b) 
  
Figure 3.17 Mean apparent hydrodynamic particle size and ζ-potential of LPDs made in water 
(VwLPDw). Samples prepared at a lipid:peptide:DNA charge ratios of 0.5:6:1 and 0.5:12:1 (final 
DNA concentration of 0.01 mg/mL). Vesicle suspension composed of DOTMA/DOPE at 1:1 
molar ratio. (a) mean apparent hydrodynamic size and ζ-potential, (b) polydispersity index (PDI) 
of mean apparent hydrodynamic size (n=3). Error from SD of three measurements of a single 
formulation at 25 ± 0.1°C. 1 repeat in Appendix II. 




The surface properties of the LPDs were evaluated by determining their surface ζ-potential. As 
can be seen from Figure 3.17(a), the LPDs possessed ζ-potentials in the range of 25 - 40 mV, 
with the LPDs prepared at the higher L:P:D charge ratio of 0.5:12:1 tending to possess the 
higher ζ-potential. Furthermore, the LPDs containing the Series II peptides tended to exhibit a 
lower ζ-potential than those containing Series I peptides. When comparing the results of the gel 
electrophoresis studies (Figure 3.10(a) and 3.10(b)), it is clear that the LPDs that exhibited a 
stronger condensation of DNA possessed a higher ζ-potential and smaller particle size.  
The surface ζ-potential can also be used as an indicator of the LPD size stability, with the 
greater the surface ζ-potential, the more stable the LPD. Figure 3.18(a) shows the variation of 
the apparent hydrodynamic size of LPDs prepared in water (i.e. VwLPDw) at an L:P:D charge 
ratio of 0.5:6:1 over a period of 10 days.  
(a)                                                                                  (b) 
  
Figure 3.18 Mean hydrodynamic particle size stability and ζ-potential of LPDs made in water 
(VwLPDw). All samples prepared at lipid:peptide:DNA charge ratio of 0.5:6:1 (0.01 mg/mL of 
pDNA). Vesicle suspension composed of DOTMA/DOPE at 1:1 molar ratio. (a) mean apparent 
hydrodynamic size, (b) polydispersity index (PDI) of mean apparent hydrodynamic size. Error 
from SD of three measurements of a single formulation (n = 3) at 25 ± 0.1°C.  
 
As can be seen the LPDs were very stable, with respect to apparent hydrodynamic size, over 
the time course tested (longer time periods were not tested). The high size stability of the LPDs 
is believed to be a consequence of their possession of a high ζ-potential. Interestingly, however, 




despite their high size stability, the PDIs recorded increased over the same period, particularly 
at 7 and 10 days suggesting either the formation of a few very large particles and/or 
contamination of the cuvettes in which the samples were standing. Note, the change is not 
shown in the size measurement which might be because of the change in count rate. 
3.1.4.2 Lipopolyplexes prepared in NaCl solutions 
In order to understand the effect of NaCl on transfection of LPDs, the above studies were 
repeated replacing the water with NaCl solution during the preparation of both the vesicles and 
LPDs (VsLPDs). The apparent hydrodynamic size and ζ-potential of the vesicles and LPDs 







Figure 3.19 Mean hydrodynamic particle size and ζ-potential of LPDs made in 0.12 M NaCl 
solution (VsLPDs) using dynamic light scattering. All samples prepared at lipid:peptide:DNA 
charge ratio of 0.5:6:1 (0.01 mg/mL of pDNA). Lipidic suspension composed of DOTMA/DOPE 
at 1:1 molar ratio. (a) mean apparent hydrodynamic size, (b) polydispersity index (PDI) of mean 
apparent hydrodynamic size. Error from SD of three measurements of a single formulation (n = 
3) at 25 ± 0.1°C.  
 
It is particularly noteworthy that the apparent hydrodynamic size of the cationic vesicles, 
prepared in 0.12 M NaCl (saline) solution, at 175 nm, are ~ 3 times larger than those prepared 
in water. The large size of the vesicles in saline would suggest that they are multilamellar in 
nature. In addition, the cationic vesicles, when dispersed in 0.12 M NaCl solution, possessed a 




lower ζ-potential of ~35 mV as opposed to ~50 mV when the vesicles were dispersed in water. 
This lower ζ-potential is likely to be a consequence of the charge screening effect of the 
electrolyte. 
Interestingly, the apparent hydrodynamic size and ζ-potential of the LPDs prepared in 0.12 M 
NaCl solution (VsLPDs) were all very similar at ~150 nm and ~25 mV, respectively. The only 
exception being the LPDs prepared containing K4BLY and made at a charge ratio of 0.5:6:1 
which were larger at ~200 nm. It is worth noting that the LPDs prepared in 0.12 M NaCl solution 
were smaller than the cationic vesicles from which they were prepared. 
Inspection of the PDIs of the LPDs (Figure 3.19(b)) indicated that, with the exception of the 
LPDs prepared using K4BLY, the PDI of the various LPDs was only ~0.15, suggesting that the 
particles are fairly monodisperse. Indeed, the VsLPDs appeared to be more monodisperse than 
their VwLPDw counterparts.  
In order to investigate the effect of NaCl concentration on transfection of LPDs, the effect of the 
various strength NaCl solutions on the size and the ζ-potential of the resulting LPDs was also 
studied. The LPDs containing (HHR)4BLY were selected for study. Figure 3.20(a) shows the 
apparent hydrodynamic size stability and the ζ-potential of LPDs containing (HHR)4BLY 
prepared in 0.008, 0.04, 0.08 and 0.12 M NaCl solutions. In this study the parent cationic 
vesicles were either made in water or NaCl solution. In the case of the LPD that were prepared 
in varying strength NaCl solution but using vesicles which had been prepared in water, these 
LPDs were denoted as VwLPDs. Figure 3.20(b) shows the polydispersity index (PDI) obtained 
for the various systems shown in Figure 3.20(a). 
As seen in Figure 3.20(a), the apparent hydrodynamic size of the cationic vesicles prepared in 
the various NaCl solutions was larger than the vesicles made in water (~60 nm) and increased 
with increasing sodium chloride solution from ~120 nm to ~300 nm. In addition, the apparent 
hydrodynamic size of the LPDs prepared fully in the various strength NaCl solutions, were 
larger than those prepared using vesicles made in water. This size increase was particularly 
noticeable at the higher NaCl concentrations of 0.08 and 0.12 M. This observation shows that 
the apparent hydrodynamic size of the LPDs was affected the apparent hydrodynamic size of 
the vesicles from which the LPDs were prepared. 




(a)                                                                        (b)
  
Figure 3.20 Mean hydrodynamic particle size and ζ-potential of LPDs containing-(HHR)4BLY 
and made in various NaCl solution (i.e. S1 = 0.008; S2 = 0.04; S3=0.08; S4=0.12 M NaCl). (a) 
mean apparent hydrodynamic size, (b) polydispersity index (PDI) of mean apparent 
hydrodynamic size. VwLPDs: LPD prepared in NaCl solutions and its parent vesicles in water. 
VsLPDs: both LPD and its parent vesicles prepared in NaCl solutions. All samples prepared at a 
lipid:peptide:DNA charge ratio of 0.5:6:1 (0.01 mg/mL pDNA). Vesicle suspension (V) 
composed of DOTMA/DOPE at 1:1 molar ratio. (Vw)s: vesicles prepared in water and diluted in 
NaCl solution. (Vs)s: vesicles prepared and diluted in NaCl solutions. Error bars are the SD of 
three measurements of a single formulation (n = 3) at 25 ± 0.1°C. 
 
Figure 3.21(a) describes the stability of the LPDs containing (HHR)4BLY and vesicles (insert) 
prepared in various NaCl solutions over time in terms of apparent hydrodynamic sizes and ζ-
potentials. The hydrodynamic sizes of the Lipofectamine 2000/DNA particles (denoted L2K/DNA) 
were also measured as they were used as a positive control in the transfection studies. 
Consistent with the results shown in Figure 3.20(a), the size of the LPDs was larger as the NaCl 
concentration increased. Moreover, the ζ-potential of the LPDs decreased as the NaCl 
concentration increased becoming 20 - 25 mV when 0.08 and 0.12 M NaCl solutions, 
respectively due to the charge screening effect of the NaCl. To note, the LPDs prepared in 
various NaCl solutions possessed the same trend in apparent hydrodynamic size and ζ-
potential as the corresponding vesicles (Vs). In addition, the apparent hydrodynamic size of the 
LPDs prepared fully in the various NaCl solutions (VsLPDs), were larger than those prepared 
using vesicles made in water (VwLPDs). The exception is that when prepared in 0.12 M NaCl 
solution (S4), the LPDs were larger in this occasion (VsLPDs) which might be due to 
contamination present in the measuring cuvettes.  








Figure 3.21 Mean hydrodynamic particle size stability and ζ-potential of vesicles, LPDs 
containing (HHR)4BLY, Lipofectamine 2000 (L2K)/DNA complexes and made in various NaCl 
solution (i.e. S1 = 0.008; S2 = 0.04; S3=0.08; S4=0.12 M NaCl). (a) mean apparent 
hydrodynamic size, (b) polydispersity index (PDI) of mean apparent hydrodynamic size. 
VwLPDs: LPD prepared in NaCl solutions and its parent vesicles in water. VsLPDs: both LPD 
and its parent vesicles prepared in NaCl solutions. All samples prepared at a lipid:peptide:DNA 
charge ratio of 0.5:6:1 (0.01 mg/mL pDNA). Vesicle suspension (V) composed of 
DOTMA/DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA). Error bars are the SD of three 
measurements of a single formulation (n = 3) at 25 ± 0.1°C. 




Regarding the size stability, the LPDs prepared in both fully and partly NaCl solutions (VsLPDs 
and VwLPDs) were relatively stable in five days. However, the particle size of the LPDs was 
noticeably increased over eight days, in particular those prepared fully in NaCl solutions with 
high NaCl concentrations (i.e. 0.08 and 0.12 M). The increased size of the LPDs prepared using 
0.08 and 0.12 M NaCl solutions may be due to their relatively low ζ-potential (20 - 25 mV). In 
comparison, the commercial vehicle Lipofectamine 2000 (L2K) formed L2K/DNA particles with 
larger size than the VsLPDs prepared using the same NaCl solution. Note that the apparent 
hydrodynamic size of the L2K/DNA complex prepared in 0.12 M NaCl increased to ~3200 nm 
within 1 day, despite the complex exhibiting a higher ζ-potential than the corresponding LPDs.  
Figure 3.21(b) displays the polydispersity indexes (PDI) of the apparent hydrodynamic sizes of 
the LPDs over time. The PDI of both the LPDs prepared fully and partially in NaCl solutions 
(VsLPDs and VwLPDs) remained stable in 5 days, although increased on day 8 for the LPDs 
prepared in 0.08 and 0.12 M NaCl solutions. As well, the vesicles from which the LPDs were 
prepared had a rising PDI, especially those prepared in 0.12 M NaCl solution. Furthermore, the 
PDI of the L2K/DNA particles was much higher and increased more quickly than those of the 
corresponding LPDs.  
A size stability study of the various VsLPDs prepared in 0.12 M NaCl solution is shown in Figure 
3.22. Consistent with the results shown in Figure 3.19(a), the LPDs containing the various 
peptides showed a narrow size distribution at ~180 nm as shown in Figure 3.22(a). The PDI of 
the LPDs was again in the range 0.15 - 0.20, suggesting that the LPDs were fairly 
monodisperse as described in Figure 3.22(b). Promisingly, the LPDs containing the various 
peptides all remained stable with respect to the apparent hydrodynamic size and the PDI, for 
periods of up to 20 days, longer than was seen with the LPDs prepared in water (Figure 3.18(b)). 









Figure 3.22 Mean hydrodynamic particle size stability of LPDs made in 0.12 M NaCl solution 
(VsLPDs). All samples prepared at a lipid:peptide:DNA charge ratio of 0.5:6:1 (final DNA 
concentration of 0.01 mg/mL). Vesicle suspension composed of DOTMA/DOPE at 1:1 molar 
ratio. (a) mean apparent hydrodynamic size, (b) polydispersity index (PDI) of mean apparent 
hydrodanamic size. Error bars are SD of three measurements of a single formulation (n = 3) at 
25 ± 0.1°C.  
 
3.1.5 Small angle neutron scattering 
The self-assembly structure of the LPDs was investigated using small angle neutron scattering 
(SANS). The structure information of DOTMA:DOPE vesicles from which the LPDs were 
prepared was also investigated. The SANS data of the preparations, the neutron scattering 
intensity (I) as a function of momentum transfer, Q, was plotted against Q. In the present model 
of the single lipid bilayer sheets and stacks, the space between sheet repeats (d-spacing) is the 
sum of the thickness of the vesicle’s lipid bilayer (L) and that of the aqueous layer (dw) as 
illustrated in Figure 3.3 (page 80). 
3.1.5.1 Lipopolyplexes prepared in D2O  
Figure 3.23 and 3.24 exhibits the SANS data for the LPDs containing peptides, R12BLY, 
K12BLY, (HHR)4BLY and (HK)6BLY prepared in D2O (at 0.5:6:1 and 0.5:12:1 lipid:peptide:DNA 
charge ratios, respectively). The scattering patterns recorded for the LPDs are very similar to 
one another and to the parent vesicles. The modelling of their SANS data was performed 




assuming the presence of single sheets. The fitted parameters including bilayer thickness are 
given in Table 3.2.  
 
 
Figure 3.23 Small angle neutron scattering (SANS) data (dots) for vesicles and the LPD 
containing various peptides and prepared at 0.5:6:1 lipid:peptide:DNA charge ratio and the best 
fit (solid line) to the data. All the LPDs prepared in D2O (0.1 mg/mL ctDNA). Vesicles used to 
prepare the LPDs composed of DOTMA:DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA) and 
were aged for ~48 h. SANS was measured at 25 ± 0.1°C on LoQ at ISIS.  





Figure 3.24 Small angle neutron scattering (SANS) data (dots) for vesicles and the LPD 
containing various peptides and prepared at 0.5:12:1 lipid:peptide:DNA charge ratio and the 
best fit (solid line) to the data. All the LPDs prepared in D2O (0.1 mg/mL ctDNA). Vesicles used 
to prepare the LPDs composed of DOTMA:DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA) and 
were aged for ~48 h. SANS was measured at 25 ± 0.1°C on LoQ at ISIS.  
 
Unexpectedly, there was no difference in the bilayer thickness/structure for the LPDs containing 
various peptides at the same charge ratio and between charge ratios. This result suggests that 
the LPDs have the same bilayer structure as the vesicles. 
   




Table 3.2 Structural parameters obtained for the vesicles, LPDs containing the peptide R12BLY, 
K12BLY, (HHR)4BLY, and (HK)6BLY derived from FISH modelling of their SANS data. LPDs 
was prepared at a DNA concentration of 0.1 mg/mL and a lipid:peptide:DNA charge ratio of 
0.5:6:1 and 0.5:12:1. Vesicles used to prepare the LPDs composed of DOTMA:DOPE at 1:1 
molar ratio (1.0 mg/mL DOTMA) and were aged for ~48 h. SANS was measured at 25 ± 0.1°C 
on SANS2D.  













Vesicles 39.7 (±0.9) 2 60.0 (±7.6) 300 0.058 727 
LPD-R12BLY (0.5:6:1) 39.7 (±2.5) 2 - 300 - 492 
LPD-K12BLY (0.5:6:1) 39.7 (±1.8) 2 - 300 - 334 
LPD-(HHR)4BLY (0.5:6:1) 39.7 (±2.5) 2 - 300 - 436 
LPD-(HK)6BLY (0.5:6:1) 39.7 (±2.2) 2 - 300 - 492 
LPD-R12BLY (0.5:12:1) 39.7 (±2.0) 2 - 300 - 347 
LPD-K12BLY (0.5:12:1) 39.7 (±1.7) 2 - 300 - 286 
LPD-(HHR)4BLY (0.5:12:1) 39.7 (±2.0) 2 - 300 - 387 
LPD-(HK)6BLY (0.5:12:1) 39.7 (±1.8) 2 - 300 - 382 
Figures in brackets indicate the standard errors on the fitted parameter values. Ratio of stack to 
sheet represents the ratio of multilamellar surface area to unilamellar surface area. SWSE is 
sum of weighted square error.  
 
3.1.5.2 Lipopolyplexes prepared D2O and diluted in Optimem or Media 
In order to clarify the effect of transfection solvents on self-assembly structure, the LPDs 
containing (HHR)4BLY and prepared in D2O is 1:1 (v/v) diluted either in Optimem or Media 
containing 10% v/v FBS. The SANS data of the LPD dilutions is shown in Figure 3.25. The 
fitting of the LPD dilutions assuming the presence of single sheets is given in Table 3.3. There 
was no difference in the scattering pattern for the LPDs diluted either in Optimem or Media, 
revealing the same internal structure. Interestingly, the intensity of the LPD dilutions was only 
0.07-fold of that of the original LPDs. It suggests that the LPDs precipitate when diluted in 
Optimem or Media. The LPDs precipitation may be resulted from absorption of serum protein 
present in Optimem or Media, which requires further investigation. In addition, the d-spacing of 
the LPD dilutions had a much higher error than that of the original, revealing a significant 
change on the structure upon contact with Optimem or Media.  





Figure 3.25 Small neutron scattering data (dots) and the best fit (solid line) to the data obtained 
for LPDs prepared using (HHR)4BLY in D2O and 1:1 diluted in Optimem and Media containing 
10% FBS. The LPDs were made at lipid:peptide:DNA charge ratio of 0.5:6:1 (0.1 mg/mL ctDNA). 
Vesicles composed of DOTMA:DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA) and were aged for 
~48 h. SANS measured at 25 ± 0.1°C on LoQ.  
 
Table 3.3 Structural parameters obtained from FISH modelling of the SANS data for LPDs 
containing (HHR)4BLY in D2O and 1:1 diluted in Optimem and Media containing 10% FBS. 
LPDs were made at lipid:peptide:DNA charge ratio of 0.5:6:1 (0.1 mg/mL ctDNA). Vesicles 
composed of DOTMA:DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA) and were aged for ~48 h. 
SANS was measured at 25 ± 0.1°C on LoQ. 























- - 300 - 0.07 109 
Figures in brackets indicate the standard errors on the fitted parameter values. Ratio of stack to 
sheet represents the ratio of multilamellar surface area to unilamellar surface area. Ratio of (I) 
reveals the ratio of diluted LPD’s scattering intensity to the original LPD’s scattering intensity. 
SWSE is sum of weighted square error. 
 
3.1.5.3 Lipopolyplexes prepared in various strength NaCl solutions  
The SANS data obtained for the (HHR)4BLY-containing LPDs prepared in the various NaCl 
solutions and the parent are shown in Figure 3.26, together with the best fits obtained for the 
data using mixed lipid bilayer sheet and stack model. The SANS data for the parent vesicles are 
shown in Figure 3.26(a), upper left, and the corresponding LPDs, upper left, are shown in 
Figure 3.26(b), and the parameters used to obtain the best fit in Table 3.3. For the vesicles, a 




bilayer thickness and d-spacing of 39.4 ±1.1 Å and 60.0 ±8.2 Å, respectively were obtained. 
These values are reassuringly consistent with the values of 39.7 ±0.9 Å and 60.0 ±7.6 Å 
obtained from an earlier experiment (see Table 3.1). The above results suggest that the 
vesicles prepared for different experiments were highly reproducible. 
For the vesicles prepared using 0.04, 0.08, 0.12 M aqueous NaCl solutions, the SANS curves 
(with the exception of the low Q region) overlapped the data obtained for the vesicles prepared 
in D2O. The high similarity suggests that the vesicles prepared in various NaCl solutions have 
the same bilayer thickness as those prepared in D2O, as evidenced by the modelling of the 
SANS data. For instance, the vesicles prepared in D2O had a bilayer thickness of 39.7 ±1.1 Å 
while the vesicles prepared using 0.04, 0.08, 0.12 M NaCl solution were 39.7 ±2.5 Å, 39.7 ±4.5 
Å, 39.7 ±6.3 Å, respectively, as shown in Appendix II Table 1. The parameters used to fit the 
SANS data obtained for the LPDs prepared in D2O using mixed lipid bilayer sheet and stack 
model are shown in Table 3.3. The bilayer thickness of the LPD prepared in D2O was 39.4 ±4.8 
Å and 39.4 ±6.4 Å, respectively, which is very similar to those obtained for the parent vesicles 
(39.7 ±1.1 Å and 40.2 ±0.8 Å). 
As mentioned above, the low Q portion of the SANS curves of the vesicles prepared in 0.04, 
0.08, 0.12 M NaCl solutions are different from those of the vesicles prepared in D2O and was 
possibly a consequence of the Porod scattering due to the presence of vesicles of large size. 
This also means that there are probably two populations of particles present in the vesicle 
suspensions prepared using the various NaCl solutions.  
Figure 3.26(a), lower left, shows the SANS profiles of the vesicles produced from bath 
sonication. Interestingly these SANS curves did not show significant difference from those 
prepared using probe sonication - despite the fact that the sizes obtained for the vesicles using 
dynamic light scattering did (the size of the probe-sonicated vesicles in 0.15 M NaCl solution 
was larger than that of the bath-sonicated (sonication time ≥ 5 min), as depicted in Appendix II 
Figure 6). The above results indicate that the greater in-put in energy due to the probe 
sonication did not cause a difference in the bilayer thickness of the vesicles. Figure 3.26(a), 
lower right, shows the SANS curves of the vesicles prepared from bath sonication and aged for 
48 h before measurement using SANS. The vesicle aging was investigated because it may 




affect the physicochemical properties of the LPDs and therefore their transfection efficiency. 
The SANS of the vesicles was measured right away after their preparation. It was also 
compared with that of the vesicles aged for 48 h. As can be seen, there was a big difference 
observed for the vesicles prepared in the aqueous NaCl solution over time, this was particularly 
noticeable in NaCl solution with higher ionic strength and is possibly due to the growth in the 
size of the vesicles as shown in Figure 3.21.  
(a) 
  





Figure 3.26 Small neutron scattering data obtained for (a) DOTMA:DOPE vesicles (1:1 molar 
ratio) prepared in various strengths of aqueous NaCl solution at 1 mg/mL of DOTMA. The 
vesicles were prepared using probe sonication (upper left panel), probe sonication and diluted 
with various strengths of NaCl solution (upper right panel), bath sonication (lower left panel), 
and bath sonication and aged for 48 h (lower right panel) and (b) LPDs prepared using 
(HHR)4BLY in various strength NaCl solutions using vesicles from (a). The LPDs were made at 
lipid:peptide:DNA charge ratio of 0.5:6:1 (0.1 mg/mL ctDNA). SANS measured at 25 ± 0.1°C on 
LoQ.  
  




Table 3.4 Structural parameters obtained from FISH modelling of the SANS data for LPDs 
containing (HHR)4BLY and prepared in D2O and their parent vesicles. LPDs were made at 
lipid:peptide:DNA charge ratio of 0.5:6:1 (0.1 mg/mL ctDNA). Vesicles composed of 
DOTMA:DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA). SANS was measured at 25 ± 0.1°C on 
LoQ and SANS2D. 










Vesicles_probe_fresh 39.7 (±1.1) 2.0 60.0 (±8.1) 300 0.068 183 
Vesicles_probe_old 39.4 (±1.1) 2.0 60.0 (±8.2) 300 0.068 650 
Vesicles_bath_fresh 40.2 (±0.8) 2.0 60.0 (±7.8) 300 0.052 323 
Vesicles_bath_old 39.3 (±1.1) 2.0 60.0 (±9.1) 300 0.057 560 
LPD (probe_fresh)-1 39.4 (±4.8) 2.0 - 300 - 189 
LPD (probe_fresh)-2 39.0 (±3.3) 2.0 - 300 ‐ 1777 
LPD (bath_fresh) 39.4 (±6.4) 2.0 - 300 - 322 
Figures in brackets indicate the standard errors on the fitted parameter values. SWSE is sum of 
weighted square error. Ratio of stack to sheet represents the ratio of multilamellar surface area 
to unilamellar surface area. 
 
 
The SANS data obtained for the LPDs prepared from the above vesicles is given in Figure 
3.26(b). Interestingly, the shape of the SANS curves of the LPDs prepared in various NaCl 
solutions were generally close to those obtained for their parent vesicles (Figure 3.26(a)). This 
observation suggests that the internal structure of the LPDs is closely related to those of the 
parent vesicles. The parameters used to fit the SANS data obtained for the LPDs prepared in 
D2O using mixed lipid bilayer sheet and stack model are shown in Table 3.3. The bilayer 
thickness of the LPD prepared in D2O was 39.4 ±4.8 Å and 39.4 ±6.4 Å, respectively, similar to 
that obtained for the parent vesicles (39.7 ±1.1 Å and 40.2 ±0.8 Å). The above results reveal 
that the presence of DNA does not influence the structure of the bilayers. Similarly, the d-
spacing of the LPDs were 60.0 ±29.0 Å and 60.0 ±34.7 Å, respectively, the same as those of 
their parent vesicles (60.0±8.1 Å and 60.0 ±7.8 Å). This observation is in line with the 
hypothesis that the structure of the LPDs is related to those of the parent vesicles. It reveals 
that the water layer between the lipid bilayers is sufficient to accommodate DNA molecules 
without any re-arrangement. Furthermore, the observation is consistent with the results of the 
earlier study shown in Table 3.1 and suggests that the LPDs prepared from different 
experiments are reproducible. It is notable that the LPDs had stronger SANS scattering at the 




first 3 points in the low Q region than their parent vesicles, which is probably a consequence of 
the scattering due to the presence of particles of large size.  
3.1.6 Small angle neutron scattering with stopped flow mode 
In an attempt to probe the formation of the lipopolyplexes (LPDs) and lipoplexes (LDs), a 
stopped flow small angle neutron scattering (SANS) experiment was performed. Figure 3.27(a) 
shows the SANS curve obtained for the LPDs containing peptide K16 (0.5:6:1 lipid:peptide:DNA 
charge ratio) using the usual ‘static’ measurement and the kinetic measurements at equilibration. 
For comparison, the scattering curve for the parent DOTMA:DOPE vesicles is also included 
(scaled to the lipid concentration contained in the LPDs). It is of note that the SANS curves 
obtained for the vesicles and the LPDs using the static method were virtually identical except for 
the background levels, which is probably a result of the scaling of the SANS data. When 
comparing the SANS data obtained for the LPDs prepared using the two different methods, 
although the LPDs were overlapped well in the intermediate Q range of 0.01 < Q < 0.05 Å-1, 
they did not overlap at high and low Q. The origin of the high background for the SANS curve 
obtained using stopped flow is believed to be due to the gas detectors fitted at the time of the 
stopped flow experiments. The origin of the deviation at low Q is still not known. The data does, 
however, suggest that at long time courses the various LPDs possessed the same structure.  
Figure 3.27(b) depicts the evolution of the SANS curves for the LPDs using stopped flow 
measured every 60 sec for a total of 10 minutes. As can be seen, the neutron scattering does 
not show any change over this time period, suggesting that any structural change probably 
occur more quickly than 60 seconds. The faster evolution (every 10 sec for a total of 1 minute) 
of the SANS curve for the LPDs is shown in Figure 3.27(c). No change was observed over this 
time period, suggesting that any structural change maybe occurs more quickly than 10 seconds. 
  









Figure 3.27  Small neutron scattering data for LPDs prepared using K16 in D2O. (a) static; (b) 
kinetic measurements (time-sliced every 60 seconds for 600 seconds, n = 14): slice 1 = 0-60 
seconds; slice 2 = 61-120 seconds; slice 3 = 121-180 seconds; slice 4 = 181-240 seconds; slice 
5 = 241-300 seconds; slice 6 = 301-360 seconds; slice 7 = 361-420; slice 8 = 421-480 seconds; 
slice 9 = 481-540 seconds; slice 10 = 541-600 seconds; (c) kinetic measurements (time-sliced 
every 10 seconds for 60 seconds, n = 14): slice 1 = 0-10 seconds; slice 2 = 11-20 seconds; 
slice 3 = 21-30 seconds; slice 4 = 31-40 seconds; slice 5 = 41-50 seconds; slice 6 = 51-60 
seconds. LPDs were made at lipid:peptide:DNA charge ratio of 0.5:6:1 (0.1 mg/mL ctDNA). 
Vesicles composed of DOTMA:DOPE at 1:1 molar ratio (1 mg/mL DOTMA) and were aged for 
~48 h. SANS measured at 25 ± 0.1°C on SANS2D. 
 
Figure 3.28(a) shows the SANS curves obtained for the parent vesicles, the LDs measured 
using the usual ‘static’ methodology and by stopped flow at equilibration. While the SANS curve 
obtained using the normal static method exhibits a distinct Bragg peak, the corresponding data 
obtained from the stopped flow methodology did not. The SANS curve obtained for the LD is 
clearly the same to that seen for the parent vesicles while its intensity is 2-fold that of the parent 
vesicles. As the mixing volume ratio is 1:1, it suggests that the parent vesicle suspension was 
not mixed with DNA solution and therefore only vesicles were ‘seen’ by neutrons. 




Figure 3.28(b) depicts the evolution of the SANS curves for the LDs obtained using stopped 
flow measured every 60 sec for a total of 10 minutes. As can be seen, the neutron scattering 
does not change over this time period, suggesting that any structural change must occur more 
quickly than 60 seconds. The 10 sec evolution for a total of 1 minute of the SNAS curve for the 
LPDs is displayed in Figure 3.28(c). There is no change observed over this time period, 
suggesting that any structural change occurs more quickly than 10 seconds. 
 




Figure 3.28  Small neutron scattering data for LDs prepared in D2O. (a) static; (b) kinetic 
measurements (time-sliced every 60 seconds for 600 seconds, n = 14): slice 1 = 0-60 seconds; 
slice 2 = 61-120 seconds; slice 3 = 121-180 seconds; slice 4 = 181-240 seconds; slice 5 = 241-
300 seconds; slice 6 = 301-360 seconds; slice 7 = 361-420; slice 8 = 421-480 seconds; slice 9 
= 481-540 seconds; slice 10 = 541-600 seconds; (c) kinetic measurements (time-sliced every 
10 seconds for 60 seconds, n = 14): slice 1 = 0-10 seconds; slice 2 = 11-20 seconds; slice 3 = 
21-30 seconds; slice 4 = 31-40 seconds; slice 5 = 41-50 seconds; slice 6 = 51-60 seconds. LDs 
were made at lipid:DNA charge ratio of 2:1 (0.05 mg/mL ctDNA). Vesicles composed of 
DOTMA:DOPE at 1:1 molar ratio (1 mg/mL DOTMA) and were aged ~48 h. SANS measured at 
25 ± 0.1°C on SANS2D.   




3.2 Discussion  
The bottle neck in the exploitation of gene therapy is the successful delivery of DNA to the 
nucleus of the target cells. The present study aim is to deliver DNA using a combination of 
cationic lipids and cationic peptides to form a complex known as a lipopolyplex (LPD). The 
ability of LPDs to deliver DNA has been assessed by measuring the level of luciferease 
transfection achieved in vitro. Significantly, the LPDs were shown to possess a far superior 
transfection efficiency in vitro when compared to their lipoplexes (LDs) and polyplexes (PDs) 
counterparts (Figure 3.1), suggesting that the presence of both lipid and peptide in a delivery 
system has a synergistic effect on the delivery of DNA. Furthermore, the synergistic effect of the 
combination of lipid and peptide on luciferase transfection was found to be correlated with the 
structure of the complexes regarding the protection it provided (Figure 3.2 and 3.4). Explaining 
the superiority of the LPDs over LDs and PDs form the point view of their structures has not 
been previously reported by others. The other factors that could contribute to the synergistic 
effect achieved using the LPDs could include their small size, their high ability to condense and 
therefore protect DNA, while at the same time being able to release from the complex (Gao et al, 
1996). 
Small angle neutron scattering (SANS) studies revealed the presence of a predominately single 
lipid bilayer in the LPDs while the LD counterparts possess a multilamellar structure and the 
PDs no structure (Figure 3.2 and 3.4). The LPDs were therefore proposed to contain a central 
core of DNA surrounded by a lipid bilayer. This proposed structure is in line with that suggested 
by Mustapa et al. (Mustapa et al, 2007) using fluorescence quenching studies of the LPDs 
containing DOTMA:DOPE 1:1 lipids and K16 targeting peptide (K16-GACRRETAWACG 
targeting to α5β1 Integrin receptors). These workers concluded that the lysine-rich portion of the 
K16 targeting peptide interacts with DNA, resulting in a tightly bound inner core of DNA and 
peptide. This inner core is surrounded by the lipid bilayer, from which the targeting portion of the 
peptides partially protruded, allowing it to interact with its target receptors. This core-shell 
structure is expected to afford the entrapped DNA protection against enzyme degradation. 
Indeed this DNA protection, presumably due to encapsulation inside the LPDs has been 
observed in agarose gel electrophoresis studies (Figure 3.10(b)), supporting the hypothesis that 
protection of DNA from enzymatic degradation leads to enhanced transfection. 




In the present study, the preparation protocol has been found to be important in determining the 
ability of the LPD to transfect cells in vitro. For example, LPDs prepared by first mixing DNA 
solution and liposome suspension and then adding peptide solution (Protocols 2 and 5) were 
shown to exhibit much inferior transfection levels compared to the other protocols used (Figure 
3.1). Small angle neutron scattering (SANS) studies of the structure of the LPDs has shown that 
the LPDs prepared using Protocols 2 and 5 possess a comparable structure to their 
multilamellar LD counterparts (Figure 3.2 and 3.4), no doubt accounting for their poor luciferase 
transfection. The structure of LPDs prepared by different protocols has not been previously 
reported before, though the multilamellar structure of the LDs has been reported in other studies 
(Kudsiova et al, 2011a and 2011b). 
In view of the synergistic effect of combining peptides and lipids in the same DNA delivery 
system, the present study has focused on the preparation of LPDs. All the LPDs were prepared 
using Protocol 1 as this method (along with Protocols 3, 4, 6) gave the highest level of 
transfection and is the method used by other researchers in the field (Gao et al, 1996, Yu et al, 
2004, Yan et al, 2012). The novelty of the current research is, in part, in the bifunctional 
peptides used to formulate LPDs.  
The bifunctional peptides used in the current research contain a branched condensing portion 
and a cyclic targeting portion, connected via a degradable linker (Figure 2.1). The novelty of 
these peptides is a combination in a single molecule of regions that can condense DNA as well 
as being biodegradable and possessing a targeting moiety. To be specific, the branched 
condensing portion of the bifunctional peptides confers effective DNA condensation (Figure 
3.10b), showing advantage over linear peptides used for DNA delivery (Chen et al, 2001). 
These peptides have been designed to have longer branches composing of either single or a 
mixture of amino acid residues than used previously (Welser et al, 2013). Moreover, the 
condensation branches are protonable in endosomes (due to the presence histidine residues) 
which has been shown to increase endosomal escape and therefore DNA transfection (Ou et al, 
2009). The degradability of the peptides can also reduce the cytotoxicity of the formulation (Kim 
et al, 2009). 
It is reassuring that the LPDs containing Series II peptides are superior in terms of transfection 
efficiency over those containing Series I (Figure 3.5) as the Series II peptides were specifically 




designed to possess histidine residues on portion of the peptides intended to condense the 
DNA. Histidine is well-known for exerting a ‘proton sponge’ effect via the imidazole rings present 
and which can result in the destabilisation of endosomes (Benns et al, 2000, Putnam et al, 
2001). The importance of the ‘proton sponge’ effect of histidine on endosomal escape and 
therefore DNA transfection has been seen in other studies. For example bafilomycin A1 is a 
specific inhibitor of vacuolar ATPase proton pump, which inhibits the protonation of histidine 
vector inside endosomes and thus prevents the endosomal escape of DNA payload. It has been 
shown that the transfection of a histidylated polylysine/DNA complex was drastically inhibited in 
the presence of bafilomycin A1 (Midoux et al, 1999). The contribution of the ‘proton sponge’ 
effect of histidine to endosomal escape and DNA transfection has also been reported for a 
histidylated polyarginine/DNA complex (Mann et al, 2014) while DNA transfection has been 
found to be proportional to the imidazole content of the imidazole conjugated polylysine 
(Putnam et al, 2001).  
Besides transfection, the physicochemical properties of the LPDs prepared using the two series 
of peptides have been evaluated. It was clear from gel electrophoresis studies that the LPDs 
are effective at condensing, protecting and releasing the DNA they encapsulate. Picogreen 
fluorescence assay, however revealed a weaker condensation of DNA when using the LPDs 
containing Series II peptides. This result is consistent with the presence of histidine residues in 
the Series II peptides, which as a consequence of being weak bases would be expected to 
possess little ability to condense DNA. The dynamic light scattering and zeta-potential 
measurements revealed that the LPDs prepared in water were highly positively charged, small 
particles that exhibited a good stability over time (Figure 3.17 and 3.18). Interestingly, the LPDs 
containing Series II peptides appeared to be larger in size than those containing Series I 
peptides, which might be a consequence of the histidine residues in Series II peptides. In 
contrast to arginine and lysine, histidine is a weak base with a pka of ~6 (the pka of arginine and 
lysine are ~12 and 10, respectively). Therefore, the histidine-containing peptides in Series II 
possess a weaker binding ability than other peptides. The weaker binding of Series II peptides 
is also observed in the gel electrophoresis studies (Figure 3.10(a)). 
One of the most exciting findings in the current study is that the LPDs prepared in 0.12 M 
aqueous NaCl solution demonstrated effective luciferase transfection in the presence of serum 




(Figure 3.7(b)). This result is significant as to our knowledge the beneficial effect of NaCl on 
DNA transfection mediated by lipopolyplexes has not been previously reported. 
It should be noted that serum contains DNA-degrading enzymes and therefore DNA needs to 
be protected to ensure effective transfection (Turek et al, 2000). Moreover, serum possesses a 
lot of proteins, the most abundant of which is albumin, which are characterised by a high 
content of charged amino acid residues. Gessner et al. have shown that positively charged 
particles predominantly adsorb negative albumin due to favourable electrostatic interactions [15, 
16]. Therefore, the positively-charged LPDs in the present studies upon exposure to serum are 
expected to become covered by negatively charged albumin, leading to a charge neutralisation 
of the LPD.  
It was clear from gel electrophoresis studies examining DNA protection by the LPDs that the 
LPDs prepared in 0.12 M aqueous NaCl solutions offered more effective DNA protection against 
DNAse I (Figure 3.11). Therefore, the effective protection afforded by the LPDs prepared in 0.12 
M NaCl solutions could be related with its effective transfection. Interestingly, LPDs prepared in 
0.12 M aqueous NaCl solution exhibit a weaker condensation of DNA as assessed by picogreen 
fluorescence assay. It might be anticipated that the weakly condensed DNA associated with the 
LPDs will be more readily released from the complex. Indeed, a study on the DNA condensation 
by cationic liposomes (DOTAP/DOPE and DOTAP/cholesterol) in the presence of NaCl has 
shown that 1.5 M NaCl, but not 0.15 M NaCl, prevented lipoplex formation and/or induced 
partial dissociation DNA from the complex (Even-Chen et al, 2012). The same study also found 
that the higher the salt concentration, DNA complexed in lipoplexes is more likely to behave like 
a free DNA as monitored by ethidium bromide intercalation. Overall, our study has shown that, 
although DNA condensation is important, it is important that a balance is obtained between 
DNA condensation (and the ability to protect DNA from degradation) and its release. 
In view of the effective luciferase transfection observed using LPDs prepared in 0.12 M aqueous 
NaCl solutions, the transfection of the LPDs prepared in various strength aqueous NaCl 
solutions (i.e. 0.008, 0.04, 0.008 M) was subsequently determined (Figure 3.9). In line with the 
effect seen with the 0.12 M NaCl concentration result, luciferase transfection increased as the 
NaCl concentration increased, revealing a beneficial effect of salt. Indeed, the salt was also 
seen to increase the protection afforded to LPDs containing the (HHR)4BLY, with increasing 




protection observed with increasing salt concentration (Figure 3.12). Once again a correlation 
seems between DNA protection and transfection efficiency. The protection afforded by the 
LPDs is consistent with our previous studies on the lipopolyplexes incorporating C14 glycerol-
based lipids (Kudsiova et al, 2011b).  
It is interesting that only when the parent vesicles were prepared in an aqueous NaCl solution 
were the resultant LPDs effective transfection agents in the presence of serum (VsLPDs > 
VwLPDs in Figure 3.9). 
It is obvious that from dynamic light scattering and zeta-potential measurements that the size of 
the resultant LPDs increased as the final NaCl concentration of the solvent increased. As is well 
established, the condensation of DNA in the LPDs is driven by charge-charge interactions 
between the positively charged peptide/lipids and the negatively charged DNA. In the presence 
of NaCl, however, these charges can be reduced resulting in a reduction of the charge-charge 
interaction. As a consequence, therefore, DNA condensation in the LPD complex is reduced 
and the size of the resultant complex increased. Undoubtedly, the increase in size of the LPDs 
prepared with increasing strength aqueous NaCl solution is due to the charge-screening effect 
of NaCl. Indeed it has previously been reported, using an ethidium bromide fluorescence assay, 
that the binding of DNA with polylysine is inversely correlated with ionic strength up to 0.8 M 
NaCl (Tang et al, 1997). 
Moreover, the increased size of the LPDs is paralleled by an increased transfection suggesting 
that, in the current study at least, the size of the LPDs can be correlated with the transfection. In 
the literature, however, the relationship between size of the DNA complex and transfection is 
variable. For example, in a study on LPDs formed using protamine, an increase in transfection 
was observed with a reduction in size of the LPDs (Gao et al, 1996). However, other workers 
have reported that larger lipopolyamine/DNA complex could form large intracellular endocytotic 
vesicles and these endocytotic vesicles could be more easily destabilized, thus facilitating DNA 
escape and transfection (Escriou et al, 1998). Unfortunately, while such correlations may be 
observed, DNA transfection is a complex process and can in fact be affected by many factors, 
often at the same time. These factors include the size/shape/surface charge/composition of the 
particles and the cell types/transfection solvents/protocols used for DNA transfection. As a 




consequence therefore, any correlation of a single factor with transfection ability may in fact be 
coincidental. 
Interestingly, the PDI of the apparent hydrodynamic size of the parent vesicles and the resultant 
LPD, both prepared in 0.12 M aqueous NaCl solution, was lower than the corresponding 
particles prepared in water (Figure 3.20(b)). The results suggest that, as the concentration of 
NaCl is increased, the formulation of the parent vesicles and the corresponding LPDs become 
more homogeneous, a property which is beneficial to the formulation of a drug delivery system. 
Moreover, the size of the LPDs prepared totally in an aqueous NaCl solution (VsLPDs) was 
larger than those partly prepared in an aqueous NaCl solution (VwLPDs). It is worth noting that 
the size of the parent vesicles prepared in NaCl solution (used for preparation of the VsLPDs) 
was also larger than that of the parent vesicles prepared in water (used for preparation of the 
VwLPDs). The increased size of the parent vesicles prepared in NaCl solutions is most likely a 
consequence of the charge screening effect. The cationic vesicles are composed of cationic 
DOTMA molecules and neutral DOPE molecules. There exists therefore charge-charge 
repulsion between head groups resulting in a lipid bilayer with a high curvature and a relatively 
small size (Figure 3.20(a)). However, in NaCl solutions, the repulsion between cationic DOTMA 
molecules is alleviated due to charge screening, leading to a lipid bilayer with a lower curvature 
and therefore larger size (Figure 3.20(a)). To note, as it has been observed that the size of the 
LPDs prepared in water was not influenced by the size of their parent vesicles (Kudsiova et al, 
2011a), it is not expected that the size of the LPDs prepared in NaCl solution is influenced by 
that of their parent vesicles as well (Figure 3.20(a) and Figure 3.21(a)). 
The concentration of 0.12 M NaCl was selected to be close to isotonic for the human body, 0.15 
M NaCl being isotonic. As a consequence of its near isotonicity, the physicochemical properties 
of the LPDs prepared in 0.12 M aqueous NaCl solution were further investigated. The dynamic 
light scattering and zeta-potential measurements performed reveal that the LPDs prepared in 
0.12 M aqueous NaCl solution were small, positively charged and stable over time (Figure 3.21 
and 3.22 respectively). The LPDs containing Series II peptides appeared to be of approximately 
the same size and zeta-potential as those containing Series I peptides. It is interesting to note 
that the LPDs prepared in 0.12 M aqueous NaCl solution were larger, but more fairly 
monodisperse, than those in water when assessed by size and polydispersity. SANS studies 




suggested that the LPDs prepared in 0.12 M aqueous NaCl solution were likely to have the 
same structure as those prepared in water and that there was no difference between the LPDs 
containing the two Series of peptides. 
Overall, it is promising that the LPDs prepared in aqueous NaCl solutions exhibit effective in 
vitro transfection in the presence of serum. In particular, 0.12 M aqueous NaCl solution is close 
to saline which is commonly used for in vivo injection. Therefore, the LPDs prepared in 0.12 M 
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Chapter 4 Lipopolyplexes containing siRNA 
4.1 Results 
4.1.1 In vitro luciferase gene silencing activity of lipopolyplexes 
The biological activity of the LPRs is evaluated by detecting in vitro luciferase silencing 
efficiency. The effect of siRNA amount is studied in the first place. The same as LPDs, the 
preparation (mixing protocols) and formulation (+/- charge ratio) of the LPRs is evaluated. 
Moreover, the preparation aqueous solutions for the LPR preparation and the silencing medium 
for cell incubation have also been thoroughly investigated, in view of the presence of 
electrolytes and serum in the body.  
4.1.1.1 Effect of siRNA amount 
Lipopolyplexes (LPRs) prepared using K4BLY and Lipofectamine 2000 (L2K) were selected to 
determine the effect of the amount of siRNA required to silence the production of luciferase by 
luciferase-transduced A549 cells. The cationic vesicles used to prepare the lipopolyplexes were 
composed of DOTMA/DOPE at a 1:1 molar ratio. The K4BLY-containing LPRs were made in 
OptiMEM (VwLPRo) at a L:P:R charge ratio of 0.5:12:1. The LPRs were diluted 1 to 4 in 
OptiMEM (VwLPRo/OptiMEM) and incubated with luciferase-transduced A549 cells for 24 h, 
after which time the cells were incubated in RPMI-1640 media containing 10% v/v FBS for 24 h. 
This incubation protocol was denoted the 24+24 h. 
L2K/siRNA complexes were initially prepared in OptiMEM at a L2K:siRNA weight ratio of 4:1 (as 
per manufactures instructions) and then diluted a further 1 in 4 with OptiMEM before incubation 
with cells using the same protocol as described for the LPRs (LPRo/OptiMEM). 
As seen in Figure 4.1(a) when naked siRNA was used at concentrations of 50 and 100 nM/well 
no luciferase gene silencing activity, and hence no knock down, was observed. In contrast when 
L2K, used as positive control, was examined over a similar concentration range it was clear that 
siRNA concentrations of 30 nM/well and above resulted in a least 80% knock down. When the 
LPRs prepared using K4BLY were examined they too exhibited a high level of known down with 
levels of at least 80% being achieved at siRNA concentrations of 50 and 100 nM/well. Excitingly 
the levels of knock down achieved with the K4BLY-containing LPRs were comparable to the 
positive control, L2K. 
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The corresponding protein assay for the cells treated with the negative control, L2K and the 
K4BLY-containing LPRs is shown in Figure 4.2(b). It is important to note that the amount of 
protein present at the end of the experiment is a good indicator of the toxicity of the formulation 
towards the transfected cells, with lower amounts of protein indicating a higher level of toxicity 
of the formulation. Encouragingly, the cells exposed to the K4BLY-containing LPR preparations 
exhibited comparable amounts of protein to the cells exposed to naked siRNA, with the 
exception of those cells exposed to the highest siRNA concentration of 100 nM/well. 
Significantly, the cells exposed to the positive control, L2K/siRNA complex exhibited the lowest 
level of protein, suggesting that this formulation is the most toxic. 
Taking both the results of the knock down study and protein assay into account, a concentration 
of 50 nM/well of siRNA was chosen for all further luciferase gene silencing activity studies. 
(a)                        (b)       
         
Figure 4.1 Luciferase gene silencing activity of naked siRNA, Lipofectamine 2000 (L2K), and 
lipopolyplexes (LPRs) containing K4BLY at different concentrations of siRNA, namely 10, 30, 50 
and 100 nM/well. (a) Knock down of positive control (+siRNA, capable to express luciferase), 
L2K, and LPRs containing K4BLY as percentage of the negative control (-siRNA, scrambled 
and incapable to express luciferase) and (b) corresponding protein assay. LPRs were made 
fully in OptiMEM (VwLPRo/OptiMEM) at L:P:R charge ratio of 0.5:12:1. L2K-containing LRs 
prepared fully in OptiMEM (LRo/OptiMEM). 24+24h incubation with luciferase-transduced A549 
cells. Error bars are the SD of three measurements of a single formulation (n = 3).  
 
4.1.1.2 Order of mixing of lipopolyplexes  
The mixing order of lipids, peptide and siRNA in the formulation of the lipopolyplexes was 
studied. The peptides H12BLY and (HR)6BLY from Series I and II, respectively, were selected 
to investigate the preparation of LPRs by different mixing protocols. In protocol 1 (denoted LPR), 
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peptide solution was added to an equal volume of vesicle suspension, followed by the addition 
of an equal volume of siRNA solution. Protocol 1 is the order of mixing commonly used by other 
researchers. In protocol 2 (LRP), siRNA solution was added to vesicle suspension followed by 
the addition of peptide solution (in equal volume). Similarly, in protocol 3 (PLR), vesicle 
suspension was added to peptide solution, followed by the addition of siRNA solution while in 
protocol 4 (PRL) siRNA solution was added to the peptide solution followed by the addition of 
vesicle suspension (in equal volume). Protocols 5 and 6 examined adding peptide and siRNA 
solution to the suspension of vesicles. In protocol 5 (RLP) and 6 (RPL), siRNA solution was first 
mixed with vesicle suspension and peptide solution respectively and then a third component 
was added to the resulting mixture (in equal volume). 
For this experiment, the vesicle suspensions and the various lipopolyplexes were prepared in 
water and so were described using the nomenclature, VwLPRw. Furthermore, the LPRs were 
prepared at a lipid:peptide:RNA charge ratio of 0.5:12:1 while the knock down experiments were 
performed using VwLPRw diluted 1 in 4 in OptiMEM (VwLPRw/OptiMEM) and transfection 
studied using the 24h+24 h incubation protocol. Naked siRNA and L2K were used as negative 
and positive control, respectively. In addition, lipopolexes (LRs) and polyplexes (PRs), prepared 
using the same two peptides were also examined, prepared in water and diluted 1 in 4 with 
OptiMEM before use (LRw/OptiMEM and PRw/OptiMEM, respectively).  
When compared to the binary complexes, namely the LRs and PRs, the ternary lipopolyplexes 
displayed a much greater level of knock down. Significantly, there was no difference in knock 
down achieved using the various protocols. Furthermore, regardless of the protocol used, 
lipopolypexes composed of the Series II peptide, (HR)6BLY, exhibited a greater level of knock 
down than the lipopolyplexes prepared using the Series I peptide, H12BLY. This observation is 
at variance with the corresponding results observed for the lipopolyplexes prepared using DNA 
(Chapter 3) as opposed to siRNA where the greatest level of transfection was achieved for 
lipopolyplexes in which the peptide was added before the vesicles. It is worth to note that the 
explanation could be due to the small molecular size of siRNA and the resulting ease of 
diffusion in solution. However, as protocol 1 is the most widely used method to prepare the 
LPRs it was decided to use protocol 1 in the following study, unless otherwise stated. 
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(a) 
(b) LPR containing H12BLY (b) LPR containing (HR)6BLY 
 
Figure 4.2 Effect of order of mixing of the lipopolyplexes (LPRs) on the knock down achieved in 
luciferase-transduced A549 cells after a 24+24h incubation: (a) knockdown and (b) 
corresponding protein assay. LPRs prepared using a Series I (H12BLY) and Series II (HR)6BLY 
peptide. 1 = LPR, 2 = LRP, 3 = PLR, 4 = PRL, 5 = RLP, 6 = RPL. Cationic vesicles composed of 
DOTMA/DOPE at 1:1 molar ratio. LPRs prepared at L:P:R charge ratio of 0.5:12:1, LRs made at 
a L:R charge ratio of 0.5:1 and PRs at a P:R charge ratio of 12:1. (+)siRNA, siRNA capable of 
expressing luciferase and (-)siRNA, scrambled siRNA, incapable of expressing luciferase. 
Knock down was performed after a 1 in 4 dilution of the LPRs, LRs and PRs in OptiMEM. Error 
bars are the SD of three measurements of a single formulation (n = 3). 
 
4.1.1.3 Effect of charge ratio achieved using the lipopolyplexes 
During preliminary studies, investigations using LPRs prepared at L:P:R charge ratios of 0.5:6:1 
and 0.5:12:1 indicated that the optimal knock down in luciferase-induced A549 cells occurred 
within this range (Figure 4.3).  
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(a) 
(b) LPR at 0.5:6:1 L:P:R charge ratio (b) LPR at 0.5:12:1 L:P:R charge ratio 
  
Figure 4.3 Luciferase gene silencing activity of lipopolyplexes (LPRs) prepared from Series I 
and Series II peptides. Knock down is of a positive control (+siRNA. capable of expression 
luciferase) expressed as a percentage of the negative control (-siRNA, scrambled, incapable of 
expression luciferase). Cationic vesicles composed of DOTMA/DOPE at a 1:1 molar ratio. LPRs 
prepared at L:P:R charge ratio of 0.5:6:1 and 0.5:12:1, respectively: (a) knock down and (b) 
corresponding protein assay. (+)siRNA, siRNA capable of expressing luciferase and (-)siRNA, 
scrambled siRNA, incapable of expressing luciferase. The knock down was performed after a 1 
in 4 dilution of the LPRs in OptiMEM (VwLPRw/OptiMEM). 24+24h incubation with luciferase-
transduced A549 cells. Error bars are the SD of three measurements of a single formulation (n 
= 3). 
 
As can be seen LPRs tended to exhibit a higher level of knock down upon increasing peptide 
content, i.e. going from a L:P:R charge ratio of 0.5:6:1 to 0.5:12:1. As a consequence therefore, 
a L:P:R charge ratio of 0.5:12:1 charge ratio was used to prepare all LPRs in the following study, 
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unless otherwise stated. It is worth noting that in agreement with the results shown in Figure 4.2, 
the luciferase-induced A549 cells incubated with the LPRs prepared using Series II peptides, 
especially (HHR)4BLY, exhibited a higher level of knock down, than those incubated with the 
LPRs prepared using Series I peptides. The only exception being the LPRs prepared with the 
Series I peptide, H12BLY, which resulted in a high level of luciferase knock down. Interestingly, 
however, irrespective of the charge ratio used, the LPRs demonstrated a comparable, if not 
better, level of knock down than the commercially available, positive control L2K. 
4.1.1.4 Effect of solvents used in preparation of the lipopolyplexes 
In the above studies, both the vesicles used to prepare the LPRs and the LPRs themselves 
were prepared in water (VwLPRw). The ability of the VwLPRw to transfect luciferase-transduced 
A549 cells was then studied after a 4-fold dilution of the LPRs in OptiMEM (VwLPRw/OptiMEM). 
However, knock down achieved in vitro using OptiMEM cannot be correlated with knock down in 
vivo because of the serum present in vivo which is absent in the in vivo experiments As a 
consequence, it was necessary, therefore to examine the knock down of LPRs in presence of 
RPMI-1640 media containing 10% v/v of fetal bovine serum (FBS) and compare this with what 
is achieved in the presence of OptiMEM. 
Preparing LPRs in water is not ideal for administration as the LPR suspension will not be 
isotonic with the body and therefore cannot be safely injected. As a consequence, therefore, the 
effect of varying the nature of the continuous phase used to prepare the LPRs has been 
investigated. The solvents used in this part of the study were water, OptiMEM, and an aqueous 
solution of 0.12 M NaCl (close to saline (0.154 M NaCl) which is isotonic with the body). In all 
cases the initial vesicles used to prepare the LPRs were made in an aqueous 0.12 M NaCl 
solution they were denoted as VsLPRs, when the LPRs were made in water they were denoted 
as VwLPRw, and in OptiMEM as VwLPRo. In this case all the LPRs were diluted 1 in 4 with 
OptiMEM before their incubation with the cells. 
As can be seen in Figure 4.4, the trend obtained in the knock down trend of LPRs prepared in 
the various solvents were broadly the same, although the level of knock down was slightly 
greater when the LPRs were prepared in OptiMEM. 
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Figure 4.4 Knock down achieved in luciferase-transduced A549 cells after a 24+24h incubation 
with lipopolyplexes (LPRs) prepared from Series I and Series II peptides. LPRs prepared at 
L:P:R charge ratio of 0.5:12:1 in (a) water (VwLPRw), (b) OptiMEM (VwLPRo) and (c) 0.12 M 
NaCl solution (VsLPRs). Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio. 
Knock down was performed after a 1 in 4 dilution of the LPRs in OptiMEM. Knock down is of a 
positive control (+siRNA. capable of expression luciferase) expressed as a percentage of the 
negative control (-siRNA, scrambled, incapable of expression luciferase). Error bars are the SD 
of three measurements of a single formulation (n = 3). Replicate experiments given in Appendix 
III.  
 
In the previous study all the LPRs were diluted 1 in 4 with OptiMEM before their incubation with 
the cells. In this part of the study, the LPRs were diluted with RPMI-1640 media containing 10% 
v/v FBS (“media”) in the place of OptiMEM (Figure 4.5). It is noteworthy that no knock down is 
seen when the LPRs are prepared in water and diluted with media (Figure 4.5(a)). In contrast, 
knock down is observed for the LPRs prepared in OptiMEM (VwLPRo) and saline (VsLPRs) 
(Figures 4.5(b) and (c) respectively) with the greatest level of knock down being achieved for 
LPRs prepared in an aqueous solution of 0.12 M NaCl. Indeed when LPRs were prepared using 
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an aqueous solution of 0.12 M NaCl in the place of water, a high level of knock down was noted 
of greater than 80% was recorded for LPRs containing either H12BLY or (HR)6BLY. This is a 
particularly exciting result and suggests that the use of an aqueous solution of 0.12 M NaCl 
enhances the knock down achieved using the LPRs. 




Figure 4.5 Knock down achieved in luciferase-transduced A549 cells after a 24+24h incubation 
with lipopolyplexes (LPRs) prepared from various peptides. LPRs prepared at L:P:R charge 
ratio of 0.5:12:1 in (a) water (VwLPRw), (b) OptiMEM (VwLPRo) and (c) 0.12 M NaCl solution 
(VsLPRs). Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio. Knock down was 
performed after a 1 in 4 dilution of the LPRs in RPMI-1640 media containing 10% v/v of FBS. 
Knock down is of a positive control (+siRNA, capable of luciferase expression) expressed as a 
percentage of the negative control (-siRNA, scrambled, incapable of luciferase expression). 
Error bars are the SD of three measurements of a single formulation (n=3). Replicate 
experiment contained in Appendix III. 
 
In the above studies, when the knock down was performed in the presence of the serum 
containing RPMI-1640 media in the place of OptiMEM, the luciferase-transduced A549 cells 
incubated with LPRs prepared in an aqueous solution of 0.12 M NaCl exhibited a high level of 
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knock down whereas those LPRs prepared in water showed no knock down. The major 
difference between the two types of media is the presence of 10% v/v of FBS in the RPMI-1640 
media. It was therefore assumed that the FBS was responsible for the lack of knock down seen. 
As it is known that RNAse is present in FBS, it was therefore decided to establish whether this 
is reason for the detrimental effect media has on the knock down achieved by LPRs diluted in 
RPMI-1640 media with FBS (Haupenthal et al, 2007). As a consequence, a gel electrophoresis 
study was performed to determine the effect of RNAase on naked (-)siRNA when dissolved in 
either water or RPMI-1640 media, without or with 10% v/v FBS alone or in the presence of 
varying concentrations of the enzyme inhibitor (RNAse A) (Figure 4.6). 
 
Figure 4.6 Agarose gel electrophoresis of naked (-)siRNA (0.01 mg/mL) dissolved in water, 
Lane (1); an aqueous solution of 10% v/v FBS, Lane (2); an aqueous solution of 10% v/v FBS 
and 2% v/v enzyme inhibitor (RNAse A), Lane (3); an aqueous solution of 10% v/v FBS and 4% 
v/v enzyme inhibitor (RNAse A), Lane (4); an aqueous solution of 10% v/v FBS and 10% v/v 
enzyme inhibitor (RNAse A), Lane (5); 10% v/v FBS in RPMI-1640 media, Lane (6); 10% v/v 
FBS and 2% v/v of enzyme inhibitor (RNAse A) in RPMI-1640 media, Lane (7); 10% v/v FBS 
and 4% v/v enzyme inhibitor (RNAse A) in RPMI-1640 media, Lane (8); 10% v/v FBS and 10% 
v/v enzyme inhibitor (RNAse A) in RPMI-1640 media, Lane (9). 
 
siRNA was dissolved in either water, FBS solution and RPMI-1640 media containing FBS. It is 
seen from Lane 2 that naked siRNA was completely degraded by 10% v/v of FBS in water 
compared to the results obtained when the siRNA was dissolved in water (Lane 1). Addition of 
RNAse inhibitor at 2% v/v siRNA dissolved in FBS solution resulted in a greatly reduced level of 
degradation (Lane 3) while addition of 4 and 10% v/v RNAse inhibitor (Lanes 4 & 5) resulted in 
little or no degradation. Note that the extra band seen on the gel when FBS was present was 
confirmed to be due to FBS (data not shown). 
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Addition of 2% v/v RNAse inhibitor to the siRNA dissolved in FBS resulted in a greatly reduced 
level of degradation (Lane 3) whereas the presence of 4% and 10% v/v RNAse inhibitor (Lanes 
4 & 5) resulted in little or no degradation of siRNA. Interestingly, when naked siRNA was 
dissolved in RPMI-1640 media with 10% v/v FBS, it was also not degraded (Lane 6), suggesting 
that any RNAse present was deactivated by the FBS contained in the RPMI-1640 media. In 
addition, the presence of up to 10% v/v RNAse inhibitor in the FBS containing RPMI-1640 
media did not alter the observation that siRNA was not degraded (Lanes 7, 8 & 9, respectively).  
As a consequence of these observations, it might quite reasonably be anticipated that siRNA 
present in LPRs prepared in water (VwLPRw) would not be degraded when the knock down 
was performed in RPMI-1640 media containing 10% v/v FBS. Any lack of any knock down in 
the luciferase-transduced A549 cells after incubation of VwLPRw/OptiMEM could therefore not 
explained by the degradation of siRNA due to RNAse. 
FBS is a negatively charged protein, whereas the LPRs are positively charged. As a 
consequence of their opposing charges in may be that expected that FBS would bind to the 
exterior surface of the LPRs and either reducing uptake of the LPRs into the cells and/or 
releasing the siRNA before it can enter the cell. 
4.1.2 Complexation, release and protection properties of lipopolyplexes 
The ability of the LPRs containing the various peptides, prepared fully in water (VwLPRw) to 
complex, release and protect siRNA was determined using gel electrophoresis (Figure 4.7). The 
ability of the LPRs to complex siRNA is shown in Lane A, while the release and protection of 
siRNA within the LPRs is shown in Lanes B and C, respectively.  
For the VwLPRw, with the exception of faint bands present in the LPRs prepared using the 
H12BLY and (HHR)4BLY peptides, there was no band attributable to intact siRNA present in 
Lane A. This observation suggests that, with the exception of H12BLY and (HHR)4BLY, siRNA 
was completely complexed within the VwLPRw prepared using both Series I and Series II 
peptides. In Lane B, strong bands attributable to siRNA were present, indicating that siRNA was 
completely released from various LPRs upon the addition of pAsp. When naked siRNA was 
treated with RNAse (Lane C), no band attributable to siRNA could be observed. In contrast, 
however, when the LPRs were treated with the same concentration of RNAse followed by pAsp 
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to release any siRNA, clear bands attributable to siRNA were observed suggesting that siRNA 
was protected when in the various VwLPRw. 
 
Figure 4.7 Complexation, release and protection of lipopolyplexes (LPRs) using 0.01 mg/mL of 
(-)siRNA. LPRs prepared at a L:P:R charge ratio of 0.5:12:1. Cationic vesicles composed of 
DOTMA/DOPE at a 1:1 molar ratio. Upper panel shows VwLPRw, and the lower panel VsLPRs. 
Lane A: complexation, Lane B: release (treated with pAsp), Lane C: protection (treated with 
RNAse A at 37 ± 0.1°C and pAsp). C = 1x RNAse A (45 units µL-1), C1 = 2.5X RNAse A, C2: 
5.0X RNAse A. Replicate experiments contained in Appendix III.  
 
LPRs prepared fully in an aqueous 0.12 M NaCl solution (VsLPRs) were also examined using 
gel electrophoresis and, as with the VwLPRw, the LPRs exhibited the ability to both fully 
complex (Labe A) and release siRNA (Lane B). Interestingly, however, when naked siRNA was 
treated with RNAse A (Lane C), there was clear band, attributable to siRNA, suggesting that 
either that the activity of RNAse was reduced in the presence of NaCl and/or else the NaCl in 
some way protects the siRNA from degradation. Indeed it has been reported that sodium salts 
activates RNAse A (Okuda et al, 2003).  
In order to investigate the effect of NaCl on the ability of RNAse A to degrade siRNA, three 
levels of enzyme were investigated, namely with standard amount of RNAse A (Lane C), 2.5 
times the standard amount (Lane C1) and 5 times the standard amount (Lane C2). As can be 
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seen, the greater the level of RNAse the greater the amount of naked siRNA was degraded. As 
a consequence of these observations which points to the reduction of RNAse activity in the 
presence of NaCl, it is not possible to unambiguously conclude that the siRNA was protected 
from RNAse A when entrapped inside the various VsLPRs. 
4.1.3 Quantification of complexation efficiency of lipopolyplexes 
The efficiency of complexation of siRNA in the various LPRs was quantified by a picogreen 
fluorescence assay which exploits the fact that picogreen, once bound to siRNA, exhibits 
greater than a 1000 times increase in fluorescence (Dragan et al, 2010). Picogreen competes 
with peptides to bind to siRNA and as a consequence, it is possible to determine the amount of 
unbound siRNA in LPR formulations by quantifying the fluorescence of picogreen.  
In this part of the study, a series of LPRs were prepared at different P:R charge ratios whilst 
keeping the L:R charge ratio constant at 0.5:1. Two preparation protocols were investigated in 
an attempt to understand the structure of the complexes. In Protocol 1, pre-formed LPRs were 
mixed with picogreen while in Protocol 2, siRNA was first mixed with picogreen and then used 
to prepare LPRs. 
The complexation efficiency of LPRs made in water and prepared by Protocol 1 is shown in 
Figure 4.8(a). For the VwLPRw prepared using the Series I peptides, ~20% of free siRNA was 
observed at a P:R charge ratio of 1:1, suggesting that ~80% of the siRNA was complexed. No 
major change in the amount of complexed siRNA was observed at higher P:R charge ratios. 
The only exception being the VwLPRw prepared with H12BLY where the extent of complexation 
gradually increased upon increasing the P:R charge ratio up to 18:1. Although LPRs prepared 
using Series II peptides demonstrated similar trend, they tended to exhibit a slightly lower level 
of complexation efficiency than the LPRs containing Series I peptides. 
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Figure 4.8 Quantification of siRNA complexed in lipopolyplexes (LPRs - VwLPRw) as 
determined as relative fluorescence units (RFU) using a picogreen fluorescence assay. LPRs 
containing 0.02 mg/mL of (-)siRNA and an LR ratio of 0.5:1 were prepared by (a) Protocol 1 and 
(b) Protocol 2. Protocol 1 = LPR + picogreen. Protocol 2 = LP + (R + picogreen). Error bars are 
the SD of three measurements of a single formulation (n = 3) at 25 ± 0.1°C. In most instances, 
the error bars are contained within the symbols.  
  
The complexation of LPRs made in water and prepared by Protocol 2 is shown in Figure 4.8(b). 
Interestingly, the complexation efficiency of LPRs prepared by Protocol 2 was similar to that of 
LPRs prepared by Protocol 1, with the exception of a slightly higher level of complexation for the 
LPRs containing H12BLY and (HHR)4BLY. 
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Figure 4.9 Quantification of siRNA complexed in lipopolyplexes (LPRs - VsLPRs) as 
determined as relative fluorescence units (RFU) using a picogreen fluorescence assay. LPRs 
containing 0.02 mg/mL of (-)siRNA and an LR ratio of 0.5:1 were prepared by (a) Protocol 1 and 
(b) Protocol 2. Protocol 1 = LPR + picogreen. Protocol 2 = LP + (R + picogreen). Error bars are 
the SD of three measurements of a single formulation (n = 3) at 25 ± 0.1°C. In most instances, 
the error bars are contained within the symbols.  
 
4.1.4 Particle size and ζ- potential measurement of lipopolyplexes 
The apparent hydrodynamic size of the vesicles and LPRs prepared in water (VwLPRw) is 
shown in Figure 4.10. When considered as a group, the LPRs prepared containing the various 
peptides, possessed apparent hydrodynamic sizes in the range of 40-55 nm (with the exception 
of the LPR containing K4BLY which exhibited a size of ~70 nm) and ζ-potential of the order of 
25-40 mV. There was no significant difference in the apparent hydrodynamic size and the ζ-
potential of the LPRs prepared at two charge ratios and with the two series of peptides. 
Generally the size of the LPRs was slightly smaller than the size of the parent vesicles. 
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(a) (b) 
 
Figure 4.10 Mean apparent hydrodynamic size and ζ-potential (a) and polydispersity index (PDI) 
(b) of lipopolyplexes (LPRs) made in water (VwLPRw). LPRs prepared at L:P:R charge ratio of 
0.5:6:1 and 0.5:12:1 using 0.025 mg/mL of (-)siRNA. Cationic vesicles composed of 
DOTMA/DOPE at 1:1 molar ratio. Error bars are SD of three measurements of a single 
formulation at 25 ± 0.1°C.  
 
The PDI of the LPRs is another indicator of the quality of the preparation in that an LPR can be 
considered to be relatively homogeneous if the PDI less than 0.1 or 0.15 at most. Interestingly 
the parent vesicles were the most heterogeneous of the preparations, exhibiting a PDI of ~0.30. 
The LPRs were all heterogeneous as they exhibited PDIs in the approximate range 0.20 - 0.275. 
In order to understand the effect of NaCl on the biophysical properties of the LPRs and 
hopefully on transfection, the above studies were repeated using a 0.12 M NaCl solution in 
replace of water. The apparent hydrodynamic size and ζ-potential of the vesicles and VsLPRs 
are shown in Figure 4.11. It is of particular note that the apparent hydrodynamic size of the 
cationic vesicles prepared in 0.12 M NaCl solution were ~3 times larger than those prepared in 
water, suggesting they were possibly multilamellar in nature. In this context, the larger the size 
of the particle, the more efficient knockdown, regardless of the presence or otherwise of serum 
(Turek et al, 2000). Furthermore, the cationic vesicles dispersed in 0.12 M NaCl possessed a 
lower ζ-potential at ~32 mV than the vesicles dispersed in water, namely as opposed to ~43 mV. 
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(a) (b) 
 
Figure 4.11 Apparent hydrodynamic size of lipopolyplexes (LPRs) made in 0.12 M NaCl 
solution (VsLPRs). LPRs prepared at L:P:R charge ratio of 0.5:6:1 and 0.5:12:1 using 0.025 
mg/mL of (-)siRNA. Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio (a) mean 
apparent hydrodynamic size and ζ-potential, (b) polydispersity index (PDI). Error bars are SD of 
three measurements of a single formulation (n = 3) at 25 ± 0.1°C. 
 
Interestingly the apparent hydrodynamic size of the VsLPRs containing R12BLY, (HHR)4BLY, 
(HR)6BLY and (HK)6BLY at a L:P:R charge ratio of 0.5:12:1 were larger than those prepared at 
the lower charge ratio of 0.5:6:1. In contrast, there was no difference in the ζ-potential of the 
VsLPRs prepared at two charge ratios. It is also worth noting that the LPRs prepared in 0.12 M 
NaCl were bigger than the cationic vesicles from which they were prepared. The PDI of the 
majority of the VsLPRs prepared at a 0.5:12:1 charge ratio was ~0.20 whereas the PDI of the 
VsLPRs prepared at the lower charge ratio of 0.5:6:1 was smaller at ~0.10. It reveals that the 
VsLPRs made at the 0.5:12:1 charge ratio were polydisperse while those made at the 0.5:6:1 
charge ratio were fairly monodisperse. 
4.1.5 Size stability of lipopolyplexes prepared in water and saline solutions 
The size of the LPRs prepared in water was constant at ~ 60 nm over the period of one week as 
seen in Figure 4.12(a). The PDI of the size of the LPRs prepared in water also remained stable 
at ~0.25 over the same period (Figure 4.12(b)). Both the size and the PDI results indicate that 
the LPRs prepared in water are stable over the time period studied. In comparison, the size of 
the LPRs prepared in 0.12 M NaCl solution (VsLPRs) increased from ~200 nm to several 
hundred nm over 1 week as shown in Figure 4.13. Correspondently, the PDI of the LPRs also 
increased over the same period. Therefore, the LPRs prepared in saline solution are less stable 
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than those prepared in water, which is probably a consequence of the reduced charge present 
on the surface of the LPRs in the presence of NaCl. Furthermore, the increased in size of the 
LPRs prepared in the presence of NaCl is due to a reduced charge-charge interaction. 
(a)                                                                         (b) 
 
Figure 4.12 Variation in apparent hydrodynamic size over time of lipopolyplexes (LPRs) made 
in water (VwLPRw). LPRs prepared at L:P:R charge ratio of 0.5:12:1 using 0.025 mg/mL (-
)siRNA. Cationic vesicle composed of DOTMA/DOPE at 1:1 molar ratio (a) mean apparent 
hydrodynamic size and ζ-potential, (b) polydispersity index (PDI). Error bars are the SD of three 




Figure 4.13 Variation in apparent hydrodynamic size over time of lipopolyplexes (LPRs) made 
in saline (VsLPRs). LPRs prepared at L:P:R charge ratio of 0.5:12:1 using 0.025 mg/mL (-
)siRNA. Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio (a) mean apparent 
hydrodynamic size and ζ-potential, (b) polydispersity index (PDI). Error bars are SD of three 
measurements from a single formulation (n = 3) at 25 ± 0.1°C. 
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4.1.6 Small angle neutron scattering study of lipopolyplexes 
Small angle neutron scattering (SANS) studies were performed to detect any difference in the 
macromolecular structure of the lipopolyplexes (LPRs) prepared using either water or NaCl 
saline solutions. The SANS data of the LPRs, the neutron scattering intensity (I) as a function of 
momentum transfer, Q, was plotted against Q. In the present model of the single lipid bilayer 
sheets and stacks, the space between sheet repeats (d-spacing) is the sum of the thickness of 
the vesicle’s lipid bilayer (L) and the thickness of the aqueous layer (dw) as illustrated in Figure 
3.3 (Chapter 3). 
4.1.6.1 Lipopolyplexes prepared in D2O 
Figure 4.14 gives the variation in the intensity of the small angle neutron scattering (I) in cm-1 as 
a function of momentum transfer (q) in Å-1 for DOPE:DOTMA vesicles, LRs and LPRs prepared 
from the vesicles - the LPRs containing the peptide (HR)6BLY - and the corresponding PRs. 
The LRs, LPRs and PRs were prepared at charge ratios of 2:1, 0.5:12:1 and 12:1, respectively. 
In all cases, all the samples were prepared in D2O as opposed to H2O in order to provide the 
contrast necessary for the SANS measurements. The much higher scattering of the parent 
vesicles is due to the higher concentration of the protonated material (here lipid) present 
compared to the other systems, for example the vesicles were measured at ~ a ninth of the lipid 
concentration of the LPRs, namely 1 mg/mL (in the parent vesicles) as opposed to 0.112 mg/mL 
of DOTMA (in the final LPRs). Furthermore, the mismatch in the backgrounds between the 
various samples is a result of the different levels of incoherent scattering due to the differences 
in the amounts of protonated material present. 
The SANS data obtained for the LPRs containing the peptide (HR)6BLY (prepared at a 
lipid:peptide:siRNA charge ratio of 0.5:12:1) and the parent DOPE:DOTMA vesicles (Figure 
4.14) were well fitted assuming the presence of single sheets of lamellae - the LPR and vesicles 
are being too large to be analysed as hollow spherical structures as may be expected for 
vesicular structures using the current SANS set-up. The parameters used to obtain the fits to 
the SANS data are given in Table 4.1. 
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Figure 4.14 Small angle neutron scattering (SANS) data (dots) and the best fit to the data (solid 
line) for DOTMA/DOPE vesicles prepared at a DOTMA concentration of 1.0 mg/mL, 
lipopolyplexes (LPRs) containing (HR)6BLY, LR and PR containing (HHR)4BLY. LPRs were 
made at a lipid:peptide:siRNA charge ratio of 0.5:12:1. LR prepared at a L:R charge ratio of 2:1 
and PR at a P:R charge ratio of 12:1. Sigma siRNA was at a concentration of 0.1 mg/mL. 
Vesicles used to prepare the LPRs composed of DOTMA:DOPE at 1:1 molar ratio and were 
aged ~48 h. SANS was measured at 25 ± 0.1°C on SANS2D. 
 
In contrast, however, it was not possible to fit the SANS data obtained for the LRs (prepared at 
a 2:1 lipid:siRNA charge ratio) assuming the presence of only single sheets as was the case for 
the vesicles and LPRs, but rather it was necessary to add some multilamellar structure to the 
single sheet model to fit the Brag peak present in the data. Indeed, the ratio of multilamellar 
surface area to unilamellar surface area of the LRs was predicted to be 0.51 represented as the 
ratio of stack to sheet as shown in Table 4.1. This observation suggests that the LR possessed 
a quite different structure to the LPRs. In addition it was also necessary to increase the value of 
the Rsigma used to model the data from ~ 300 to ~ 800 suggesting that the bilayers present in the 
LRs are much more rigid in nature. This result is perhaps not unexpected due to the high rigidity 
of siRNA. In line with previous studies (Kudsiova et al, 2011), the scattering pattern obtained for 
the PR was very weak, probably a consequence of their large size and ‘fluffy’ (unstructured) 
nature. 
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Table 4.1 Structural parameters obtained for the vesicles, LPRs containing the peptide R12BLY, 
K12BLY, (HR)6BLY, and (HK)6BLY and LRs derived from FISH modelling of their SANS data. 
LPRs was prepared at a sigma siRNA concentration of 0.1 mg/mL and a lipid:peptide:siRNA 
charge ratio of 0.5:12:1 and 0.5:6:1 and LR prepared at a sigma siRNA concentration of 0.05 
mg/mL and a L:R charge ratio of 2:1. Vesicles used to prepare the LPR composed of 
DOTMA:DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA) and were aged ~48 h. SANS was 
measured at 25 ± 0.1°C on SANS2D.  











Vesicles 38.7 (± 0.8) - - 300 - 727 
LPR-R12BLY (0.5:12:1) 38.7 (± 1.2) - - 300 - 358 
LPR-K12BLY (0.5:12:1) 38.7 (± 1.1) - - 300 - 453 
LPR-(HR)6BLY (0.5:12:1) 38.7 (± 1.1) - - 300 - 426 
LPR-(HK)6BLY (0.5:12:1) 38.7 (± 1.0) - - 300 - 322 
LPR-R12BLY (0.5:6:1) 38.7 (± 1.1) - - 300 - 387 
LPR-K12BLY (0.5:6:1) 38.7 (± 0.6) - - 300 - 147 
LPR-(HR)6BLY (0.5:6:1) 38.7 (± 0.8) - - 300 - 210 
LPR-(HK)6BLY (0.5:6:1) 38.7 (± 0.7) - - 300 - 194 
LR (2:1) 32.7 (± 2.3) 4 56.6 (±2.0) 800 0.51 3552 
Figures in brackets indicate the standard errors on the fitted parameter values. Ratio of stack to 
sheet represents the ratio of multilamellar surface area to unilamellar surface area. SWSE is 
sum of weighted square error.  
 
Figure 4.15 and 4.16 shows the SANS data for the LPRs containing peptides, R12BLY, K12BLY, 
(HR)6BLY and (HK)6BLY prepared at 0.5:12:1 and 0.5:6:1 charge ratios. The scattering pattern 
recorded for the LPRs are very similar to one another and to the parent vesicles. The bilayer 
thickness of the various LPRs determined by modelling their SANS data assuming the presence 
of single sheets are given in Table 4.1. Significantly there was no difference in the bilayer 
thickness/structure for the LPRs containing various peptides at the same charge ratio and 
between charge ratios. This result suggests that the LPRs have the same bilayer structure as 
the vesicles. The similar observation was made for the LPDs. 
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Figure 4.15 Small angle neutron scattering (SANS) data (dots) and the best fit to the data (solid 
line) for lipopolyplexes (LPRs) containing R12BLY, K12BLY, (HK)6BLY and (HR)6BLY. LPRs 
were made at lipid:peptide:siRNA charge ratio of 0.5:12:1 and contained 0.1 mg/mL sigma 
siRNA. Vesicles used to prepare the LPRs composed of DOTMA:DOPE at 1:1 molar ratio and 
were aged ~48 h. SANS was measured at 25 ± 0.1°C on SANS2D. 
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Figure 4.16 Small angle neutron scattering (SANS) data (dots) and the best fit to the data (solid 
line) for lipopolyplexes (LPRs) containing R12BLY, K12BLY, (HK)6BLY and (HR)6BLY. LPRs 
were made at lipid:peptide:siRNA charge ratio of 0.5:6:1 and contained 0.1 mg/mL sigma siRNA. 
Vesicles used to prepare the LPRs composed of DOTMA:DOPE at 1:1 molar ratio and were 
aged ~48 h. SANS was measured at 25 ± 0.1°C on SANS2D. 
 
4.1.6.2 Lipopolyplexes prepared in D2O and diluted in Optimem or Media 
The LPRs containing (HR)6BLY and prepared in D2O is diluted either in Optimem or Media 
containing 10% FBS (1:1 v:v). The SANS data of the LPR dilutions is shown in Figure 4.17. The 
fitting of the LPR dilutions assuming the presence of single sheets is given in Table 4.2. The 
scattering intensity of the LPR dilutions was much lower than that of the original LPRs. It 
suggests that the LPRs precipitate when diluted in Optimem or Media due to the coverage of 
serum proteins present in Optimem or Media which is the same as the LPDs. There was no 
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difference in the scattering pattern for the LPRs diluted either in Optimem or Media, revealing 
the same bilayer structure. 
 
Figure 4.17 Small neutron scattering data (dots) and the best fit (solid line) to the data obtained 
for LPRs prepared using (HR)6BLY in D2O and 1:1 diluted in Optimem and Media containing 10% 
v/v FBS. The LPRs were made at lipid:peptide:siRNA charge ratio of 0.5:6:1 (0.1 mg/mL sigma 
siRNA). Vesicles composed of DOTMA:DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA) and were 
aged ~48 h. SANS measured at 25 ± 0.1°C on SANS2D.  
 
Table 4.2 Structural parameters obtained from FISH modelling of the SANS data for LPRs 
containing (HR)6BLY in D2O and 1:1 diluted in Optimem and Media containing 10% v/v FBS. 
LPRs were made at lipid:peptide:siRNA charge ratio of 0.5:6:1 (0.1 mg/mL sigma siRNA). 
Vesicles composed of DOTMA:DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA) and were aged 
~48 h. SANS was measured at 25 ± 0.1°C on SANS2D. 











Ratio   
of (I) 
SWSE 








39.7 (±33.9) - - 300 - 0.03 60 
Figures in brackets indicate the standard errors on the fitted parameter values. Ratio of stack to 
sheet represents the ratio of multilamellar surface area to unilamellar surface area. Ration of (I) 
reveals the ratio of diluted LPR’s surface area to the original LPR’s. SWSE is sum of weighted 
square error.  
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4.1.6.3 Lipopolyplexes prepared in NaCl solutions 
In order to determine the effect of sodium chloride on the structure of the vesicles and the 
resulting LPRs, the  SANS profile of the LPRs prepared in various strengths of NaCl solution, 
namely 0.04, 0.08 and 0.12 M prepared at a lipid:peptide:siRNA charge ratio of 0.5:6:1 and 
containing the peptide (HHR)4BLY is shown in Figure 4.18.  
 
Figure 4.18 Small angle neutron scattering (SANS) data (dots) and the best fit to the data (solid 
line) for lipopolyplexes (LPRs) containing (HHR)4BLY. LPRs were made at lipid:peptide:siRNA 
charge ratio of 0.5:6:1 and contained 0.1 mg/mL sigma siRNA. Vesicles used to prepare the 
LPRs composed of DOTMA:DOPE at 1:1 molar ratio and were aged ~48 h. SANS was 
measured at 25 ± 0.1°C on SANS2D. 
 
Unfortunately it did not prove possible to fit the SANS data over the whole Q range. It is 
interesting to see, however, that the LPRs prepared in NaCl solutions was well fitted in the high 
Q region (0.03 - 0.10 Å-1) using sheet model. This observation suggests that perhaps more than 
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one structure of particle is present in the LPR preparation and that the main population within 
the LPR suspension has a structure of a single lipid bilayer. It should be noted that the increase 
in the SWSE is due to poor fit of the data at low Q. The thickness of the single bilayer obtained 
from the Fish modelling of this portion of the SANS curve is shown in Table 4.3. It was also 
possible to fit the SANS data for the LPRs prepared in the presence of NaCl well assuming the 
presence of hard spheres. The small size of these structures does not agree with the size of the 
LPRs obtained by dynamic light scattering which were much larger, once again suggesting the 
presence of more than one population of particle. 
Table 4.3 Structural parameters obtained for the lipoolyplexes (LPRs) containing (HHR)4BLY 
prepared in NaCl solutions derived from FISH modelling of their SANS data. The LPRs was 
prepared at a sigma siRNA concentration of 0.1 mg/mL and a lipid:peptide:siRNA charge ratio 
of 0.5:12:1 and 0.5:6:1. Vesicles used to prepare the LPRs composed of DOTMA:DOPE at 1:1 
molar ratio (1.0 mg/mL DOTMA) and were aged ~48 h. SANS was measured at 25 ± 0.1°C on 
SANS2D. 










Vesicles in D2O 36.9 (±0.4) - - 300 - 6179 
LPR in 0.04 M NaCl 36.9 (±3.9) - - 300 - 5880 
LPR in 0.08 M NaCl 36.9 (±5.9) - - 300 - 14992 
LPR in 0.12 M NaCl 36.9 (±9.0) - - 300 - 4050 
Figures in brackets indicate the standard errors on the fitted parameter values. SWSE is sum of 
weighted square error. Ratio of stack to sheet represents the ratio of multilamellar surface area 
to unilamellar surface area. 
 
 
4.1.7 Kinetic small angle neutron scattering  
The formation of the lipopolyplexes (LPRs) and lipoplexes (LRs) was detected using a stopped 
flow SANS. The SANS curve obtained for the LPRs containing peptide K16 (0.5:6:1 
lipid:peptide:siRNA charge ratio) using the usual ‘static’ measurement and the kinetic 
measurements (at equilibration state) is shown in Figure 4.19(a). The scattering curve for the 
parent DOTMA:DOPE vesicles is also displayed and scaled to the lipid concentration contained 
in the LPRs. When comparing the SANS data obtained for the LPRs prepared in two ways, the 
LPRs were overlapped well in the Q range of 0.01 < Q < 0.05 Å-1, but they did not overlap at the 
high and low Q area. Again, the origin of the high background for the SANS curve obtained 
using stopped flow is believed to be due to the gas detectors fitted at the time of the stopped 
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flow experiments. This data, however, suggests that at long time courses the various LPRs had 
the same structure.  
Figure 4.19(b) depicts the evolution of the SANS curve for the LPRs using stopped flow 
measured every 60 sec for a total of 10 minutes. It can be seen that the neutron scattering does 
not change over this time period, suggesting that any structural change must occur more quickly 
than 60 seconds. The faster evolution (every 10 sec for a total of 1 minute) of the SANS curve 
for the LPRs is shown in Figure 4.19(c). There is no change in the neutron scattering over this 
time period, suggesting that any structural change occurs more quickly than 10 seconds. 
 
 
(a)  (b) 
(c) 
 
Figure 4.19 Small angle neutron scattering data for lipoplexes (LPRs) containing peptide K16 (a) 
static; (b) kinetic measurements time-sliced at 60 sec intervals over 600 sec (n = 14): slice 1 = 0 
- 60 sec; Slice 2 = 61 - 120 sec; Slice 3 = 121-180 sec; Slice 4 = 181 - 240 sec; Slice 5 = 241 - 
300 sec; Slice 6 = 301 - 360 sec; Slice 7 = 361 – 420; Slice 8 = 421-480 sec; Slice 9 = 481 - 
540 sec; Slice 10 = 541 - 600 sec; (c) kinetic measurements time-sliced at 10 sec intervals over 
60 sec: slice 1 = 0-10 seconds; slice 2 = 11-20 seconds; slice 3 = 21-30 seconds; slice 4 = 31-
40 seconds; slice 5 = 41-50 seconds; slice 6 = 51-60 seconds. LPRs were made at a 
lipid:peptide:siRNA charge ratio of 0.5:6:1 and contained 0.1 mg/mL sigma siRNA. Vesicles 
composed of DOTMA:DOPE at 1:1 molar ratio and were aged ~48 h. SANS measured at 25 ± 
0.1°C on SANS2D. 
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Figure 4.20(a) shows the SANS curve obtained for the LRs measured using the usual ‘static’ 
methodology and stopped flow at equilibration. While the SANS curve obtained using the 
normal static method exhibits a distinct Bragg peak, the corresponding data obtained from the 
stopped flow methodology did not. This lack of a Bragg peak is most likely due to the high 
background obtained for this sample masking the Bragg peak. The SANS curve obtained for the 
LR is clearly different to that seen for the parent vesicles. 






Figure 4.20 Small angle neutron scattering data for lipoplexes (LRs) (a) static; (b) kinetic 
measurements time-sliced at 60 sec intervals over 600 sec (n = 17): slice 1 = 0-60 sec; Slice 2 
= 61-120 sec; Slice 3 = 121-180 sec; Slice 4 = 181-240 sec; Slice 5 = 241-300 sec; Slice 6 = 
301-360 sec; Slice 7 = 361-420; Slice 8 = 421-480 sec; Slice 9 = 481-540 sec; Slice 10 = 541-
600 sec; (c) kinetic measurements (time-sliced every 10 seconds for 60 seconds, n = 14): slice 
1 = 0-10 seconds; slice 2 = 11-20 seconds; slice 3 = 21-30 seconds; slice 4 = 31-40 seconds; 
slice 5 = 41-50 seconds; slice 6 = 51-60 seconds. LRs were made at a lipid:siRNA charge ratio 
of 2:1 and contained 0.05 mg/mL (-)siRNA. Vesicles composed of DOTMA:DOPE at 1:1 molar 
ratio and were aged ~48 h. SANS measured at 25 ± 0.1°C on SANS2D. 
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Figure 4.20(b) depicts the evolution of the SANS curve for the LRs obtained using stopped flow 
measured every 60 sec for a total of 10 minutes. As can be seen the neutron scattering does 
not change over this time period, suggesting that any structural change must occur more quickly 
than 60 seconds. The 10 sec evolution for a total of 1 minute of the SANS curve for the LPRs is 
displayed in Figure 4.20(c). No change was observed over this time period, suggesting that any 
structural change must occur more quickly than 10 seconds. 
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4.2 Discussion 
As reported in Chapter 3, DNA formulated as an LPD using the novel peptides developed in this 
study, exhibits effective transfection thereby influencing protein production. As DNA can only 
exert its effect in the nucleus of the cell, it can be concluded therefore that DNA has been 
translocated into nucleus by formulating it as a lipopolyplex. As with DNA, siRNA also plays an 
important role in the cellular regulation of proteins. Of particular interest in this part of the study 
is siRNA's ability to down regulate or 'silence' the production of a particular protein. The 
silencing effect of siRNA is achieved by its complimentarily binding to mRNA, resulting in the 
breakdown of mRNA (Montgomery et al, 1998) and a halting of protein production. Significantly 
in terms of gene delivery, as siRNA exerts its silencing effect in the cytosol rather than nucleus, 
it means it has to overcome fewer barriers to its site of action (Scholz et al, 2012). 
In the present study, siRNA, as with DNA, has been complexed with a combination of lipid and 
bifunctional peptides to form a lipopolyplex (LPR). The ability of the LPRs to deliver successfully 
siRNA was assessed by measuring the level of luciferase expression in vitro. The negative 
control used in the study was a scrambled version of the siRNA, (-)siRNA, used such that the 
greater the difference in luciferase expression between siRNA and the negative control, the 
more effective the silencing.  
It is interesting to note that, in the present study, the LPRs were far more effective at silencing 
protein production than their lipoplex (LR) and polyplex (PR) counterparts (Figure 4.2(a)). As 
was seen with DNA formulated as an LPD, the presence of both lipid and peptide in the siRNA 
containing LPR formulation exerted a beneficial effect on the delivery of siRNA. Again in 
agreement with the early studies on DNA, small angle neutron scattering (SANS) studies 
indicated that, while the counterpart LRs and PRs exhibited a multilamellar structure and no 
distinct structure, respectively the LPRs contained a lipid bilayer, predominantly in the form of a 
single bilayer (Figure 4.14). It was hypothesized in the present study that the differences in 
structure of the types of siRNA complex contributed to the synergistic effect on luciferase 
silencing observed in the presence of both lipid and peptide. By analogy with the LPD 
complexes studied, it is not unreasonable to assume that the LPRs contained a central core of 
siRNA and peptide surrounded by a bilayer of lipid. It is interesting that the structure of the lipid 
bilayer in the parent vesicles and the LPRs is the same and indeed the same as the bilayers 
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present in the LPDs, as evidenced by the SANS studies (Tables 3.1 and 4.1), suggesting that 
during the formation of the LPRs (and indeed LPDs) the vesicle bilayer must open and re-seal 
to allow entry of the peptide and siRNA (or DNA) which apparently forms the core of the 
nanoparticle. In support of the proposed structure of the lipopolyplexes in which siRNA is 
encapsulated inside lipid bilayer, it is of note that siRNA was protected from enzymatic 
degradation as seen by the gel electrophoresis studies (Figure 4.7).  
In contrast to the situation observed for the LPDs, the preparation protocol of the LPRs had no 
effect on the ability of the LPRs to silence protein in vitro as the same level of silencing 
observed irrespective of preparation method (Figure 4.2(a)). It reveals that siRNA can be 
successfully delivered into cytosol no matter what preparation protocols. As the siRNA exerts its 
effect in cytosol of the cell, effective silencing can only be achieved if siRNA is released intact 
from the endosomes. It is worth noting that both the lipid, DOPE (Xu et al, 1996) and the 
histidine containing peptides (Tang et al, 1997, Midoux et al, 1999, Putnam et al, 2001) are 
potentially capable of facilitating the endosomal escape of the complex containing siRNA or of 
siRNA itself. 
Regarding the effect of the bifunctional peptides, it is interesting to note that once again, the 
LPRs containing Series II peptides exhibited a superior silencing power over those containing 
Series I, presumably due to the presence of histidine residues in the Series II peptides (Figure 
4.2(a) and 4.3(a)). In the Series II peptides, because of the presence of the histidine residues, it 
is expected that they behave like ‘proton sponges’ facilitating the endosomal escape of siRNA 
(Tang 1997, Midoux 1999, Putnam 2001). Additionally, the LPRs containing H12BLY peptides 
also exhibited a strong silencing activity (Figure 4.2(a), 4.3(a), 4.4, 4.5). Interestingly the LPDs 
containing H12BLY were not effective at delivering DNA (Figure 3.5(a), 3.7(a), 3.7(b), 3.8(a)). 
This difference might be a consequence of the different sites of intracellular action of siRNA and 
DNA. A major barrier for both the delivery of siRNA and DNA is their escape of the endosome. 
DNA in addition, has the additional barrier of nuclear translocation to overcome. An explanation 
as to different effects seen in the siRNA and DNA lipopolyplexes containing H12BLY is that 
while the H12BLY is able to facilitate the endosomal escape of siRNA and DNA due to its ability 
to act as a proton sponge, it does not promote the entry of DNA into the nucleus.  
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It is interesting, however, that the Series II peptides which contain a mixture of amino acids (HR 
or HK) are able to deliver DNA to nucleus of the cell as evidenced by the effective transfection 
of LPDs containing these peptides (Figure 3.5(a), 3.7(a), 3.7(b), 3.8(a)). In this context, it is of 
note that the effectiveness of these peptides in delivering DNA to the nucleus could be a 
consequence of the presence of the R/K sequence which is also present in nuclear 
translocation signal (NLS) peptides such as large T antigen NLS (126PKKKRRV132) and 
nucleoplasmin NLS (155KRPAATKKAGQAKKKK170) (Kalderon et al, 1984, Dingwall et al, 1991, 
Vives et al, 1997). Moreover, it was found that only a single NLS peptide is sufficient to carry 
DNA to cell nucleus, revealing an efficient NLS-mediated nuclear delivery (Zanta et al, 1999). 
As was seen with the LPDs, the LPRs containing K4BLY exhibited a better activity than those 
containing K12BLY. The reason for this difference is not obvious. However, as was observed 
with the LPDs, the formation of a strong complex between the DNA and the rest of the 
lipopolyplexes was not beneficial for its subsequent release, leading to poor transfection. In may 
be therefore that the shorter length branches present in K4BLY in comparison to K12BLY might 
result in the easier release of siRNA leading to a better silencing. Indeed, it has been reported 
that LPRs containing linear peptides were more condensed and stable than branched peptide 
formulations, although in this case their silencing activity was lower (Tagalakis et al, 2013). 
Moreover, it is interesting to note that LPRs prepared at a higher charge ratio tended to show 
more effective silencing (Figure 4.3(a)) while the LPDs prepared at a lower charge ratio were 
superior (Figure 3.5(a)). The difference in charge ratio requirement could be because DNA 
molecules are large and supercoiled while siRNA molecules are smaller and more rigid (Figure 
1.1 and Table 1.1). Therefore, siRNA are expected to require more cationic materials to 
associate with and to facilitate their delivery, supported and evidenced by other studies (Byrne 
et al, 2013, Gu et al, 2014). 
Regarding physicochemical properties of the LPRs, gel electrophoresis studies showed that the 
LPRs are effective at associating with, protecting and releasing the siRNA they encapsulate, as 
similar observation was made for the LPDs. The picogreen fluorescence assay, however, 
revealed a weaker condensation of siRNA with the lipopolyplexes when using the LPRs 
containing Series II peptides. This result is probably a consequence of the presence of histidine 
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residues in the Series II peptides, which due to it being a weak base would be expected to 
possess little ability to associate with siRNA. 
Dynamic light scattering and ζ-potential measurements revealed that the LPRs prepared in 
water were very small particles with a positive charge (Figure 4.10(a)). In contrast to what was 
seen with the LPDs, the LPRs containing Series II peptides are the same size as those 
containing Series I peptides. The same size resulting from different peptides might be due to the 
same state that siRNA is complexed in the LPRs. It is reasonable to speculate that siRNA is 
associated with cationic materials rather than condensed due to the small size and rigid 
molecular structure of siRNA. Indeed, no conformational change was observed for the siRNA 
complexed in the LPRs as suggested by others’ studies (Kudsiova et al, 2014). It is worth noting 
that unlike LPRs, LPDs containing Series II peptides possessed a larger size than those 
containing Series I (Figure 3.17). It is likely that DNA underwent a conformational change from 
the B-form to the more tightly packed C-form when condensed in the LPDs, an effect reported 
by others (Welser et al, 2013), supporting the hypothesis that the size of the LPD/LPR particles 
is related with the condensation/association state of DNA/siRNA. In addition, the size of the 
LPRs was larger and less stable than that of the LPDs when prepared in 0.12 M NaCl solution 
(Figure 4. 11(a), Figure 3.22(a)). It is consistent with the above assumption as well.  
It is encouraging that the beneficial effect of NaCl on siRNA silencing mediated by 
lipopolyplexes in the presence of serum has also been observed for the LPRs (Figure 4.5(c)). 
To note, the intrinsic RNA-degrading enzyme activity of serum has been displayed in gel 
electrophoresis experiments (Figure 4.6). However, in the present study, it is not possible to 
correlate the siRNA silencing observed with the protection against enzyme degradation afforded 
by the LPRs prepared in 0.12 M NaCl, because naked siRNA was not completely degraded by 
RNAase A at the concentration investigated (Figure 4.7).  
Moreover, the LPRs prepared in 0.12 M NaCl solution exhibit a weaker association of siRNA as 
assessed by the picogreen fluorescence assay (Figure 4.8 and 4.9). As with the LPDs, the 
weaker association is thought to be due to the charge screening effect of the salt. Furthermore, 
the LPRs containing peptides with histidine residues exhibit the weakest association, supporting 
the hypothesis that release from the complex is important for good silencing, an observation 
consistent with the results obtained for the LPDs. 
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Last but not least, the effective silencing seen with LPRs prepared in 0.12 M NaCl solution may 
be also the result of enhanced endosomal escape initiated by lipids. The lipids used in the LPR 
formulation include DOPE. DOPE typically forms non-bilayer structures, which are able to 
destabilise membranes and thereby facilitate the endosomal escape of DNA/siRNA complex 
(Figure 1.10) (Xu et al, 1996). The other lipid present in the LPRs/LPDs formulations is DOTMA. 
DOTMA is a bilayer lipid that has head and tails of similar volume. As the head of DOTMA 
molecule is positive, the repulsion of the charged heads of the adjacent DOTMA molecules can 
be reduced in the presence of NaCl due to a charge screening effect, resulting in a smaller 
effective head group volume. As a consequence, in the presence of NaCl, the DOTMA molecule 
could also adopt a cone-like structure favouring the formation of a reversed hexagonal structure, 
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Chapter 5 Conclusion 
The aim of the present study is to establish a vector to deliver DNA/siRNA to targeted cancer 
cells. The vector established contains a ternary combination of cationic DOTMA:DOPE Lipids, a 
cationic novel Peptide, and a DNA/siRNA payload, denoted LPDs/LPRs. These LPDs/LPRs 
have shown far superior in vitro transfection/silencing over their binary LD/LR or PD/PR 
counterparts, which is found to be related with their structures. The special design of the novel 
peptides with a DNA/siRNA binding portion and a receptor targeting portion has contributed to 
the effective transfection/silencing of the LPDs/LPRs. In particular, Series II peptides are 
characteristic of histidine residues on their DNA/siRNA binding portion, conferring ‘buffering 
effect’ to facilitate endosomal escape and therefore its transfection/silencing.  
Further in vitro transfection/silencing studies have shown that the LPDs/LPRs, irrespective 
prepared in water or NaCl solution (0.12 M), possessed the effective transfection/silencing when 
performed in Optimem (75% v/v). However, only the LPDs/LPRs prepared in NaCl solution 
(0.12 M) exhibited the effective transfection/silencing when performed in RPMI-1640 media 
containing 10% v/v FBS (75% v/v), revealing the importance of NaCl present in the formulation. 
Moreover, the transfection of the LPDs prepared in NaCl solutions has been found to be 
proportional to NaCl concentration (up to 0.12 M).  
A comprehensive study on the physicochemical properties of the LPDs/LPRs prepared in NaCl 
solution (0.12 M) has been performed. In the complexation, release and protection studies 
performed by gel electrophoresis, all the LPDs/LPRs irrespective of in water or NaCl solutions 
have shown effective complexation and release properties. However, the LPDs/LPRs prepared 
in NaCl solutions (0.12 M) afforded better protection than those in water.  Moreover, the 
protection capability of the LPDs increased with the NaCl concentration (up to 0.12 M). The 
protection of DNA/siRNA afforded by the LPDs/LPRs is found to be due to its encapsulation in a 
lipid bilayer as suggested by small angle neutron scattering experiments. Therefore, the 
transfection/silencing efficiency of the LPDs/LPRs can be correlated with their protection 
capability. 
Furthermore, picogreen fluorescence assay has revealed a weaker DNA/siRNA condensation in 
the LPDs/LPRs when prepared in NaCl solution due to the charge screening effect of salt. The 
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weak DNA/siRNA condensation has been seen to be more obvious for the LPDs/LPRs 
containing Series II peptides due to the presence of histidine residues. In addition, the 
LPDs/LPRs prepared in NaCl solution are larger in apparent hydrodynamic size than those in 
water, consistent with looser condensation in the presence of NaCl. The loose DNA/siRNA 
condensation is beneficial to the release of the DNA/siRNA encapsulated in the LPDs/LPRs, 
which might contribute to their effective transfection/silencing.  
Overall, the results of this study have suggested that the LPDs/LPRs containing the bifunctional 
peptides are effective DNA/siRNA delivery vector in vitro. However, there are still some issues 
to be solved. Firstly, the cellular fate of the resultant LPDs/LPRs needs to be illustrated, which 
may provide an insight into the related mechanism of effective DNA/siRNA delivery afforded by 
functionalised peptides and lipids, such as endosomal escape and nuclear translocation of DNA. 
On the other hand, the morphology and more detailed internal structure of the effective 
LPDs/LPRs should be studied which relates to their physicochemical properties and biological 
activities, providing useful information to the design of novel DNA/siRNA delivery vector. To be 
specific, the morphology of the LPD/LPR particles can be visualised using cryo-electron 
microscopy while the complexing state of the DNA/siRNA might be detected by small angle X-
ray scattering. Besides, the stoichiometry of components of LPDs/LPRs can be detected using 
fluorescence correlation spectroscopy. Secondly, the effect of preparation and serum on the 
structure and physicochemical property of the LPDs/LPRs should be further clarified. Last but 
not least, the candidate LPDs/LPRs should be tested for safety and transfection/silencing 
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Appendix I HPLC analysis and mass spectra of peptides 
1. H12BLY, Mw. 5238 
H H H H H H H H H H H H
H H H H H H H H H H H H





Purification was carried out as described in Chapter 2 Methods (Method B). Analysis (Method 
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2. R12BLY, Mw. 5695 




RR R R R R R R R R R R
RR R R R R R R R R R R  
Purification was carried out as described in Chapter 2 Methods (Method B). Analysis (Method 
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3. K12BLY, Mw. 5022 
K K K K K K K K K K K K
K K K K K K K K K K K K





Purification was carried out as described in Chapter 2 Methods (Method B). Analysis (Method 
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4. K4BLY, Mw. 2972 




K K K K
K K K K  
Purification was carried out as described in Chapter 2 Methods (Method A). Analysis (Method 
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5. (HHR)4BLY, Mw. 5390 
H H R H H R




H H R H H R
H H R H H R H H R H H R  
Purification was carried out as described in Chapter 2 Methods (Method A). Analysis (Method 
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6. (HR)6BLY, Mw. 5466 
H R H R H R




H R H R H R
H R H R H R H R H R H R  
Purification was carried out as described in Chapter 2 Methods (Method A). Analysis (Method 
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7. (HK)6BLY, Mw. 5130 
H K H K H K H K H K H K
H K H K H K H K H K H K





Purification was carried out as described in Chapter 2 Methods (Method B). Analysis (Method 
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8. (RK)6BLY, Mw. 5359 
R K R K R K R K R K R K
R K R K R K R K R K R K





Purification was carried out as described in Chapter 2 Methods (Method B). Analysis (Method 







- 187 - 
Appendix II Repeats of LPD results 
1. Transfection 
(a) transfection (24+24h) (a) transfection (4+44h) 
(b) protein assay (24+24h) (b) protein assay (4+44h) 
Figure 1 (a) levels of luciferase transfection and (b) protein assay after 24+24h (left panel) and 
4+44h (right panel) incubation of A549 cells with LPDs. LPDs were prepared fully in water at a 
L:P:D charge ratio of 0.5:6:1, and mixed in a 1:3 volume ratio of LPDs in water and OptiMEM 
(VwLPDw/OptiMEM). The final DNA concentration was 0.0025 mg/mL. Vesicles used to prepare 
the LPDs composed of DOTMA:DOPE at 1:1 molar ratio. Error bars are the SD of triplicate 
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(a) transfection (repeat 1) (a) transfection (repeat 2) 
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(b) protein assay (repeat 1) (b) protein assay (repeat 2) 
(b) protein assay (repeat 3) (b) protein assay (repeat 4) 
Figure 2 (a) levels of luciferase transfection and (b) protein assay in A549 cells after exposure 
to LPDs using a 4+44 h incubation protocol. LPDs were prepared fully in water or 0.15 M NaCl 
solution and diluted with 75% v/v OptiMEM (VwLPDw/OptiMEM and VsLPDs/OptiMEM). LPDs 
were prepared at a L:P:D charge ratio of 0.5:6:1. Cationic vesicles used to prepare the LPDs 
were composed of DOTMA/DOPE lipids at 1:1 molar ratio. Error bars are the SD of 3 
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(a) transfection (repeat 1) (a) transfection (repeat 2) 
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(b) protein assay (repeat 1) (b) protein assay (repeat 2) 
(b) protein assay (repeat 3) (b) protein assay (repeat 4) 
Figure 3 (a) levels of luciferase transfection and (b) protein assay in A549 cells after exposure 
to LPDs using a 4+44 h incubation protocol. LPDs were prepared fully in 0.15 M NaCl solution 
and diluted with 75% v/v Media containing 10% FBS (VsLPDs/Media). LPDs were prepared at a 
L:P:D charge ratio of 0.5:6:1. Cationic vesicles used to prepare the LPDs were composed of 
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2. Agarose gel electrophoresis 
Repeat 1  Repeat 2 
Figure 4 condensation, release and protection properties of LPDs (VwLPDw and VsLPDs) 
using agarose gel electrophoresis (0.025 mg/mL of pDNA). LPDs were prepared at 
lipid:peptide:DNA charge ratio of 0.5:6:1. The effect of the peptide component on DNA 
condensation (Lane A), DNA release (Lane B), and protection from DNAse I (Lane C) was 
studied. Lane A: DNA or LPD. Lane B: DNA and LPDs treated with pAsp. Lane C: LPDs treated 
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3. Dynamic light scattering  
(a)  (b) 
Figure 5 Mean apparent hydrodynamic particle size and ζ-potential of LPDs made in water 
(VwLPDw). Samples prepared at a lipid:peptide:DNA charge ratios of 0.5:6:1 (final DNA 
concentration of 0.01 mg/mL). Vesicle suspension composed of DOTMA/DOPE at 1:1 molar 
ratio. (a) mean apparent hydrodynamic size and ζ-potential, (b) polydispersity index (PDI) of 
mean apparent hydrodynamic size (n=3). Error from SD of three measurements of a single 
formulation at 25°C. 
 
(a)  (b) 
Figure 6 Mean apparent hydrodynamic particle size of vesicles made in water (Vw) and 0.15 M 
NaCl solution (Vs). The size of the vesicles was reduced by bath and probe sonication 
respectively over 80 min. Vesicle suspension composed of DOTMA/DOPE at 1:1 molar ratio 
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4. Small angle neutron scattering  
 
 
Figure 7 Small neutron scattering data obtained for DOTMA:DOPE vesicles (1:1 molar ratio) 
prepared in various strengths of aqueous NaCl solution at 1 mg/mL of DOTMA. The vesicles 
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Table 1 Structural parameters obtained from FISH modelling of the SANS data for probe-
sonicated vesicles in various NaCl solutions (fresh) in Figure 7. Vesicles composed of 
DOTMA:DOPE at 1:1 molar ratio (1.0 mg/mL DOTMA). SANS was measured at 25 ± 0.1°C on 
LoQ. 













Vesicles_0.04 M NaCl 39.7 (±2.5) - - 300 0 7478 
Vesicles_0.08 M NaCl 39.7 (±3.5) - - 300 0 15333
Vesicles_0.12 M NaCl 39.7 (±6.3) - - 300 0 75351
Figures in brackets indicate the standard errors on the fitted parameter values. SWSE is sum of 
weighted square error. Ratio of stack to sheet represents the ratio of multilamellar surface area 
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Appendix III Repeats of LPR results 
1. Knock down 
 
(a) knock down (repeat 1) (a) knock down (repeat 2) 
(b) protein assay (repeat 1) (b) protein assay (repeat 2) 
Figure 1 (a) knock down and (b) protein assay in luciferase-transduced A549 cells after a 
24+24h incubation with LPRs at L:P:R charge ratio of 0.5:12:1 in  water and 1 in 4 dilution in 
OptiMEM (VwLPRw/OptiMEM). Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio. 
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(a) knock down (repeat 1) (a) knock down (repeat 2) 
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(b) protein assay (repeat 1) (b) protein assay (repeat 2) 
 
(b) protein assay (repeat 3)  
Figure 2 (a) knock down and (b) protein assay in luciferase-transduced A549 cells after a 
24+24h incubation with LPRs at L:P:R charge ratio of 0.5:12:1 in  OptiMEM and 1 in 4 dilution in 
OptiMEM (VwLPRo/OptiMEM). Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio. 
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(a) knock down (repeat 1) (a) knockdown (repeat 2) 
(b) protein assay (repeat 1) (a) knockdown (repeat 2) 
Figure 3 (a) knock down and (b) protein assay in luciferase-transduced A549 cells after a 
24+24h incubation with LPRs at L:P:R charge ratio of 0.5:12:1 in saline and 1 in 4 dilution in 
OptiMEM (VsLPRs/OptiMEM). Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio. 
Knock down was performed after a. Error bars are the SD of three measurements of a single 
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(a) knock down (b) protein assay  
Figure 4 (a) knock down and (b) protein assay in luciferase-transduced A549 cells after a 
24+24h incubation with LPRs at L:P:R charge ratio of 0.5:12:1 in  water and 1 in 4 dilution in 
Media (VwLPRw/Media). Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio. Error 
bars are the SD of three measurements of a single formulation (n = 3). 
 
 
(a) knock down (b) protein assay 
Figure 5 (a) knock down and (b) protein assay in luciferase-transduced A549 cells after a 
24+24h incubation with LPRs at L:P:R charge ratio of 0.5:12:1 in OptiMEM and 1 in 4 dilution in 
Media (VwLPRo/Media). Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio. Error 
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(a) knock down (repeat 1) (a) knock down (repeat 2) 
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(b) protein assay (repeat 1) (b) protein assay (repeat 2) 
(b) protein assay (repeat 3) (b) protein assay (repeat 4) 
Figure 6 (a) knock down and (b) protein assay in luciferase-transduced A549 cells after a 
24+24h incubation with LPRs at L:P:R charge ratio of 0.5:12:1 in  saline and 1 in 4 dilution in 
Media (VsLPRs/Media). Cationic vesicles composed of DOTMA/DOPE at 1:1 molar ratio. Error 
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2. Agarose gel electrophoresis 
 
 
repeat 1                                                                repeat 2 
 
Figure 7 Complexation, release and protection of LPRs using luciferase (-)siRNA (0.01 mg/mL). 
LPRs prepared at L:P:R charge ratio of 0.5:12:1. Cationic vesicles composed of DOTMA/DOPE 
at 1:1 molar ratio. Upper panel shows VwLPRw, and the lower panel VsLPRs. Lane A: 
Complexation. Lane B: Release (treated with pAsp). Lane C: Protection (treated with RNAse A 
and pAsp).  
 
 
 
 
